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The IGF system has an important role in growth and development. IGF-II is a 
recognised fetal growth promoter. However, its physiological role in post-natal life 
remains uncertain, although it is maintained in the circulation at a substantially high 
level throughout life, exceeding IGF-I levels. IGF-II has been strongly linked to body 
weight and obesity in genetic studies and more recent evidence suggests a metabolic 
role. We examined fat depot differences in the actions of IGF-II in respect to growth 
and metabolism. We used an established adipocyte, cell culture system of matched 
pairs of visceral and subcutaneous fat biopsies from 20 normal weight children 
undergoing routine surgery for non-malignant, non-septic conditions. Multiple cell 
culture techniques were used to examine the role of IGF-II; cell counting and tritiated 
thymidine incorporation were used to assess the effect on proliferation. Oil Red O 
staining was used to assess preadipocyte differentiation, western blotting and reverse 
transcription polymerase chain reaction techniques were employed to assess the levels 
of adipogenesis markers and levels of the receptors and insulin receptor isoforms. 
Metabolic function was assessed by radioactive glucose uptake assay. We speculated 
a specific effect of IGF-II on visceral adipocytes in relation to the differential 
distribution of insulin receptor isoforms between visceral and subcutaneous fat depots. 
Initial characterisation of receptor levels indicated that visceral preadipocytes have 
higher levels of insulin receptor isoform A than those of subcutaneous preadipocytes. 
With differentiation, insulin receptor isoform B was increased; however, visceral 
adipocytes still maintained a higher expression of IR-A than that of subcutaneous 
adipocytes. A difference in IGF-IIR/M6P and IGF-IR was also seen between the fat 
depots. IGF-II promoted preadipocyte proliferation, and when preadipocytes were 
differentiated for 14 days in the presence or absence of IGF-II it prompted 
preadipocyte differentiation in subcutaneous preadipocytes but showed an opposing 
effect restricting visceral preadipocyte differentiation, which was confirmed by 
reductions in differentiation markers: PPARγ, adiponectin and in triglyceride staining. 
Additionally, IGF-II reduced mRNA expression of the insulin receptor in adipocytes, 
 ii 
and downregulated IR-A and GLUT4 abundance and corresponding glucose uptake in 
visceral adipocytes.  
To further elaborate whether IGF-II plasma levels can be used as a potential biomarker 
of fat distribution, data from a lifecourse cohort, ALSPAC, were used to correlate 
early IGF-II levels with fat distribution measured by DXA scans during puberty. 
Interestingly, and in broad agreement with our cell culture data, cord blood IGF-II was 
negatively correlated with total mass and, in particular, trunk fat mass and showed a 
positive association with subcutaneous fat mass measured in the legs and arms, with 
adjustment of age and sex confounders but no association with lean, fat-free mass. In 
conclusion, IGF-II is a regulator of preadipocyte differentiation and metabolism by 
acting in a depot-specific manner as a differential modulator of fat accumulation 
favouring less visceral fat deposition in children, as well as being a suggested early-
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1.1 Obesity    
Obesity is defined by the World Health Organization (WHO) as an abnormal or 
excessive fat accumulation that may impair health (WHO 2000). Individuals are 
classified as overweight or obese in terms of their body mass index, or BMI. BMI 
is calculated by dividing a person’s weight in kilograms by his or her height in 
metres squared [kg/m2], with a BMI over 25 classified as overweight, while a BMI 
of 30 or above is considered obese. The BMI classification is shown in Table 1-1. 
Table 1-1 Body mass index (BMI) classification (WHO 2000) 
Classification BMI (kg/m2) 
Underweight < 18.5 
Normal range 18.5 – 24.9 
Overweight ≥ 25 
Pre-obese 25 – 29.9 
Obese I 30 – 34.9 
Obese II 35 – 39.9 
Obese III ≥ 40 
 
Obesity is a global problem, with 39% of men and 40% of women aged 18 or 
above considered overweight worldwide and a total of more than half a billion 
adults worldwide being obese. A minimum of 2.8 million people die yearly as a 
result of being overweight or obese. In fact, 65% of the world's population live in 
countries where more people die of being overweight and obese than being 
underweight. Overweight and obesity are responsible for 44% of the diabetes 
burden, 23% of the ischaemic heart disease burden and between 7% and 41% of 
certain cancer burdens (WHO 2016). 
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The worldwide prevalence of obesity has nearly doubled between 1980 and 2008. 
In 2008, 10% of men and 14% of women in the world were obese in comparison 
with 5% of men and 8% of women in 1980. The highest prevalence in the world 
was in the United States, where 38.2% of both sexes were obese. The lowest 
percentage was in South East Asia, where around 3% of both sexes were obese 
(OECD 2017). In the United Kingdom, 26% were classified as obese, and more 
than 600 thousand were admitted to the National Health Service (NHS) hospitals 
in relation to obesity (PAS 2018).   
 
1.1.2 Childhood obesity 
Obesity is classified somewhat differently in children, with BMI calculated 
according to their age and sex. If a child’s BMI is at or above the 85th percentile 
for his or her age, then he or she is at risk of becoming overweight. If a child’s 
BMI is at or above the 95th percentile, the child is classified as obese (Ghosh 
2014). The epidemic of childhood obesity has increased in the past four decades, 
with a surge in recent years. Furthermore, this increase in prevalence is not 
exclusive to higher income countries but also occurs in middle- and low-income 
counties as illustrated in Figure 1-1.  
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Figure 1-1 Prevalence trends for childhood overweight and obesity in the USA and 
eight low-income and middle-income countries. (adapted from (Lobstein, Jackson-Leach 
et al. 2015)) 
 
More than 41 million children worldwide under the age of 5 are overweight or 
obese (WHO 2016). In the US, the obesity prevalence has more than doubled in 
children between 1980 and 2010, with more than one third of the children and 
adolescents being overweight or obese in 2010 (Taber, Chriqui et al. 2011). In the 
UK, the 2015/16 National Child Measurement Programme (NCMP) showed that 
obesity or overweight prevalence among 4–5-year olds (reception) was 20% and 
among 10–11-year olds (year 6) was 33%. Childhood obesity is of particular 
concern as 25% of obese adults were overweight as children and if overweight 
begins before 8 years of age, obesity in adulthood is likely to be more severe 
(Freedman, Khan et al. 2005). In addition to the increase of obesity risk in 
adulthood, childhood obesity might be associated with long term health 
manifestation regardless of adult body weight (Must, Jacques et al. 1992). This 
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highlights the importance of early periods of growth monitoring and body weight 
related interventions, as they may have a huge impact on health status later in life.  
1.1.3 Consequences of childhood obesity  
Adult obesity-associated diseases are now becoming a paediatric problem; obese 
children are at a higher risk of developing related systemic and psychological 
problems (Dietz 2004, Lo, Chandra et al. 2014). The medical consequences of 
childhood obesity include dyslipidaemia, hypertension and increased 
cardiovascular disease risks (Stabouli, Kotsis et al. 2005). Increasing rates of type 
2 diabetes mellitus were noted in American ethnic minorities in association with 
increased obesity rates (Rocchini 2002). Development of glucose intolerance 
(Wabitsch, Hauner et al. 1994), non-alcoholic fatty liver disease (Schwimmer, 
Deutsch et al. 2006) and cholelithiasis (Friesen and Roberts 1989) have also 
increased. In addition to the medical impact, psychosocial consequences have 
been observed including increased rates of anxiety, depression and weight-related 
social problems associated with bullying and low self-esteem (Puder and Munsch 
2010). 
 
1.2 The adipose tissue  
1.2.1 Adipose tissue types  
Adipose tissue is a specialised tissue that functions as the major storage site for fat and 
is found in mammals in two different forms: white and brown adipose tissue. They are 
composed of connective tissue, vascular and inflammatory cells and mainly white or 
brown adipocytes. The adipocytes in white adipose tissue (WAT) contain large 
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unilocular lipid droplets and in addition to its fat storage role, WAT is considered an 
active endocrine organ that regulates many major functions in the body, such as insulin 
sensitivity and lipid metabolism, by its ability to secrete multiple hormones, like 
leptin, angiotensinogen, adipsin, adiponectin and resistin that play an important role 
in physiological and metabolic functions (Trayhurn and Beattie 2001, Galic S 2010). 
WAT stores excess energy as triglycerides and releases the energy in the form of free 
fatty acids. It is the main type of adipose tissue found in adult humans as it distributed 
throughout the body in subcutaneous regions, surrounding visceral organs and 
extremities (Nedergaard 2008).  
By contrast, brown adipose tissue (BAT) is found mostly in rodents, small mammals 
and in human infants. It is histologically distinct from WAT, as it is composed of 
multiloculated adipocytes that contain large numbers of mitochondria accounting for 
their brown colour (Nedergaard 2004). The importance of brown adipocytes lies in 
their ability to change stored chemical energy into heat, which occurs through the 
expression of uncoupling protein-1 (UCP1) found in the inner mitochondrial 
membrane. This protein permits dissipation of the mitochondrial proton gradient 
which is used to promote the production of ATP (Himms-Hagen 1990). For many 
years, BAT was thought to be absent in human adults, but recent fluorodeoxyglucose 
positron emission tomography studies of normal humans have identified regions of 
high glucose uptake that represent metabolically active tissue (Cypess, Lehman et al. 
2009) mainly traced in the upper parts of the human body, particularly the 
supraclavicular and the neck regions and some in the paravertebral, para-aortic, 
mediastinal and suprarenal areas (Cypess, White et al. 2013).  
A new adipocyte cell was recently added to the white and brown adipocytes, known 
as beige adipocytes or inducible ‘brown-like’ adipocytes. These cells are clusters of 
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UCP1-producing adipocytes with a heat generating ability, but develop in WAT due 
to different stimulation, such as agonists of the β-adrenergic receptor or peroxisome 
proliferator-activated receptor γ (PPARγ) (Vitali, Murano et al. 2012). This is 
considered a fundamental difference from brown adipocytes as they express high 
levels of UCP1 under basal or unstimulated conditions (Klaus, Ely et al. 1995). The 
beige adipocytes have a multilocular lipid droplet morphology and a high 
mitochondrial content, but whether they serve different functions in comparison to 
brown adipocytes is still to be determined (Wu, Boström et al. 2012). The adipose 
tissue types are shown in Figure 1-2. 
 
 
Figure 1-2 Origins of white, beige and brown adipocytes (adapted from (Peirce, 
Carobbio et al. 2014))  
Brown adipose tissue originates from myogenic factor 5 (MYF5+) expressing cell lineage and 
is formed by UCP1+ brown adipocytes, while white adipose tissue originates from non-
myogenic expressing lineage and is formed by UCP1- white adipocytes and UCP1+ beige 
adipocytes. The expansion of adipose tissue is due to proliferation and differentiation of 
adipocyte precursors which originate from mesenchymal precursor cells. 
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1.2.2 Molecular regulation of adipocyte differentiation 
As indicated in the previous section (1.2.1), the adipocytes originate from multipotent 
mesenchymal precursor cells that can differentiate into mature cells of multiple 
mesenchymal tissues including fat and bone (Zuk, Zhu et al. 2002). The preadipocytes 
can become dormant or be processed to become differentiated adipocytes. For the 
differentiation phase, preadipocytes withdraw from the cell cycle, which usually 
occurs through contact inhibition, however cell-to-cell contact might not be an 
absolute requirement for growth arrest as 3T3-F44A cells were able to differentiate in 
suspension culture without contact inhibition (Hayashi, Nixon et al. 1981). After the 
growth arrest stage, the committed cells undergo clonal amplification, which is 
achieved by at least one round of cell division and DNA replication (Fajas 2003). 
Following the clonal expansion phase and with the appropriate combination of 
mitogenic and adipogenic signals, the cells will continue to differentiation. The 
preadipocytes will go through multiple biochemical and morphological changes 
leading to the accumulation of triglycerides in the vesicles that is associated with 
cytoskeletal remodelling and changes in the level and type of extracellular matrix 
(ECM). A fusion of visceral triglycerides will occur towards the end of the terminal 
differentiation phase, leading to the formation of the round mature adipocyte 
appearance (MacDougald and Lane 1995).  
The regulation of preadipocyte differentiation occurs at the genetic level, leading to 
an increase in the levels of many transcription factors, including peroxisome 
proliferator-activated receptor gamma (PPARγ) and CCAAT/enhancer binding 
protein (C/EBP), as well as increased levels of multiple lipid metabolism proteins, 
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such as fatty acid synthase (FASN), lipoprotein lipase (LPL), GLUT4, stearyl CoA 
and angiotensinogen (Rosen, Walkey et al. 2000).  
1.2.2.1 Transcription factors PPARγ, C/EBPα, ADD-1/SREBP-1 and Pref-1 
 
The C/EBP transcriptional factors C/EBPβ and C/EBPδ are involved in the early 
stages of adipogenic induction, followed by PPARγ and C/EBPα, which act 
cooperatively to activate one another and are involved in the growth arrest phase 
required for differentiation (Mandrup and Lane 1997). Furthermore, the promoter 
region of PPAR has binding sites for C/EBP (Mandrup and Lane 1997, Michalopoulos 
and DeFrances 1997). PPARγ activation induces the exit from the cell cycle and 
PPARγ is considered the most specific transcriptional factor for adipocyte 
differentiation (Grégoire, de Broux et al. 1992). The adipocyte determination and 
differentiation factor-1/sterol regulatory element-binding protein-1 (ADD-1/SREBP-
1) is also expressed early in the process and stimulates the expression of many genes 
needed for lipogenesis in vivo (Ericsson, Jackson et al. 1997). ADD-1/SREBP-1 in 
combination with C/EBPβ and C/EBPδ induce the expression and/or activity of 
PPARγ, the controller of adipocyte differentiation (Fajas, Fruchart et al. 1998, Saladin, 
Fajas et al. 1999). 
In contrast to these stimulatory transcription factors, preadipocyte factor 1 (Pref-1) 
acts as an inhibitor of adipocyte differentiation. Pref-1 is highly expressed in 
preadipocytes and its expression is decreased with differentiation. Pref-1 functions to 
maintain the preadipocyte phenotype, possibly by interacting with the extracellular 
matrix (ECM) (Smas and Sul 1993, Sul 2009). It was also reported to have an 
inhibitory effect on adipogenesis in vivo (Wang, Kim et al. 2006). 
In the terminal differentiation phase, adipocytes increase de novo lipogenesis and 
become insulin-sensitive, which is associated with an increase in lipid metabolism 
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enzyme transcription and protein levels including glycerol-3-phosphate 
dehydrogenase and fatty acid synthase as well as other non-lipid metabolism related 
genes, like adipocyte-specific fatty acid binding protein (aP2). The stages of 
preadipocyte differentiation are demonstrated in Figure 1-3.  
 
Figure 1-3 Illustration of the stages of preadipocyte differentiation (adapted from 
(Chen, Roether et al. 2008)) 
The multipotent stem cell has the ability to differentiate to adipocytes, myoblasts, 
chondroblasts and osteoblasts. When exposed to the appropriate adipogenic environment these 
stem cells will give rise to preadipocytes, which undergo clonal expansion phase and reach 
terminal differentiation. The transcriptional regulation associated with this process is shown 
on the right, the arrows indicate the approximate duration. Abbreviations: IGF-I, insulin-like 
factor-1; pref-1, preadipocyte factor 1; C/EBP, CCAAT/enhancer binding protein; PPARγ, 
peroxisome proliferator-activated receptor γ.  
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1.2.2.2 Cytoskeletal remodelling  
The process of adipogenesis leads to dramatic morphological and cytoskeletal 
changes. Interestingly, these cytoskeletal rearrangements facilitate insulin signalling, 
as they provide support for key signalling components such as insulin receptor 
substrate (IRS), following Tyr-phosphorylation IRS acts as an anchor for other 
downstream molecules including SH2 (Src homology 2 domain) and p85 regulatory 
subunit of PI3K (Whitehead, Clark et al. 2000). Activation PI3K pathway lead to 
phosphorylation of Akt which is involved in GLUT4 glucose uptake (Taguchi and 
White 2008), and PKC family members which regulates actin cytoskeleton (Jacinto, 
Loewith et al. 2004). Maintaining the microtubule network arrangements are needed 
for the movement of GLUT4 vesicles from the intracellular compartments to the 
plasma membrane (Kanzaki and Pessin 2001). The changes in ECM level and type are 
seen with differentiation, including alteration in the basement membrane and the 
reticular fibre network, leading to differences in cellular adhesion properties, and 
remodelling of cell components allowing reorganisation and adipocyte gene 
expression (Gregoire, Smas et al. 1998). 
 
1.2.3 Adipose tissue fat depots 
 
Fat develops in many anatomical locations including subcutaneous, mesenteric, 
gluteal, femoral and intra-abdominal. The intra-abdominal fat is classified into 
visceral or intraperitoneal/perinephric adipose tissue and is found inside the peritoneal 
cavity. Subcutaneous adipose tissue lays anteriorly to the abdomen wall or back 
muscles. This classification is important because metabolic risks are found to be 
related more to body fat distribution rather than total body fat (Wajchenberg 2000). In 
Chapter 1: General introduction  
 12 
addition, differences in multiple internal characteristics were reported between the fat 
depots, including differences in the composition, endocrine secretions, hormonal 
responses and metabolic function. Figure 1-4 shows the anatomical distribution of 
subcutaneous and visceral fat.  
 
Figure 1-4 illustration of abdominal visceral and subcutaneous fat distribution 
(adapted from www.mayoclinic.org). 
Vertical cross section showing visceral adiposity as the fat surrounded by the visceral cavity 
and subcutaneous adiposity defined as the fat outside the visceral cavity. 
 
1.2.3.1 Anatomical and developmental differences  
 
Subcutaneous fat accounts for most of the body fat. The widespread distribution of 
subcutaneous fat has systemic venous drainage, whereas the internal location of 
visceral fat maintains direct drainage via the portal vein, facilitating direct access of 
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secreted FFAs and adipokines by visceral cells to the liver (Mårin, Andersson et al. 
1992, Wajchenberg 2000).  
Visceral and subcutaneous adipocytes can differ in their characteristics from early 
development, where the adipocyte precursor cells from subcutaneous fat are easier to 
differentiate, which may help to explain why subcutaneous fat expansion occurs 
mainly by hyperplasia in comparison to visceral fat that expands predominantly by 
hypertrophy of existing cells. The pattern of gene expression in subcutaneous cells has 
many similarities with the gene expression of brown fat in comparison with visceral 
adipocytes which have a different genetic expression profile (Macotela, Emanuelli et 
al. 2012). 
Visceral and subcutaneous fat have separate parasympathetic innervation and visceral 
fat has an increased sympathetic supply, which may have a role in influencing fat 
storage in adipocytes (Bartness 2002).   
1.2.3.2 Molecular and cellular differences  
Multiple differences between visceral and subcutaneous cells in terms of receptor 
distribution and cellular signalling have been reported. Visceral cells have higher 
levels of glucocorticoid (Lundholm, Rebuffe‐Scrive et al. 1985), androgenic 
(Freedland 2004) and adrenergic receptors (Hellmer, Marcus et al. 1992) than 
subcutaneous cells, which leads to an increase in catecholamine related lipolysis in 
visceral fat (Imbeault, Couillard et al. 2000). Instead, oestrogen receptors are more 
dominant in subcutaneous fat, with a higher density in females leading to more gluteal-
femoral accumulation of fat in comparison to males (Pedersen, Hansen et al. 1996).  
Furthermore, fat-depot differences in hormonal secretion have been noted. Visceral 
adipocytes are able to secrete more adiponectin (Motoshima, Wu et al. 2002) and 
angiotensinogen (Dusserre, Moulin et al. 2000) than subcutaneous fat. In addition, 
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pro-inflammatory cytokines, like TNF-α and IL-6, are higher in visceral cells 
(Lemieux, Pascot et al. 2001, Weisberg, McCann et al. 2003), whereas subcutaneous 
cells show more leptin production than visceral cells (Wajchenberg 2000).  
These molecular differences increase the association between metabolic risks and 
visceral fat because of the accumulation of inflammatory macrophages and pathologic 
tissue expansion with a positive energy balance leading to rapid enlargement of 
existing adipocytes (hypertrophy) with poor vascularisation, which may be associated 
with fibrosis and an increased level of inflammatory cytokines. This form of expansion 
may further progress to cause ectopic fat accumulation in different body locations, 
such as the liver, pancreas and skeletal muscles (Stefan, Kantartzis et al. 2008, 2011).  
1.2.3.3. Metabolic fat-depot differences  
Insulin stimulated glucose uptake is higher in visceral adipocytes than in subcutaneous 
adipocytes in children (Grohmann, Sabin et al. 2005) and in adults (Lundgren, Burén 
et al. 2004). In contrast, insulin inhibition of lipolysis is decreased in visceral 
adipocytes relative to subcutaneous adipocytes (Zierath, Livingston et al. 1998). 
Visceral cells have increased lipolytic activity. The mechanism whereby visceral 
adipocytes are more insulin-sensitive for glucose uptake but less insulin-sensitive for 
inhibition of lipolysis has not been fully elucidated.   
The clinical significance of these structural and metabolic differences between the fat 
depots shows that increased visceral obesity is associated with a higher metabolic risk 
(Rexrode, Carey et al. 1998) as well as increased risk of coronary heart disease 
(Yudkin, Kumari et al. 2000), stroke (Amato, Giordano et al. 2010), diabetes and 
metabolic syndrome (Lemieux and Despres 1994), thereby affecting individual life 
expectancy. Indeed, abdominal obesity is associated with higher mortality rates 
regardless of the BMI level (Zhang, Shu et al. 2007). 
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1.3 The insulin-like growth factor system 
The insulin-like growth factor (IGF) system is a complex network essential for 
regulation of cell growth, proliferation and survival. It is important in embryonic and 
postnatal development as the system affects almost all the body organ systems. IGFs 
were identified in the early 1950s as somatomedins, however, when their insulin-like 
actions were discovered later, the term insulin-like growth factors was later introduced 
in 1976 (Rinderknecht and Humbel 1976). 
The IGF system is composed of two soluble ligand peptide hormones IGF-I and IGF-
II, which have high structural similarity to insulin. Multiple transmembrane receptors 
exist, the IGF-I receptor, the insulin receptor (IR), the IGF-II receptor and hybrid 
IR/IGF-IR. There are also six circulating high affinity IGF binding proteins (IGFBP-
1 to 6) that also regulate the system (Rechler 1993). The majority of circulating IGFs 
(90%) are bound in complexes consisting of IGF-I or IGF-II and IGFBP-3 (to a lesser 
extent IGFBP-5) and the 85 kDa acid-labile subunit (ALS), which is a glycoprotein 
synthesised by the liver (Rajaram, Baylink et al. 1997). These complexes lead to more 
stabilisation and elongation of the half-life of the IGFs to 16–24 h. Around 10% of 
IGFs are found circulating as binary complexes with IGFBPs, which cross the 
capillary endothelium to act as a pericellular reservoir of IGFs, with a half-life of 20–
30 minutes. The remaining less than 1% is free in the circulation; this unbound form 
has a very short half-life like insulin of a few minutes (Baxter 2014). The free bioactive 
hormone binds and activates a receptor tyrosine kinase (RTK) receptor, which recruits 
intracellular substrate proteins leading to biological effects (Braun, Bitton-Worms et 
al. 2011). The half-life of IGFs in the circulation is illustrated in Figure 1-5. 
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Figure 1-5 The insulin-like growth factor (IGF) system in the circulation 
(adapted from (Baxter 2014))  
IGFs are mainly secreted by the liver and can also be produced by other organs. They act in 
an autocrine or paracrine manner and in addition to their presence in the circulation, they are 
found in binary complexes with IGFBP-1–6. Binary complexes with IGFBP-3 and IGFBP-5 
can form a ternary complex with the acid-labile subunits (ALS). The figure illustrates the 
circulating half-lives of free and bound IGF.  
 
The binding between IGFs and IGFBPs leads to a more stable complex with lower 
dissociation rates. However, this binding can be locally regulated by proteolytic 
enzymes (IGFBP-proteases) including matrix metalloproteinases, metalloproteinase 
28 (ADAM 28) and pregnancy associated plasma protein A (PAPPA-1) (Nakamura, 
Miyamoto et al. 2005, Boldt and Conover 2011), which can specifically increase 
cleavage of the IGF binding proteins and alter IGF bioavailability (Laursen, 
Overgaard et al. 2001).  
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1.4 IGF system ligands  
1.4.1 IGF-II  
 
1.4.1.1 Structure  
IGF-II is a 7.5 kDa peptide mainly secreted by the liver, with 62% homology with 
IGF-I and consists of 67 amino acids. It is expressed from the 30 kb IGF-II gene 
located on chromosome 11p15.5, interestingly, next to the insulin gene.  
Serum levels of IGF-II remain stable during adult life, with a concentration of 700 
ng/ml and only show a minimal decline with ageing (Bennett, Wahner et al. 1984, 
Humbel 1990). In comparison with IGF-I, its levels are more abundant in the serum 
and remain unchanged during pregnancy as it acts as an important regulator of fetal 
growth and development, but its physiological role in adults is less well understood.  
Free IGF-II circulates at low concentrations (picomolar) and its biological activity 
follows binding to the IGF-IR, IR-A isoform and IGF-I/IR hybrid receptors. It acts in 
an endocrine, autocrine and paracrine manner and IGF-IR activation is thought 
mediate most of the biological effects of IGF-II. IR-A binds IGF-II with a greater 
affinity than IGF-I. It is generally known that activation of the IR-A receptor by IGF-
II is mitogenic, whereas insulin binding generates a metabolic response (Frasca, 
Pandini et al. 1999). IR-A is broadly distributed, and its physiological function is yet 
to be fully determined.  
The lack of clear understanding of the physiological role of IGF-II in humans may be 
due to its overlapping effects with IGF-I and the lack of naturally occurring inherited 
conditions that result in a deficiency of IGF-II (Braun, Bitton-Worms et al. 2011).  
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1.4.1.2 IGF-II regulation  
IGF-II is precisely regulated and at many levels, its gene is regulated by imprinting; it 
is only expressed by the paternal allele in most tissues, and its maternal allele is not 
expressed normally. The imprinting control region (ICR) regulates the expression of 
IGF-II and H19 genes in somatic cells, in the maternal cells ICR is hypomethylated 
and will bind to the nuclear protein CCCTC-binding factor (CTCF), which acts as an 
insulator protein. This binding occurs at four sites leading to the inhibition of IGF-II 
proximal promoter activity due to the isolation from its distal enhancer. In paternal 
cells however, the ICR is methylated leading to CTCF binding inhibition, this will 
promote IGF-II expression through its connection with the downstream enhancer 
(Szabó, Tang et al. 2004) as shown in Figure 1-6. This regulation of IGF-II 
methylation and expression is dysregulated in multiple pathological conditions 
including obesity and cancer (Chen, Ip et al. 2000, Cui, Onyango et al. 2002). 
 
 
Figure 1-6 Model of IGF-II imprinted genetic expression (adapted from 
(Kameswaran and Kaestner 2014)) 
The H19-IGF-II locus on the maternal allele has unmethylated ICR, which allows the 
attachment of the CTCF suppressor protein, causing loss of connection between the IGF-II 
promoter and its downstream enhancer. In the paternal allele, the ICR is methylated and the 
connection is persistent between IGF-II and its enhancer. 
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In the serum, IGF-II is bound to IGFBPs to regulate its bioactivity. This binding affects 
the free levels of IGFs, for instance, a higher concentration of IGFBP-1 was related to 
greater suppression of the IGF-II free level (Juul 2003). At the tissue level, IGF-II 
actions depend on the tissue expression of its targeted receptors as it binds the IGF-
IR, the IR and with higher affinity to the IR-A: IGF-II also has its own receptor (IGF-
IIR/M6P) which acts as a clearance receptor to promote further regulation of IGF-II 
levels (Kornfeld 1992). Unlike IGF-I, IGF-II is weakly regulated by growth hormone, 
as GH only influences its levels indirectly by increasing the production of IGFBP-3 
from the liver and ALS ternary complex formation. This explains why IGF-II levels 
are not influenced by puberty (Wolf, Kramer et al. 1994). 
 
1.4.1.3 The role of IGF-II in growth  
IGF-II has a well-established role as an essential embryonic growth promoter: 
knocking out IGF-II in mice leads to severe growth retardation in utero but knocking 
out the same gene after birth had no effect on normal growth. Therefore, IGF-II is 
fundamental for normal embryonic growth but not crucial for postnatal development 
in mice (DeChiara, Efstratiadis et al. 1990). The role of IGF-II in humans may be more 
extensive, as unlike mice, in which the level of IGF-II is negligible after weaning, the 
serum levels in humans remains relatively high and constant throughout adult life 
(Soares, Ishu et al. 1985). Multiple studies have shown that IGF-II has a role in intra-
uterine growth in humans, as it is abundantly secreted by the placenta; IGF-II helps to 
increase the formation of mesoderm cells, improve nutrient transport, trophoblast 
invasion and proliferation, survival of cytotrophoblasts and promotes organ 
development. IGF-II promotes angiogenesis through its regulation of vascular 
endothelial growth factor (VEGF), which stimulates differentiation of endothelial 
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cells (Irwin, de las Fuentes et al. 1993, Schwartz, Hudgins et al. 1993). The role of 
IGF-II postnatally is less understood, however, a recent report suggested that IGF-II 
is also important in growth promotion in humans after birth (Begemann, Zirn et al. 
2015). Other studies also suggest a role in postnatal bone development and cartilage 
growth (Uchimura, Hollander et al. 2017). 
1.4.1.4 The role of IGF-II in metabolism  
Physiologically IGF-II is reported to have insulin-like effects; its overall actions are 
anabolic and result in the lowering of blood glucose levels: IGF-II acts on the liver to 
reduce hepatic glucose output and increase glucose storage as glycogen. In muscles, 
IGF-II also helps to decrease blood glucose level by facilitating glucose uptake and 
oxidation, and stimulating the synthesis of both lipids and proteins (Rajpathak, Gunter 
et al. 2009). IGF-II serum levels are related to the nutritional status of the individual, 
as its levels are decreased with malnutrition (Wolf, Kramer et al. 1994) and increased 
with obesity, both total (Buchanan, Phillips et al. 2001) and free IGF-II (Frystyk, 
Skjaerbaek et al. 1999); this change in serum levels being reversible with weight loss 
(Belobrajdic, Frystyk et al. 2010). IGF-II was indicated as a prognostic marker to 
predict future weight gain in a study that followed both sexes for four years. The study 
showed that higher levels of IGF-II at baseline were protective against future weight 
gain (Sandhu, Gibson et al. 2003). In addition, higher levels of IGF-II and IGFBP-2 
were associated with increased HDL cholesterol in diabetic patients (Narayanan, Fu 
et al. 2013).   
In genetic studies, many associations between IGF-II polymorphisms and weight have 
been reported. A study of 1,474 men demonstrated that Apal AA is associated with 
lower body weight but higher serum IGF-II levels (O'Dell, Miller et al. 1997), but this 
was contradicted by another study indicating no difference in BMI or fat mass between 
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Apal AA and other IGF-II genotypes (Roth, Schrager et al. 2002). Furthermore, it has 
been suggested that high in utero expression of the paternal IGF-II allele may cause 
fat deposition postnatally in the offspring (Le Stunff, Fallin et al. 2001), and the level 
of IGF-II methylation at birth may contribute to the development of obesity and weight 
gain in early childhood (Perkins, Murphy et al. 2012) .  
Adipocytes have the ability to secrete more IGF-II than IGF-I (Gude, Frystyk et al. 
2012). The metabolic actions of IGF-II in terms of glucose uptake and inhibition of 
lipolysis are less potent than IGF-I and insulin as demonstrated in an in vitro culture 
study using the 3T3-L cell line. This was explained by the lesser affinity of IGF-II for 
the IGF-IR in comparison to IGF-I (Siddals, Westwood et al. 2002). In primary 
adipocytes where the IR is additionally expressed, IGF-II was more potent in 
activating the insulin receptor than IGF-I (Bäck, Brännmark et al. 2011).  With this 
strong association with body weight, and the high expression of IGF-II in adipose 
tissue, it would be interesting to explore if IGF-II has regulatory actions on fat cells, 
especially on visceral adipocytes as they express a higher level of insulin receptors 
than subcutaneous adipocytes and these are predominantly the IR-A isoform 
(Lefebvre, Laville et al. 1998).  
 
1.4.2 Insulin  
 
Insulin plays a major role in regulating glucose uptake and metabolism. It is secreted 
from the pancreatic β-cells into the blood and acts as an anabolic hormone that 
promotes glucose uptake and storage mainly through its actions on the liver, muscles 
and adipose tissue. 
Insulin maintains blood glucose levels within a narrow range by increasing glucose 
absorption from the blood to the liver and fat tissue by promoting the translocation of 
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the glucose transporter (GLUT4) from the cytoplasm to the cell surface. The anabolic 
effects of insulin include promoting glycogen formation, protein synthesis and 
lipogenesis. By contrast, insulin reduces lipolysis, glycogenolysis and protein 
breakdown and inhibits the production of glucose from the liver. In addition to its 
metabolic effects, insulin also promotes cell growth and differentiation (Alan and 
Kahn 2001). 
Insulin is composed of two polypeptide chains, which consist of an A chain with 21 
amino acids and the B chain has 30 amino acids; the chains are linked together by two 
disulphide bonds, and an extra disulphide bond is created within the A chain. The 
additional C-peptide chain is cleaved when insulin becomes biologically active (De 
Meyts 2004). 
Insulin is essential for survival and any disturbances in insulin levels can lead to 
metabolic instability in the form of diabetes, with high fasting and postprandial 




IGF-I shares 50 to 70% structural similarity to insulin. It is predominantly secreted by 
the liver into the circulation (Schwander, Hauri et al. 1983). IGF-I is also expressed in 
other tissues including adipocytes (Frystyk 2004). The primary regulator of IGF-I is 
growth hormone (GH) and it is important in cell proliferation, growth, apoptosis and 
migration, thereby affecting organism size and longevity (Holt, Simpson et al. 2003).   
The adult serum levels of IGF-I reach around 100–200 ng/ml. These levels vary with 
age, being half that of adult levels at birth and increasing to adult levels around 
puberty, however the highest level of IGF-I is found during puberty, with an almost 
three fold increase in concentration (Humbel 1990, Frystyk 2004). This increase 
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during puberty is accompanied with the pubertal-GH surge, after which levels decline. 
The pubertal surge is associated with an increase in IGFBP-3 levels, but with a 
maintained predominance in IGF-I secretion leading to an overall increase in free IGF-
I (Juul, Dalgaard et al. 1995).  
Knockdown of the IGF-I gene in mice caused deficient embryonic growth and 
consequent dwarfism and infertility in the offspring (Adams, Epa et al. 2000). In 
humans, loss of functional IGF-I causes pre- and postnatal growth retardation and 
occasionally, developmental retardation and partial or total deafness (Duyvenvoorde, 
Losekoot et al. 2007).  
Although IGF-I is generally considered a key postnatal growth factor, as it stimulates 
the growth of several cell types, it also has other significant metabolic effects either 
by its direct effect on targeted tissues or indirectly through facilitating the actions of 
GH. IGF-I lowers blood glucose levels by directly promoting tissue glucose uptake in 
muscle and supressing glucose production from the liver. In addition, IGF-I helps to 
increase insulin sensitivity (Guler, Zapf et al. 1987) and has an antilipolytic effect on 
adipose tissue, promoting protein synthesis (LeRoith and Yakar 2007) .  
The GH-IGF axis is a fundamental regulator of childhood growth, influenced by 
multiple factors, including nutritional and hormonal regulation. Obesity is associated 
with decreased levels of GH, and increased adiposity, predisposing more to central 
adiposity (Berryman, Glad et al. 2013). The levels of GH are inhibited by increased 
concentrations of IGF-I, insulin and free fatty acids. Obesity may alter the GH-IGF 
axis through increasing insulin in the portal veins in association with insulin 
resistance, the suppression of IGFBP-1, which may increase free levels of IGF-I 
(Lewitt, Hilding et al. 2008) leading to reduction in GH. Furthermore, in obesity there 
is an amplified IGF-I response to GH and an increase in GH receptor expression 
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leading to the absence of IGF-I suppression. However, total IGF-I levels showed 
inconsistent associations with obesity; levels were lowered, increased or showed no 
changed in obese individuals (Rasmussen, Hvidberg et al. 1995). Furthermore, the 
increase in FFAs associated with obesity can cause a reduction in GH levels. 
Interestingly, the reduction in FFAs by the use of the antilipolytic drug ‘ acipimox’ 
lead to a restoration of GH release (Cordido, Peino et al. 1996).   
 
1.5. IGF binding proteins (IGFBPs) 
IGF binding proteins (IGFBP) are major regulators of the bioavailability of IGFs as 
the IGFBP-IGF binding complexes help to transport IGFs in the circulation, facilitate 
their movement out of the vascular compartment, elongate the half-life of the 
hormones and inhibit them from binding to their corresponding receptors. There are 
six high affinity IGFBPs (1–6), which are structurally related. They bind IGFs with 
high affinity but do not bind to insulin (Wetterau, Moore et al. 1999). The affinity of 
IGFBPs is almost similar for IGF-I and IGF-II, however some binding proteins have 
preferable binding, like IGFBP-6 which is reported to have a higher affinity for IGF-
II (Rechler 1993). 
IGFBPs have various functions and different levels of expression, their main function 
is to regulate the action of IGFs, but they can also function independently of the IGFs, 
as regulators of cell growth, apoptosis and gene transcription (Lawrence, Oxvig et al. 
1999, Wetterau, Moore et al. 1999). The most abundant IGFBP in serum is IGFBP-3 
and its binding to IGFs is highly regulated by GH (Juul, Dalgaard et al. 1995). IGFBP-
2, the second most abundant binding protein in serum, and IGFBP-4 have overall 
inhibitory actions, while the effects of IGFBP-1 varies, inhibiting the actions of IGFs 
Chapter 1: General introduction  
 25 
when phosphorylated and facilitating their effects when dephosphorylated (Jones and 
Clemmons 1995). 
1.5.1 IGFBPs in adipogenesis 
IGFBPs have an important role in adipogenesis and metabolism, both directly and 
indirectly through the regulation of IGFs. IGFBP-1 inhibited the effect of IGF-I on the 
differentiation of preadipocytes, and IGFBP-1 overexpression in mice helped to 
reduce diet-induced obesity (Rajkumar, Modric et al. 1999, Siddals, Westwood et al. 
2002). However, when IGFBP-1 was overexpressed in mice, it led to the development 
of age-related glucose intolerance. IGFBP-1 levels change during the day, with low 
levels after meals, that correlates with its regulation by insulin (Crossey, Jones et al. 
2000).  
IGFBP-2 is secreted by white preadipocytes during the process of adipogenesis 
(Boney, Moats-Staats et al. 1994) and its serum levels decrease with obesity both in 
adults (Nam, Lee et al. 1997) and in children (Frystyk, Skjaerbaek et al. 1999, 
Ballerini, Ropelato et al. 2004). Studies have also shown that high IGFBP-2 
expression can be protective against obesity and its related complications (Wheatcroft, 
Kearney et al. 2007). In addition, IGFBP-2 also has fat-depot specific differences as 
visceral adipocytes secrete more of this binding protein, and silencing IGFBP-2 
promotes adipogenesis and lipogenesis in visceral but not subcutaneous white 
adipocytes (Yau, Russo et al. 2014). 
Interestingly, in addition to their IGF-dependent effects, IGFBPs have also been 
reported to exert adipose tissue IGF-independent biological actions. IGFBPs were 
found to act independently by having their own cellular receptors and/or regulate 
nuclear interactions, and in adipose tissue, IGFBP-3 reduced 3T3-L1 preadipocyte 
differentiation in a non-IGF-I-dependent manner (Chan, Schedlich et al. 2009). This 
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was confirmed using an IGFBP-3 mutant (has less affinity to IGF-I) that showed 
similar results to the wild-type IGFBP-3 (Chan, Schedlich et al. 2009). IGFBP-3 binds 
directly to RXRα, causing regulation of PPARγ transcription by modulating RXRα 
PPARγ dimerisation. IGFBP-2 also has IGF independent nuclear binding interactions 
but the consequences of this have still not been defined (Miyako, Cobb et al. 2009). 
Table 1-2 summarises the major actions of IGFBPs in adipose tissue. 
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Table 1-2 Role of IGF binding proteins in adipose tissue regulation (Baxter and 
Twigg 2009) 
IGFBP                              Regulatory action References 
IGFBP-1 Inhibit IGF-I stimulated differentiation in 3T3-L1 
preadipocytes 
Inhibits IGF-I stimulated clonal expansion in 3T3-
L1 preadipocytes 
Impaired adipogenesis in IGFBP-1 transgenic mice 
(Nueda, García-Ramírez 
et al. 2008) 
(Siddals, Westwood et al. 
2002) 
 
(Rajkumar, Modric et al. 
1999) 
IGFBP-2 Moderate expression level in rat adipose tissue 




Winterhalter et al. 1994) 
(Wheatcroft, Kearney et 
al. 2007) 
IGFBP-3 Inhibited preadipocyte differentiation in 3T3-L1 
preadipocytes 
Reduced insulin stimulated glucose uptake in 3T3-
L1 adipocytes and human visceral adipose tissue 
Stimulated preadipocytes differentiation in 
preadipocytes from children 
 
(Chan, Schedlich et al. 
2009) 
(Chan, Twigg et al. 2005) 
 
(Grohmann, Sabin et al. 
2005) 
IGFBP-4 Moderate expression in rat adipose tissue 
Higher expression in visceral adipose tissue in 
comparison to subcutaneous tissue in fetal baboon 
preadipocytes 
(Gosteli-Peter, 
Winterhalter et al. 1994) 
(Tchoukalova, 
Nathanielsz et al. 2009) 
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IGFBP-5 Highly expressed in porcine adipose tissue 
Expression is reduced with differentiation 
(Hausman, Poulos et al. 
2006) 
(Gardan, Mourot et al. 
2008) 
IGFBP-6 No published data  
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1.6 IGF receptors  
1.6.1 The IGF-I (IGF-IR) and insulin receptor (IR) 
 
 
Figure 1-7 Structure of the IGF receptors (adapted from (Hawkes and Kar 2004))  
The structure of insulin, IGF-I, insulin/IGF-I hybrid and IGF-II/M6P receptors. IGF-I and 
insulin receptor are highly similar in structure and both belong to the tyrosine kinase receptor 
family. This cell surface hetero-tetramer receptor consists of two α and two β subunits 
connected by disulphide bonds. The IGF-I/IR hybrid receptor is composed of IGF-I α β and 
insulin α β hemi-molecules. IGF-II/M6P receptor is a transmembrane receptor composed of 
an amino-terminal signal sequence, large extra-cytoplasmic domain, a single transmembrane 
region and a cytoplasmic tail. 
 
Chapter 1: General introduction  
 30 
1.6.1.1 Receptor structure 
The IGF-I (IGF-IR) and IR receptors belong to the tyrosine kinase family of receptors 
and they share almost 84% structure similarity. These two cell membrane receptors 
are composed of a pair of α and β subunits connected by disulphide bonds (Siddle, 
Ursø et al. 2001). The α subunits are located extracellularly and contain the ligand 
binding sites, whereas the β subunits are transmembrane and have tyrosine kinase 
domains (Werner, Weinstein et al. 2008) as illustrated in Figure 1-7. What determines 
the physiological responses to specific- receptor activation is still being investigated 
but in general, the IGF-IR is thought to mediate mitogenic effects, with the IR 
mediating metabolic actions. Each receptor has higher affinity for their corresponding 
ligand but additionally, they also bind to the other ligand with lower affinity. IGF-II 
can bind to the IGF-IR (6-fold lower affinity than IGF-I) and to insulin receptors with 
different affinities depending upon the isoform of the insulin receptor present 
(Chisalita, Nitert et al. 2006, Werner, Weinstein et al. 2008). Studies also showed 
differences in intracellular receptor signalling, ligand dissociation rates and RTK 
domains that influence the signal outcome (Blakesley, Scrimgeour et al. 1996, 
Sasaoka, Ishiki et al. 1996, Dupont and LeRoith 2000, Kim and Accili 2002, Bouzakri, 
Zachrisson et al. 2006). The IR α subunit has two binding sites known as Site 1 and 
Site 2, when insulin binds, it activates the low affinity Site 1 on one α-subunit, then 
the high affinity Site 2 on the other α-subunit, binding to both sites are important for 
high affinity binding (Ward, Lawrence et al. 2007). For IGF-I only one α subunit 
binding site is required to bind the IGF-IR.  
Knockout of the IR in mice had no effect on birth size but caused a rapid loss of 
metabolic function in terms of hyperglycaemia, hyperinsulinemia and pancreatic β cell 
failure leading to metabolic ketoacidosis and death. In humans, mutations of the IR 
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results in severe growth retardation at birth and postnatal developmental delay 
(Wertheimer, Lu et al. 1993, Accili, Drago et al. 1996, Nakae, Kido et al. 2001). In 
mice loss of the IGF-IR, severely affects growth and causes multiple abnormalities, 
leading to death within minutes, which clearly illustrates the importance of these two 
receptors (Nakae, Kido et al. 2001). 
1.6.1.2 Receptor function  
Activation of the IGF-IR or IR is associated with phosphorylation of two different 
pathways. Ligand binding leads to initial autophosphorylation, causing multiple 
substrate molecules like IRS-1, 2 and src homology 2/collagen alpha proteins (SHC) 
to bind. This results in phosphatidylinositol 3-kinase (PI3K)-AKT/protein kinase B 
(PKB) activation, which is mainly responsible for metabolic activities (Myers, Backer 
et al. 1992), and the mitogen-activated protein kinase (MAPK) pathway, which is 
involved in regulating cellular growth, proliferation and differentiation (Pouysségur, 
Volmat et al. 2002). 
PI3K activation results in the conversion of PIP2 to PIP3, leading to the activation of 
AKT causing an increase in glucose uptake. Furthermore, activation of the pathway 
induces phosphorylation of 4EBP-1, leading to the release of eIF4E and promoting 
protein synthesis (Morita, Gravel et al. 2015). In addition, mTOR will lead to S6K 
phosphorylation, which also results in protein synthesis, and in addition activates anti-
apoptotic transcription factors leading to lower cellular apoptosis (Magnuson, Ekim et 
al. 2012). 
In contrast, the MAPK pathway is associated with SHC phosphorylation, and the 
formation of the GRB2 and SOS1 complex that activates Ras, MAP kinases, SRF and 
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ELK1 leading to mitogenic signalling and regulation of apoptosis (Siddle 2011). 
Figure 1-8 illustrates the signalling pathways of IGF-IR and IR. 
 
Figure 1-8 Insulin-like growth factor I (IGF-IR) and insulin (IR) receptor 
signalling pathways (adapted from (Pollak, Schernhammer et al. 2004)) 
Ligand attachment is associated with activation of two downstream pathways; PI3K pathway 
(left) which is involved in metabolic functions. MAPK pathway (right) which is involved in 
growth related functions.  
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1.6.2 Insulin-like growth factor-II/mannose 6-phosphate receptor (IGF-
IIR/M6P) 
1.6.2.1 Receptor structure  
In contrast to the structure of the IGF-I and IRs, the insulin-like growth factor-
II/mannose 6-phosphate (IGF-IIR/M6P) receptor is completely different. The IGF-
II/M6P receptor is a type I transmembrane glycoprotein with no intrinsic tyrosine 
kinase activity. The receptor protein structure consists of three domains; the N-
terminal extracellular region which is comprises 15 repeated segments of 147 amino 
acids, each segment has a cationic-dependent mannose-6-phosphate receptor, which 
resembles the M6P receptor in structure, but only the third and the ninth repeated 
segments have M6P binding sites. The IGF-II binding site-2 is located on the eleventh 
repeating segment (Figure 1-7). Interestingly, the IGF-II eleventh segment is close to 
the thirteenth segment, which has a fibronectin type II-like insert, that enhances IGF-
II binding to its binding segment (Marron-Terada, Hancock et al. 2000). Furthermore, 
the extracellular region in the repeating segments have cysteine residues that facilitate 
the formation of disulphide bonds required for receptor folding (Hille, Waheed et al. 
1990, Dahms and Hancock 2002). 
The second receptor domain is the single membrane spanning region and the last 
region is the cytoplasmic tail which possesses phosphorylation sites for multiple 
kinases, for example protein kinase C (PKC) and casein kinase I, II (MacDonald, 
Coussens et al. 1988, Körner, Nürnberg et al. 1995). The receptor is also present in 
the cytoplasm and can be recycled to the cell surface by multiple factors like IGF-I 
and insulin (Hawkes and Kar 2004).   
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1.6.2.2 Receptor function  
The IGF-II/M6P functions as an endocytosis facilitator for M6P-ligands to be 
activated or degraded in the lysosomes by the receptor’s ability to carry the newly 
formed lysosomal enzymes to the trans-Golgi network (TGN) to be placed at targeted 
organelles or moved extracellularly. 
The other well recognised function of IGF-II/M6P is to act as an IGF-II clearance 
receptor, which regulates the circulating levels of IGF-II (Rodríguez, Gaunt et al. 
2004). IGF-IIR/M6P  knockout in the mouse was associated with fetal over growth 
(Hébert 2006). Nevertheless, inhibition of the IGF-IIR/M6P  was not associated with 
a decrease in the growth promoting actions of IGF-II in cardiac cells (Hawkes and Kar 
2004), and the receptor was not involved in the mitogenic effects of IGF-I or IGF-II 
in fibroblasts (Furlanetto, Dicarlo et al. 1987). Yet, IGF-IR receptor suppression 
caused a reduction in IGF-I related signalling (Hébert 2006). The biological effects of 
IGF-II signalling through the IGF-II/M6P receptor is still unclear, mainly because of 
the absence of tyrosine kinase activity. 
The IGF-IIR/M6P is involved in cell proliferation and cell differentiation as other 
ligands have the capacity to bind this receptor. For example, transforming growth 
factor-β (TGF-β), which is known as an inhibitor of cell growth and differentiation in 
many cells (Hawkes and Kar 2004, Hébert 2006), inhibits differentiation of 
preadipocytes to mature adipocytes  (Sparks, Allen et al. 1992, Petruschke, Röhrig et 
al. 1994). Another IGF-IIR/M6P ligand is the cellular repressor of E1A-stimulated 
gene (CREG), which regulates differentiation and also acts as a repressor of cellular 
proliferation (Han, Guo et al. 2008). The CREG inhibitory effects were reported in 
smooth muscle cell growth in vitro (Han, Liu et al. 2005) and in NIH3T3 fibroblasts 
(Han, Guo et al. 2008).  
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1.7 Molecular basis of the role of IGF in adipogenesis  
Adipogenesis is a multi-levelled cascade involving multiple transcription factors. This 
process involves lineage commitment of mesenchymal stem cells, then preadipocyte 
expansion, followed by preadipocyte differentiation. Transcription factors C/EBP and 
PPARγ are important in initiating the signalling cascade to promote adipocyte 
differentiation: PPARγ initiates transcription by dimerising to RXR alpha (Rosen and 
MacDougald 2006). The process is further described in section 1.2.2. 
IGF-I is secreted by the liver, and also secreted locally by the adipose tissue. It acts as 
an important regulator of preadipocyte growth and has a stimulating effect on 
adipogenesis in vitro (Smith, Wise et al. 1988, Christoffersen, Tornqvist et al. 1998). 
In comparison to proliferating preadipocytes, differentiating preadipocytes have 
suppressed IGF-I induced MAPK activation via the MEK inhibitor, leading to 
adipogenesis stimulation in 3T3-L1cell lines (Boney, Gruppuso et al. 2000). IGF-I is 
also involved in the clonal expansion of 3T3-L1 (Siddals, Westwood et al. 2002). IRS-
1/2 signalling is important in adipogenesis as IRS-1/2 deficient fibroblasts have 
dysregulated PI3K signalling and this is associated with lower adipogenic expression 
of the differentiation markers PPARγ and C/EBP (Miki, Yamauchi et al. 2001). The 
importance of IGF-I in adipose tissue growth was also observed when a reduction in 
IGF-IR abundance was associated with multiple organ growth deficits, particularly for 
adipose tissue causing a reduction in preadipocyte proliferation (Holzenberger, 
Hamard et al. 2001). In addition, an AKT-knockout mouse model exhibited failed 
adipogenesis and dysregulation of the transcription factor PPAR (Peng, Xu et al. 
2003). Reports have also indicated that IGF-I can oppose the effect of Pref-1 which 
acts as a powerful suppressor of adipogenesis and is highly expressed in preadipocytes 
(Zhang, Nøhr et al. 2003). Taken together, this indicates that IGF-I is an important 
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regulator of adipogenesis, mainly mediated through activation of the IRS-
1/PI3K/AKT pathway. Dysregulation of this pathway is associated with pathogenesis 
and obesity (Maccario, Tassone et al. 2001, Gleeson, Lissett et al. 2005). The 
mechanism of IGF-I action in preadipocyte growth is illustrated in Figure 1-9.  
 
 
Figure 1-9 Illustration of the role of the IGF system in preadipocyte growth 
(adapted from (Kawai and Rosen 2010))  
IGFBPs regulates IGF-I availability to its cognate receptor, IGF-I activates PI3K pathway in 
adipogenesis. In addition, IGFBPs have IGF-independent actions; IGFBP-3 binds RXRα and 
regulates PPARγ transcriptional levels in adipocytes. IGF-I can also be locally secreted, acting 
in an autocrine/paracrine manner. 
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1.8 Insulin receptor isoforms 
 
1.8.1 Structure and function 
The insulin receptor was initially reported to have two sequences that differed by 12 
amino acids and more recently it was determined that this 12 amino acid difference 
was due to the alternative splicing of exon 11 leading to the formation of two IR 
isoforms, IR-B (11+) that included the 12 amino acid residue (residues 717-728) at 
the carboxyl end of IR α-subunit and IR-A (11-) that lacked the 12 amino acid residue, 
that enabled these isoforms to act differently in many functional and physiological 
aspects (Seino, Seino et al. 1989). Figure 1-10 illustrates the structural differences in 
the IR isoforms.  
 
Figure 1-10 Structure of insulin receptor alternative splicing (adapted from 
(Westermeier, Sáez et al. 2016)) 
The insulin receptor gene (INSR) consists of 22 exons and is found on chromosome 19. The 
exclusion or inclusion of exon 11 in the insulin receptor mRNA, in the insulin receptor-α 
subunit, leads to the formation of two insulin receptor isoforms IR-A and IR-B.  
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The two isoforms vary in their tissue distribution. IR-A is generally considered a fetal 
isoform and is highly expressed in fetal tissues like liver, kidney and muscles. IR-B is 
highly expressed in adult tissues, mainly in liver, and is linked to tissue differentiation 
(Mosthaf, Grako et al. 1990). IR-A is also expressed in adult tissues with IR-B in 
tissues like fat and muscles (Belfiore, Frasca et al. 2009).  
The alternative splicing also affects the receptor affinity for hormones; IR-A has 
higher affinity for insulin (1.7 fold) and IGF-II (10 fold) in comparison to IR-B, which 
has no affinity to IGF-II. In addition, IR-A is reported to have a higher internalisation 
rate in response to insulin, but IR-B has more efficient insulin signalling transmission 
(Vogt, Carrascosa et al. 1991, Kellerer, Lammers et al. 1992). Studies also indicate 
some differences in the signalling pathways used by these two isoforms. With 
pancreatic β cells, insulin promotes insulin production and β-glucokinase transcription 
through activation of the class I PI3-K pathway via IR-A. However, IR-B signalling 
occurs through the class II PI3-K pathway (Leibiger, Leibiger et al. 2001). IGF-II can 
induce different cellular outcomes depending upon the receptor that mediates its 
actions: in haematopoietic cells activation of IR-A by IGF-II protects the cells from 
apoptosis, whereas IGF-II activation of IR-B was more powerful in inducing cell 
differentiation (Sciacca, Prisco et al. 2003). Table 1-3 summaries the major differences 
in IR isoform structure and function.   
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Table 1-3 Summary of the major differences between insulin receptor isoform A and B 
IR-A IR-B References 
 
Predominant in fetal tissues 
and adult rat: pancreas, brain 
placenta and spleen 
 
Predominant in human 
adult tissues and in 
tissue targets of the 
metabolic effects of 
insulin 
 
(Moller, Yokota et al. 1989) 
 (Goldstein & Dudley, 1990) 
(Sugimoto et al., 2000), 
(Serrano, Villar et al. 2005), 
(Frasca, Pandini et al., 2008) 
 
High affinity to insulin and 
IGF-II with stronger affinity 
to IGF-II than insulin 
 
 
No affinity to IGF-II 
 
 
(Vogt et al., 1991), (Kellerer et 
al., 1995) 
Higher insulin internalisation 
rate 
More insulin signal 
efficiency 
 
Mitogenic, IR signalling 
from endosomes 
Metabolic, IR signalling 
from plasma membrane 
 
 
(Giudice, Leskow et al., 2011) 
Stimulates MAPK pathway 
and ERK1/2 phosphorylation 




Linked to cancer and insulin 
resistance 
 (Frasca et al., 1999b) (Sciacca 
et al., 1999) (Savkar et al., 
2001) 
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1.8.2 Insulin receptor isoforms in growth and metabolism  
Insulin receptor isoform expression varies developmentally and in a tissue-related 
manner. The change in receptor expression is important in the regulation of growth 
and tissue function. Preadipocytes express the IR and the IGF-IR, with an increasing 
expression of IR with differentiation. Interestingly, a study in BAT, where either IR 
or IGF-IR were knocked out, showed that each receptor has a distinct regulatory role 
in promoting adipogenesis and the regulation of associated signalling molecules (Bäck 
and Arnqvist 2009, Bäck, Brännmark et al. 2011). Furthermore, in a fat-specific IR 
and IGF-IR knock out (FIGIRKO) mouse model, both insulin and IGF-I were needed 
for WAT and BAT growth. The unique receptor distribution change with 
differentiation indicates that the IGF-IR is less important in adipocytes when they 
became more insulin dependent (Boucher, Mori et al. 2012). In support of this, 
knockout of the IR in mature adipocytes causes a reduction in adipose tissue and 
associated insulin resistance, whereas IGF-IR deletion had minimal effects on fat mass 
and on glucose uptake (Yakar, Kim et al. 2005), indicating the importance of insulin 
signalling in mature adipocytes (Sakaguchi, Fujisaka et al. 2017).  
Insulin receptor isoforms also change with differentiation, in mice brown adipocytes, 
the IR-B ratio increased with differentiation (Serrano, Villar et al. 2005); this pattern 
of isoform shift was also observed in hepatic cells HepG2 in vitro (Kosaki and Webster 
1993) and in vivo, where IR-B expression was increased by 35% from fetal to adult 
liver (Giddings and Carnaghi 1992). This alternative splicing phenomena and the shift 
in insulin receptor isoform expression is also observed in other tissues, like osteoblasts 
in which precursor cells express high levels of IR-A but express more IR-B on 
differentiation to mature osteoblasts (Avnet, Perut et al. 2012). Similar changes in 
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isoform expression have been observed in the mammary gland (Neville, Webb et al. 
2013) and in alveolar cells (Rowzee, Ludwig et al. 2009). 
This pattern of IR isoform shift could also indicate a distinctive functional role 
between these isoforms, the important role of these isoforms in the physiological 
regulation of tissue growth and differentiation. This is most likely through the ability 
to mediate different effects of insulin and IGF. Although some reports examined the 
IR isoform change with differentiation in adipose tissue, little is mentioned about fat-
depot differences in expression. This has mainly been reported in mouse models 
indicating a difference in isoform distribution (Serrano, Villar et al. 2005, Vienberg, 
Bouman et al. 2011), or similar amounts of IR-A and IR-B between adipose cells of 
different fat-depots (Vienberg, Bouman et al. 2011). Although humans have more 
distinct fat-depot differences than mice and fat distribution is more related to 
metabolic health risks, there are less reports indicating the receptor isoform expression 
and as far as we known no reports indicated fat depots differences in children. IR-A 
was expressed more in human fetal fibroblasts and IR-B was increased in adults 
adipocytes (Blanquart, Achi et al. 2008), others indicated higher IR-A levels in human 
fibroblasts and adipocytes (Moller, Yokota et al. 1989) . 
In metabolism, the higher expression and phosphorylation of IR-B in hepatic HepG2 
cells in comparison to IR-A indicates that IR-B might be more involved in metabolic 
regulation (Kosaki, Pillay et al. 1995). Liver specific insulin receptor knock out 
(LIRKO) mouse models in which IR-B predominates, show dysregulation of glucose 
and lipid metabolism through effects on glucose homeostasis, gluconeogenesis and 
lipid production. However, in specific IR-B but not IR-A knockout, IR-A was shown 
to compensate for IR-B actions in the liver (Diaz-Castroverde, Baos et al. 2016). The 
use of isoform insulin specific analogues showed that IR-B was more related to 
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glycogen regulation in liver and muscles, and lipogenesis in adipose tissue, whereas 
IR-A was more associated with glycogen synthesis in muscles (Vienberg, Bouman et 
al. 2011). Although overall studies indicate a more potent metabolic role of IR-B, the 
role of insulin receptor isoforms in human metabolism is still not clear. 
Interestingly, dysregulation of IR isoforms was noted in multiple diseases in relation 
to growth and metabolism. The altered insulin receptor ratio favouring increased 
expression of IR-A has been found in many cancers for example, breast, lung and 
colon (Frasca, Pandini et al. 1999, Sciacca, Costantino et al. 1999). Furthermore, 
changes in receptor isoform expression are associated with metabolic pathologies like 
diabetes, with IR-A expressed to a higher degree than IR-B in liver (Huang, Bodkin 
et al. 1996) and muscle tissue (Huang, Bodkin et al. 1994) of diabetic monkeys. 
However, human reports are inconsistent showing an increased expression of IR-B/IR-
A in fat and muscle from obese and diabetic patients (Sesti, D'Alfonso et al. 1995), 
higher IR-A/IR-B in muscle of diabetic patients (Norgren, Arner et al. 1994) and 
similar expression of the two isoforms in skeletal muscle (Benecke, Flier et al. 1992). 
In addition, myotonic dystrophy patients show a lower level of IR-B in muscle tissue 
and this was associated with impaired insulin responses (Savkur, Philips et al. 2001). 
These inconsistences in the reports of IR isoform expression in diabetes may be 
attributed to the complexity of the disease, hyperglycaemia, age, stage of the disease 
and genetic variation (Escribano, Beneit et al. 2017).  
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1. 9 General Hypothesis  
With a limited understanding of the postnatal role of IGF-II and the lack of data on 
children, this study aimed to investigate the physiological role of IGF-II by conducting 
a series of experiments using primary cultures of matched pairs of subcutaneous and 
visceral adipocytes from children to test the hypothesis that IGF-II is an important 
regulator of adipocyte physiology with specific effects on visceral adipocytes. It was 
hypothesised that the differential distribution of IR isoforms, particularly IR-A 
between visceral and subcutaneous adipocytes will allow IGF-II to have a profound 
effect of visceral cells leading to a fat-depot differences on adipose cell expansion and 
metabolism. 
 
1.10 Study aims and objectives 
• We aim to study fat-depot receptor distribution in children, by characterising 
the differences in IGF receptor (IGF-IR, IR, IR-A and IR-B) expression 
between subcutaneous and visceral preadipocytes, and differentiated 
adipocytes. 
• Investigate the effect of IGF-II on preadipocyte growth, by the assessment of 
proliferation and differentiation in a fat-depot specific manner. 
• Determine the differences in IGF-II regulation in subcutaneous and visceral 
cells by examining the roles of the IGF-IIR/M6P and IGFBP-3. 
• Evaluate the role of early IGF-II serum levels as a biomarker of body fat 
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2.1 Adipose tissue biopsy collection  
 
2.1.1 Ethical issues 
 
The study was approved by the NRES Committee South West – Exeter (REC 
reference: 14/SW/0109 on 3rd July 2014. An invitation to the study and a written 
information sheet were sent by post (along with the surgery admission letter) to all 
potential subjects. Parents/legal guardians were approached by Dr.Maiadah Alfares 
for a verbal explanation of the study on the morning of admission for surgery. Children 
aged over 5 years were also given a simple information sheet explaining the basics of 
the research. They were then left, for at least 60 minutes, to consider whether or not 
they wanted to participate. All of those recruited signed three written consent forms: 
one for the hospital records, one for the patient to keep, and one for the study files.  
Approval of the study, information sheets and the consent form are supplemented in 
Appendix (9.1-9.4).  
2.1.2 Subject recruitment 
 
Participants for this study were recruited from the paediatric urology surgical ward 
who were attending the Royal Hospital for Children (Bristol) for non-malignant and 
non-septic operations that require intra-abdominal access. All the recruited children 
were between 0 and 8 years old and operations such as elective pyeloplasties, 
nephrectomies and hemi-nephrectomies were best for providing paired subcutaneous 
and visceral adipose tissue samples. It was anticipated that most children recruited 
using this method would have a relatively ‘normal’ weight for age and sex. Our aim 
was to establish a cryopreserved bank of paired subcutaneous and visceral fat cultures 
from 20 subjects.  
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Exclusion criteria: Children undergoing surgery for any emergency and those in 
whom surgery did not necessitate intra-abdominal access as part of the procedure. 
Families who might not adequately understand verbal explanations or written 
information given in English were also excluded. 
Data collection: Prior to surgery the child had his or her height and weight measured 
as per routine and the following details were recorded: date of birth, date of operation, 
birth weight and gestation, gender, and ethnicity. 
2.1.3 Sample collection 
 
Fat tissue samples were collected by the Consultant Paediatric Surgeons in the Bristol 
Royal Hospital from children at the beginning of the operation. Two pea-sized pieces 
of subcutaneous and visceral fat biopsies (0.2–0.5g) were collected and transferred 
immediately to the laboratory in a solution composed of phosphate-buffered saline 
(PBS) and 20mg/ml bovine serum albumin (BSA). 




General sterile cell culture plastic was purchased from Greiner Bio-One 
(Gloucestershire, UK), serological pipettes were acquired from Corning Incorporated 
(Amsterdam, Netherlands), Pasteur pipettes were bought from Fisher Scientific 
(Loughborough, UK), syringes were from Terumo (Leuven, Belgium), and 0.2μM 
filters were from Appleton Woods (Birmingham, UK). Cryogenic vials were obtained 
from NUNC (Roskilde, Denmark) and the haemocytometer was from Hirschmann 
(8100104). The incubators were from SANYO (MCO-18AIC), hoods were from 
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BIOMAT (Class II, Medical Air Technology, Manchester, UK), and the centrifuge 
was from MSE (Centaur2).                
2.2.2  Tissue culture reagents  
 
All reagents were obtained from Sigma-Aldrich (Gillingham, UK) unless stated 
otherwise. 
• Penicillin/streptomycin – Penicillin (1x106 IU/vial) and streptomycin 
sulphate (1g/vial).They were stored at -20°C in 5ml aliquots (Lonza, 
Berkshire, UK). 
• L-glutamine – 14.6g of L-glutamine in 500ml sterile distilled water, filter-
sterilised and stored at -20°C in 5ml aliquots (Lonza, Berkshire, UK). 
• Phosphate-buffered saline (PBS) – PBS tablets (Oxoid Ltd., Basingstoke, 
UK) were used with one tablet/100ml of dH2O. The prepared solution was 
sterilised by autoclaving at 121°C for 15 minutes and then stored at room 
temperature. 
• Trypsin EDTA solution (TE) – 10x TE (Lonza, BE 02-007E, Berkshire, UK) 
was diluted with sterile ddH2O to make 1x. Then the solution was aliquoted 
into 5ml tubes and stored at -20°C. 
• Dimethylsulfoxide (DMSO) – Sigma D8779.  
• Trypan blue – Lonza, 17-942E, 0.4% (diluted to a working solution of 
0.165% with PBS).  
• Hank’s balanced salt solution (HBSS) – Gibco 14060-040 (Paisley, UK).  
• Type II collagenase – Sigma C6885. 
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• All plasticware used in the culture and differentiation of the human adipocytes 
was coated with 0.2% gelatine solution: 1g gelatine (Sigma G9391, 
Gillingham, UK) in 500ml distilled water and autoclaved. 
• Tissue culture medium used for the culture of primary human preadipocytes 
and a mouse 3T3-L1 fibroblast cell line are listed in Table 3.  
Table 2-1 Media components used for culture of primary human preadipocytes 
and 3T3-L1 fibroblast cell line (Green and Meuth 1974, Grohmann, Sabin et al. 
2005). 
Cell type Media components 
3T3-L1 growth media Dulbecco’s modified Eagle’s medium 
(DMEM) supplied with either normal 
(5mM, 1g/L) or high (25mM, 4.5g/L) 
glucose obtained from BioWhittaker 
(Verviers, Belgium), supplemented with 
4mM L-glutamine, 10% NCS (Gibco, 
Paisley, UK), 5000U/ml penicillin, and 
5000µg/ml streptomycin. 
3T3-L1 differentiation media Dulbecco’s modified Eagle’s medium 
(DMEM), 4.5g/l glucose or normal 
glucose (1g/L), 25mM HEPES, 
supplemented with 4mM L-glutamine, 
10% US certified FBS, 5000U/ml 
penicillin, and 5000 µg /ml streptomycin 
(Lonza, Berkshire, UK).  
Days 0–3: basic differentiation media + 
0.25µM dexamethasone (Sigma D8893), 
166nM insulin (Novo Nordisk, West 
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Sussex, UK), and 0.5nM IBMX (Sigma 
I5879).  
Days 3–5: basic differentiation media + 
166nM insulin. 
Days 5–7: basic differentiation media 
only.  
3T3-L1 preadipocyte serum-free 
media (SFM)  
 
DMEM supplemented with 
4mM L-glutamine, 5000U/ml penicillin, 
and 5000µg/ml streptomycin. 
Human preadipocyte growth media DMEM/Ham’s F12 with 15mM Hepes 
and 15mM NaHCO3 (Gibco 31330-
038), supplemented with 20% HiFBS, 
5000U/ml penicillin, 5000µg/ml 
streptomycin, and 1% L-glutamine 
(Lonza, Berkshire, UK). 
Basic preadipocyte differentiation 
media 
DMEM high glucose (4.5g/L) or normal 
glucose (1g/L) supplemented with 33μM 
biotin (Sigma B4639), 10μg/ml 
apotransferrin (Sigma T2036), 1μM 
dexamethasone (Sigma D8893), 0.2nM 
3,3,5.-triiodothyronine (Sigma T6397), 
17μM pantothenate (Sigma P5155), 
5000U/ml penicillin, and 5000µg/ml 
streptomycin, 1% L-glutamine, and 1% 
fungizone (Fisher Scientific 10658154, 
Paisley, UK).  
Days 0–3: basic differentiation media + 
100nM insulin + 25uM IBMX + 10uM 
Rosiglitazone (Sigma R2408). 
Days 3–10: basic differentiation media 
+ 100nM insulin.  
Days 10–14: basic differentiation media 
only. 
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Human preadipocyte serum-free 
media (SFM) 
DMEM/Ham’s F12 with 15mM Hepes 
and 15mM NaHCO3, supplemented 
with 5000U/ml penicillin, 5000µg/ml 
streptomycin and 1% L-glutamine. 
 
2.2.3 General cell culture techniques 
 
2.2.3.1  Cell passaging 
 
• Cells were washed with PBS before detaching the cells with trypsin (1ml/T75 
flask, 5ml/T175 flask). 
• Cells were incubated with trypsin for 5 minutes at 37°C. 
• Trypsin was deactivated by adding fresh growth media (5ml/T75 flask, 
10ml/T175), and the cell suspension was centrifuged at a relative centrifugal 
force (rcf) of 80g for 5 minutes to pellet the cells. 
• The supernatant was aspirated, and the cells were resuspended in 5ml of fresh 
growth media; this process represented an increase in the passage number of 
the cells by 1. Cells were then either counted for plating or seeded into other 
flasks for further growth.  
 
2.2.3.2  Cell counting (trypan blue dye exclusion assay): 
 
After trypsinisation, 50μl of cell suspension were mixed with an equal volume of 0.4% 
trypan blue solution (Lonza, 17-942E) that was loaded into both chambers of a clean 
haemocytometer with an adherent coverslip (Hirschmann, 8100104), as shown in 
Figure 2-1. Viable bright cells in the centre square were counted under a light 
microscope (dead cells will appear as dark blue). Viable cells in the centre square of 
Chapter 2: Material and methods 
 51 
the top and bottom grids were counted at a x10 magnification using an EMM single 
hand counter (Jencons, 670-032), which were added together and then multiplied by 
x104 to give the total number of cells per ml of cell suspension. 
 
 
Figure 2-1 Haemocytometer slide for cell counting. 
A haemocytometer with a glass coverslip showing the top and bottom counting grids (right) 
and a haemocytometer diagram indicating the area of counting under the microscope (left).   
 
2.2.3.3  Cryopreservation and resurrection 
 
2.2.3.3.1 Cryopreservation  
 
Cells were grown to 80–90% confluency in either T75 or T175 flasks, trypsinised, 
counted, and then centrifuged at 80g for 3 minutes. After removing the supernatant, 
cells were resuspended in the appropriate cell-specific media containing 10% DMSO 
at a concentration of either 5x105, 1x106 or 2x106 cells/ml, depending on the cell 
number.  1ml of cell mixture was put into each cryovial and appropriately labelled. 
The cryovials were then placed in a Mr. Frosty freezing container (Thermo Scientific) 
and stored at -80°C for 24 hours before being transferred to the liquid nitrogen storage 
tanks (Taylor-Wharton, LS48000). 
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2.2.3.3.2 Resurrection (thawing frozen cells) 
 
Cells were removed from liquid nitrogen and rapidly thawed to ensure maximum cell 
viability by swirling the vial in a 37°C water bath for 1 minute. Once thawed, 1ml of 
growth media was added dropwise to the vial and then the cell solution was transferred 
into a universal tube containing 4ml of growth media. This mixture was placed into a 
T175 or T75 containing 25ml or 10ml of growth media. Following 24 hours of 
incubation at 37°C, to allow the cells to attach, the media was replaced with fresh 
growth media to remove any traces of DMSO and dead cells. 
2.2.4 Culture and differentiation of 3T3-L1 fibroblast mouse cell line 
 
3T3-L1 cells are a continuous sub-strain of 3T3 (Swiss albino) cells developed by 
clonal isolation and they convert from fibroblast-like cells (preadipocytes) to 
adipocytes.  They were obtained from ATCC® CL-173™ and were grown to 70% 
confluency in a T75 flask.  For experimentation, cells were plated into a 24-well plate 
with a seeding density of 2x104 or into six-well plates at a seeding density of 8x104 
per well (according to the manufacturer’s instructions) and induced to differentiate 
over 7 days using a differentiation media described in Table 3.  
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2.2.5 Isolation and culture of primary subcutaneous and visceral 
preadipocytes 
 
The technique of preadipocyte isolation, culture and differentiation was developed 
within our laboratory and fully characterised by Dr. M. Grohmann (Grohmann, Sabin 
et al. 2005). The isolation of subcutaneous and visceral preadipose cells (Figure 2-2) 
was performed using an adapted method of Hauner et al. (Hauner, Entenmann et al. 
1989) as follows:  
• The adipose tissue was washed three times in 10ml of Hank's balanced salt 
solution (HBSS) and then was cut into 1mm3 pieces. 
• Tissue was digested with 10ml of 1mg/ml type II collagenase in HBSS for 
60 minutes at 37°C in a shaking water bath (150 cycles/min). 
• Adipocytes were separated from the stromal vascular cells through 
centrifugation at 100g for 3 minutes. 
• The pellet of sedimented preadipocytes (typically <1000 cells) was 
resuspended in preadipocyte growth media and seeded onto a T75 coated 
with 0.2% gelatine and maintained at 37°C in a humidified atmosphere of 
5% CO2.  
• Media was changed every 72 hours until confluency was obtained (7–14 
days) and then cells were passaged into three T175 flasks. Upon confluency, 
50% of the cells were frozen and the remainder were used for the 
experiment.  
For differentiation, subcutaneous and visceral preadipocytes were seeded in six-well 
plates and after 16 hours they were induced to differentiate for 14 days using the 
preadipocyte differentiation medium described in Table 3. The experimentation 
Chapter 2: Material and methods 
 54 
seeding densities were 0.017x106 for the 24-well plate and 0.2x106 for the six-well 
plate. To maintain consistency, experiments were performed using cell passages 3–5.  
 
 
Figure 2-2 Preparation of subcutaneous and visceral fat samples obtained from 
children.  
Collected visceral and subcutaneous fat samples were washed, dissected into small pieces and 
digested in type II collagenase at 37°C. The stromal vascular cells were then filtered, 
centrifuged, and the sedimented preadipocytes were resuspended in growth media and 
cultured.  
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Oil-soluble dyes help to stain lipids by being more soluble in natural fats than in the 
solvent in which they are dissolved. The oil-soluble dyes are strongly coloured and 
not soluble in water. 
2.3.2 Procedure 
 
Oil Red O (ORO) was used to evaluate the level of preadipocyte differentiation, and 
ORO stain stock was made up by dissolving 0.25g Oil Red O stain powder (Sigma 
O0625) in 50ml of isopropanol which had been stored for up to 6 weeks in the dark. 
A working solution of ORO was made by adding 10ml of ORO stock solution to 
6.67ml of distilled water; this solution was then mixed and left for 10 minutes before 
being syringe-filtered to remove any large residual particles. The working solution had 
a shelf life of 2 hours and was made up fresh before use. Fully differentiated cells were 
washed twice in PBS before being fixed in 10% formalin for 10 minutes. Cells were 
then stained with the ORO working solution for 10 minutes. The stain was then 
removed, and the cells were washed a further two times with 60% isopropanol for 10 
seconds per wash to eliminate any excess stain. The cells were then washed with 
distilled water and viewed using light microscopy.  
Following the image capture, the level of staining was quantified by leaching the stain 
with 100% isopropanol (1ml/well) followed by spectrophotometry (FLUOstar 
Optima, BMG LABTECH) at 490nm.  
  
Chapter 2: Material and methods 
 56 
2.4 Western immunoblotting  
 
2.4.1 Protein extraction from cells 
 
Following trypsin cell detachment from the culture flasks, cells were centrifuged, and 
the desired cell pellets were obtained as described in Section 2.2.3.1. Lysis buffer was 
used to release the proteins of interest. It was made with the following reagents: 10mM 
Tris HCL, 50mM sodium chloride, 5mM EDTA, 15mM sodium pyrophosphate, 
50mM sodium fluoride, 1% Triton X-100, and 100µM sodium orthovanadate, and was 
adjusted to pH 7.6 and stored at 4°C. 10µl/ml of the protease inhibitor cocktail (Sigma 
P8340) and 10µl/ml of the phosphatase inhibitor cocktail (Sigma P5726) were added 
fresh to the lysis buffer before it was used.  The lysis buffer mixture was made up to 
an appropriate volume and added to the cell pellet in an Eppendorf, resuspended and 
incubated on ice for 5–10 minutes. The cells were centrifuged at 80g for 5 minutes at 
4°C and the cell extract was moved to a pre-cooled microcentrifuge tube and stored at 
-20°C for later use. 
2.4.2 Protein concentration estimation  
 
2.4.2.1  Principle  
 
The total protein concentration within cell lysates was measured using a 
bicinchoninic acid assay (BCA) colorimetric reaction. The importance of this is in 
standardising the concentration of proteins between samples when loading to gels 
for western blot analysis. The principle of this assay is that protein peptide bonds 
cause a reduction in Cu2+ to a Cu1+ cuprous ion. Then the two bicinchoninic acid 
molecules chelate with the Cu1+ ion in an alkaline solution, leading to the formation 
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of a purple-coloured complex that can absorb light at a 540nm wavelength. The 
principle of the BCA assay is illustrated in Figure 2-3. 
 
Figure 2-3 Principle of bicinchoninic acid assay (BCA). Adapted from (Smith, Krohn 
et al. 1985). 
The proteins will induce a reduction of Cu2+ to a Cu1+ ion, and then the BCA will chelate with 
the Cu1+ in an alkaline environment, leading to the production of a purple-coloured complex. 
Absorbance will be measured by a spectrometer.  
 
2.4.2.2  Equipment 
 
• Plate reader (FLUOstar Optima, BMG LABTECH). 
2.4.2.3  Reagents 
 
• Bicinchoninic acid (BCA) Protein Assay Kit (Pierce, Rockford, IL) containing:  
1) BCA Reagent A: Sodium carbonate, sodium bicarbonate, bicinchoninic acid and 
sodium tartrate in 0.1M sodium hydroxide. 
2) BCA Reagent B: 4% cupric sulphate. 
• Albumin standard ampules, 2mg/ml, containing bovine serum albumin (BSA) 
(Fisher Scientific #BP9701-100, UK) at 2.0mg/ml in 0.9% saline and 0.05% 
sodium azide. 
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2.4.2.4  Procedure 
 
Table 2-2 Protein standard concentration range. 
Vial Standard 
concentration 
BSA (l) Lysis 
buffer 
A 2000μg/ml 300μl of stock 0 
B 1500μg/ml 375μl of stock 125 
C 1000μg/ml 325μl of stock 325 
D 750μg/ml 175μl of vial B 175 
E 500μg/ml 325μl of vial C 325 
F 250μg/ml 325μl of vial E 325 
G 125μg/ml 325μl of vial F 325 
H 25μg/ml 100μl of vial G 400 
 
Protein standards were prepared by diluting a stock of 2mg/ml BSA solution with 
the same lysis buffer used to lyse the cells; the concentration range (0.025–2.0mg/ml) 
preparation is listed in Table 2-2. These were stored at -20°C until required. Before 
protein estimation, lysates were centrifuged at 14,000g for 5 minutes. 5μl of each 
standard was loaded into a 96-well plate in duplication, followed by a blank (5μl 
lysis buffer) in duplication and 5μl of each lysate in duplication. The plate layout is 
represented in Figure 2-4. BCA Protein Assay Reagents A and B were then mixed at 
a ratio of 50:1 and 200μl was added into each well. The samples were then incubated 
at room temperature for 30 minutes prior to spectrophotometric determination of 
colour change at 540nm using the MARS software package (BMG LABTECH). 
Protein concentrations were determined from the generated standard curve and the 
mean of the two values was used. 
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Figure 2-4 Layout of the 96-well plate used for protein concentration estimation 
assay.  
Protein standards were loaded from low to high concentrations, followed by a blank (lysis 
buffer) and the unknown protein samples. All were added in duplicates.  
 
2.4.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
 
2.4.3.1  Principle 
 
SDS-PAGE is mainly used to separate complex protein mixtures according to size. 
Sodium dodecyl sulphate (SDS) is a detergent that solubilises hydrophobic molecules, 
and also carries a negative charge; thus, any cells that are incubated with SDS will be 
liberated of proteins because the membranes will be dissolved. The solubilised 
proteins are covered with negative charges and will migrate towards the positive 
electrode when placed in an electric field. 
Specific percentages of acrylamide in the gel can be used depending on the size of the 
protein and the degrees of separation needed. Correct polymerisation of the gel is 
essential, as it forms a cross-linked polymer matrix which is used to support and 
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separate the molecules. The polymerisation catalysts incorporated into the gel are 
ammonium persulphate (APS) and N,N,N',N tetramethylethylenediamine (TEMED), 
the latter of which triggers the formation of persulphate free radicals from the APS 
which initiate the acrylamide polymerisation.  
2.4.3.2  Equipment  
 
• The Mini-PROTEAN Tetra cell system (including glass plates, combs, clamps, 
gel tank with lid and buffer dam, casting base and frames, and sample loading 
guides) (Bio-Rad 165-8000).  
• Power pack (Pharmacia, LK-BS5 500/400). 
 
 
Figure 2-5 Western blot SDS-PAGE gel running equipment. Picture obtained from   
www.bio-rad.com. 
The running system helps to separate proteins according to the molecular size. The electrical 
current will run through the buffer and this will force the negatively charged protein molecules 
to run towards the positive anode. 
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2.4.3.3  Reagents 
 
Table 2-3 Western blotting reagents. 
Reagent Description 
 
40% Acrylamide Gel Solution Bis-
Acrylamide (Geneflow #A2-0075, UK) 
 
Ratio of 37.5:1 and stored at 4°C. 
 
(1.5M pH 8.8) Tris Base (Thermo Fisher 
Scientific #BP152-1, UK) 
18.16g of Tris base was added into 70ml 
dH2O. Then the pH was adjusted to 8.9 
before the solution was made up to 100ml 
and stored at 4°C. 
 
(0.5M pH 6.8) Tris Base (Thermo Fisher 
Chemicals #1185-53-1, UK) 
17.33g of Tris base was added into 70ml 
dH2O. Then pH was adjusted to 6.8 before 
the solution was made up to 100ml and 
stored at 4°C. 
 
10% SDS (Fisher Scientific #BP166-
500, UK) 
50g was aliquoted into 400ml of gentle 
warmed dH2O. The pH was adjusted to 7.2 
before the solution was made up to 500ml 
and stored at room temperature. 
 
10% APS (Sigma-Aldrich #A6761, UK) 
1g was added into 10ml of ddH2O and 
stored at 4°C. The solution needed to be 
used within 3–4 months. 
TEMED (Fisher Scientific #T/P190/04, 
UK) 
Stored at room temperature. 
Butanol (Fisher Scientific, UK) Made up at a 1:1 ratio with dH2O. 
 10x Tris-buffered saline TWEEN 20 
[TBS-T]  
12.1g Tris base, 40g NaCl (Fisher Scientific 
#S/3120/65) and 5ml TWEEN 20 (Sigma-
Aldrich #P2287, UK) dissolved in 500ml 
dH2O. The solution was calibrated with HCl 
and NaOH for a pH value of 7.6. 
1x TBS-T 100ml 10x TBST diluted in 900ml dH2O. 
3% BSA (Fisher Scientific #BP9701-
100, UK) 
1.5g BSA dissolved in 1x TBS-T. 
5% BSA 2.5g BSA dissolved in 1x TBS-T. 
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5% milk (powder, non-fat dry milk) 2.5g milk (Sainsbury's) dissolved in 1x 
TBST. 
2x Laemmli sample buffer 4% SDS, 20% glycerol, 10% 2-
mercaptoethanol, 0.004% bromophenol 
blue, and 0.125M Tris HCl; pH 6.8. 
 
2.4.3.4  Procedure  
 
The resolving and stacking gels were made according to Table 2-4. The resolving 
gel portions are poured between glass plates 1.5mm apart and allowed to polymerise 
under a layer of butanol, which ensures a smooth interface whilst speeding up the 
polymerisation process. Once the gel has set, the butanol overlay is poured off and 
the gel is washed with dH2O before pouring the stacking gel and inserting a 10-well 
comb. After the stacking gel has polymerised, the combs are removed and the gels 
are transferred to the running apparatus. The chambers and tank are filled with 
running buffer prior to loading with the samples. 
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Table 2-4 SDS-PAGE gel preparation. 













10.6ml 9.6ml 8.6ml 6ml 
40% acrylamide  4ml 5ml 6ml 1.25ml 
Tris buffer 5ml (1.5M pH 
8.8) 
5ml (1.5M pH 
8.8) 






200μl 200μl 200μl 100μl 
10% APS 
  
200μl 200μl 200μl 100μl 
TEMED 
  
20μl 20μl 20μl 15μl 
     
• 10x running buffer: was made using Tris base 30.3g (BP152-1 Fisher Scientific, 
UK), glycine 144g (BP381-5 5kg Fisher Scientific), SDS 10g, and dH2O, which 
was made up to 1 litre and then 1x running buffer was prepared by taking 100ml 
of 10x running buffer and adding it into 900ml of dH2O. 
2.4.3.5  Sample preparation  
 
Samples were spun at 12,000g for 10 minutes at 4°C to allow any fat to solidify and 
be removed. Correct volumes according to protein concentration were aliquoted into 
Eppendorfs with an equal volume of 2x Laemmli sample buffer (Sigma Life Sciences, 
S3401-1VL) containing anionic detergent (SDS), glycerol to increase the sample 
density and bromophenol blue dye to enable visualisation. Samples were heated to 
100°C using an AccuBlock™ Digital Dry Bath (Labnet International) and a heating 
block for 5 minutes to denature the proteins before loading onto the gel.  
2.4.3.6  Electrophoretic separation 
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The gel was run by limited volts (125–200V) according to the number of gels in the 
tank and for 45–90 minutes based on the separation required and protein size.  




• Mini Trans-Blot electrophoretic cell (Bio-Rad 170-3930).   
• Supported nitrocellulose membrane (Amersham, RPN119B). 
• Thick paper (Bio-Rad 1703967). 
• Power pack (Pharmacia, LK-BPS 500/400). 
 
Figure 2-6 Mini Trans-Blot electrophoretic cell compartments. Picture obtained 
from www.bio-rad.com. 
The transfer system is essential in promoting the migration of the proteins from the SDS-
PAGE gel to the nitrocellulose membrane, which is facilitated by the electrical current run 
which moves the proteins towards the positive electrode. The cooling unit is needed to help 
prevent overheating. 
 
10x transfer buffer: Tris base 30.3g and glycine 144g were dissolved in dH2O to 
make up to 1 litre. Then 1x transfer buffer was prepared by taking 100ml of 10x 
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transfer buffer and adding 200ml of methanol (Fisher Scientific, M/3950/17, UK) and 
700ml of dH2O. 
2.4.3.7.2 Procedure 
 
• Gels were removed from the running tank and soaked in 1x transfer buffer along 
with the nitrocellulose membrane, sponges and the thick paper for 10 minutes.  
• A transfer sandwich was made with the following layout:  
On the black side of the cassette: sponge – thick paper – gel – membrane – thick paper 
– sponge (as illustrated in Figure 2-6). 
 
Figure 2-7 Layout of the western blotting transfer sandwich.  
The sandwich is arranged by the demonstrated order, which allowed proteins to transfer from 
the SDS-PAGE gel to the supported nitrocellulose membrane.  




• The sandwich was placed in the transfer tank, filled with 1x transfer buffer and 
was run by limited volts (90V) for 90 minutes. 
 
2.4.3.8  Blocking  
 
Blocking to prevent non-specific binding is achieved by incubating the membrane in 
a dilute solution of protein (typically 5% or 3% BSA or 5% non-fat dried milk in Tris-
buffered saline TWEEN 20 [TBS-T]) for 1 hour at room temperature with gentle 
agitation. The protein from the solution then attaches to the membrane at all sites 
where the target proteins have not attached, so when the antibody is added the only 
places for it to attach to are the binding sites of the target protein. This helps to 
minimise background to ensure clearer results.  
2.4.3.9  Primary antibody 
 
After blocking, the membrane was probed with a primary antibody that was diluted in 
TBS-T containing 5% BSA, 3% BSA or 5% milk (according to the manufacturer’s 
specification) and incubated overnight at 4°C. The properties of the antibodies used 
are listed in Table 2-5.
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(D3V8C) 5% milk 1:1000 αR 1:2000 275 
IGFBP-3 
Santa Cruz 
(sc-6003) 5% milk 1:1000 αG 1:2000 42–44 
β-Actin 
Sigma 




(MAB374) 5% milk 1:5000 αM 1:5000 35 
Abbreviations: αM: anti-mouse antibody, αR: anti-rabbit antibody, αG: anti-goat antibody. 
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2.4.3.10 Secondary antibody 
 
After washing in TBS-T for three 5-minute periods, the membrane was incubated with 
the corresponding secondary antibody (Table 2-5), which is a diluted horseradish 
peroxidase-conjugated (HRP) directed against the species in which the primary 
antibody was raised, for 60 minutes at room temperature. Then the washing steps were 
carried out again.  
2.4.3.11 ECL detection  
 
Following antibody incubation, the blots were washed three times for 5 minutes each 
at room temperature with TBST before the bands were visualised by SuperSignal 
West-Dura (Pierce, Rockford, IL) or Femto (Pierce, Rockford, IL)  and incubated for 
5 minutes with constant pipetting over the membrane and were visualised using the 
ChemiDoc XRS+ system and Image Lab software (170-8265, Bio-Rad, CA). Western 
blots were quantified using Image J 1.46r software (National Institutes of Health, 
Bethesda, MD) after scanning.  
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There are multiple techniques with which to assess the level of cell proliferation and 
one of the most reliable and sensitive is that of directly measuring DNA synthesis. For 
that reason, we used a tritiated thymidine incorporation assay (TTI) to examine the 
rates of proliferation in primary human preadipocytes. In this assay a radioactive 
nucleoside, 3H-thymidine, is combined into new strands of chromosomal DNA during 
mitotic cell division. A scintillation beta counter is used to measure the radioactivity 
in DNA recovered from the cells in order to determine the extent of cell division that 
has occurred in response to a test agent (Kaplan, Bott et al. 1992). 
2.5.2 Equipment 
 
• β-Scintillation Counter (Tri-Carb 2900TR, PerkinElmer Precisely, USA). 
• Scintillation vials (Pony Vials, PerkinElmer, USA). 
• Plate Rocker Platform (Bellco Biotech, NJ, USA). 
2.5.3 Reagents 
 
Table 2-6 Tritiated thymidine incorporation assay reagents. 
Reagent Description 
[3H]-thymidine (GE, Healthcare) 0.004µCi/ml stock (3μl of 3H-thymidine in 
750μl SFM).  
Trichloroacetic acid solution (TCA) (Merck 
Ltd, Middlesex, UK)  
5% TCA; 5g of TCA was added into 100ml 
ddH2O and stored at 4°C. 
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1M sodium hydroxide solution (NaOH, 
S/4880/60, Fisher Scientific Ltd., 
Leicestershire, UK) 
20g of NaOH was dissolved into 500ml 
ddH2O and stored at room temperature.  
Scintillation fluid Ultima Gold, 6013329, Packard Bioscience 
Ltd. 
 
2.5.4 Protocol  
 
Cells were seeded onto 24-well plates in growth media and allowed to attach for 24 
hours. Complete media was replaced with SFM for 24 hours. On the following day, 
cells were dosed with (7.81,15.62,31.25,62.5,125,250,500 ng/ml) of recombinant 
human IGF-I, IGF-II peptide (GroPep, Adelaide, Australia) or insulin (Novo Nordisk, 
West Sussex, UK). After 48 hours (as required), 0.004µCi of [3H]-thymidine (25μl per 
well) was added for the last 4 hours at 37oC, 5% CO2. Media was removed and cells 
were incubated with 500µl 5% trichloroacetic acid (TCA) at 4oC for 10 minutes. The 
TCA was removed and the cells were lysed in 500µl of 1M sodium hydroxide for 1 
hour at room temperature on a plate rocker. The incorporation of [3H]-thymidine into 
DNA was determined by scintillation counting; the sample (300µl) was mixed with 
2ml of scintillation fluid and counted on a β-Scintillation Counter using 
QuantaSmartTM software. Data were recorded as disintegration per minute (DPM). 
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The technique is dependent on primer-based enzymatic amplification of a targeted 
DNA sequence. The importance of this technique is in allowing a small DNA sample 
to be amplified into millions of copies complementary to the template strand. The 
steps of DNA generation are illustrated in Figure 2-8. 
 
Figure 2-8 Quantitative polymerase chain reaction principle, indicating the 
processes of DNA amplification. Picture adapted from www.laboratoryinfo.com. 
The DNA amplification is started by heat denaturing DNA to single strands, followed by 
primers annealing to their complementary sequence in the template DNA. Then, elongation 
will occur by DNA polymerase, which adds bases to the 3’ end of each primer, allowing 
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elongation in the 5’ to 3’ direction. One cycle will produce two separated pieces of double-
stranded DNA, which will be further amplified in the following cycle.   
 
2.6.2 RNA extraction 
 
Cultured cells were washed with PBS twice and then 1ml of Trizol (Invitrogen, 
Auckland, New Zealand) per six-well plate was added whilst pipetting up and down 
repeatedly. The homogenised lysates were moved to an RNase-free 1.7ml Eppendorf 
tube and incubated for 5–7 minutes at room temperature to ensure complete 
dissociation of nucleoprotein complexes. Then, 0.2ml of chloroform (Fisher 
Scientific, 10293850) was added to each Eppendorf. Samples were then shaken 
vigorously for 15 seconds and incubated for 10 minutes at room temperature. 
Following centrifugation with a relative centrifugal force of 12,000g (PrismR, Labnet 
International) for 15 minutes at 4oC, the upper colourless aqueous layer containing the 
RNA was transferred to new Eppendorfs (DNA and protein were left behind in the 
interphase and organic phases respectively). Then, 0.5ml of isopropanol (Fisher 
Scientific, 10284200) was added into the Eppendorf and incubated at room 
temperature for 10 minutes. The samples were centrifuged at 12,000g for 10 minutes 
at 4oC. The supernatant was removed carefully and the RNA pellet was washed with 
70% ethanol (Fisher Scientific, 10437341) and air-dried shortly before dissolving in 
around 10–12µl of RNase-free water (Thermo Scientific, SH30538.01). 
2.6.3 RNA quantification 
 
RNA was quantified using a NanoPhotometer (Implen, Munich, Germany). The 
LabelGuard Microliter Cell was inserted into the cell holder and the nucleic acid 
measurement option was selected in the Nanovolume application; the system was 
calibrated first through the use of 1μl RNase-free water applied into the centre of the 
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Microliter Cell. This was followed by 1μl sample quantification. The ratio of 
absorbance at 260 to 280 reflects the purification of the RNA sample. Good-quality 
RNA is indicated by a 260:280 ratio of between 1.8 and 2.0. 
2.6.4 RNA purification 
  
Extracted RNA was treated with deoxyribonuclease I (DNase I) to eliminate any 
genomic DNA contamination. This was carried out by using a DNase I Kit (Thermo 
Fisher Scientific, 18047019) according to the manufacturer’s instructions. Briefly, the 
RNA sample in 8µl of DNase-free water was mixed with 2µl of the master mix, which 
was formed by adding 1µl of 10x reaction buffer and 1µl of DNase (volume/reaction), 
and incubated at room temperature for 15 minutes, which was followed by the addition 
of 1µl DNase stop solution to each sample. The samples were incubated for 10 minutes 
at 70oC and then placed on ice in preparation for the next reverse transcription step.  
2.6.5 Reverse transcription  
 
The cDNA was generated by using the high-capacity RNA-to-cDNA Kit (Applied 
Biosystems, P/N 4387406). On ice, 1µl of RNA in 9µl DNase/RNase-free water was 
prepared and mixed with 11µl of the master mix generated using the ingredients listed 
in Table 2-7. The mixtures were placed into the PTC-200 Peltier Thermal Cycler (MJ 
Research, Waltham, MA) along with a negative control (RNA treated as indicated but 
with no addition of the reverse transcriptase buffer). The program was set to incubate 
the samples at 37°C for 1 hour and then heat up to 95°C and cool down to 4°C, being 
maintained indefinitely. This allows the reaction to stop. Generated cDNA was stored 
at -20°C for future use.  
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Table 2-7 RNA-to-cDNA Kit reverse transcription master mix ingredients.  
Ingredients Volume/reaction (µl) 
2x reverse transcriptase buffer 
(includes dNTPs, random octamers, and 
Oligo dT-16) 
10 
20x reverse transcriptase enzyme 




2.6.6 Quantitative PCR (qPCR) 
 
qPCR depends on the detection of PCR products made by reactions with a fluorescent 
molecule that reports an increase in the amount of DNA with a proportional increase 
in the fluorescent signal. With the use of SYBR Green Jumpstart™ Taq Readymix™ 
(Sigma, S4438) a master mix was prepared using the components listed in Table 2-8. 
The mix was created in PCR tubes (Alpha Laboratories, LW2340) in which 2µl of 
cDNA was mixed with 10µl of the master mix. The mixture was vortexed and then 
loaded into a 96-well plate in duplicates. In addition, water and cDNA (without the 
reverse transcriptase enzyme) negative controls were added to rule out possible 
contamination.  
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Table 2-8 qPCR condition. 






95oC   10 minutes       40 times 
95oC   15 seconds        
                                   
60oC   1 minute     
 
Melt curve: A melt curve at 
every 0.3oC from 60 to 95oC was 
measured for each experiment to 




SYBR Green JumpStart 
Taq ReadyMix (Sigma) 
(20mM Tris-HCL, pH 8.3, 
100mM KCL, 7mM MgCl2, 
0.4mM each dNTP (dATP, 
dCTP, dGTP, TTP), 
stabilisers, 0.05 units/µl Taq 
DNA polymerase, JumpStart 
Taq antibody, and SYBR 
Green I) 
5 
Internal reference dye 0.1 
Forward primer pairs 
(10µM) 
1 (1µM) 





An optically clear sealing sticker (Sarstedt, 95.1994) was used to seal the 96-well plate 
before it was quickly centrifuged using a plate spinner (MPS 1000 Mini PCR Plate 
Spinner) to ensure the movement of the added mixture to the bottom of the wells.  The 
plate was inserted into the ABI StepOne Plus Real-Time PCR System (Applied 
Biosystems, 4376600) and the program for the thermal cycles was set as indicated in 
Table 2-8.  The relative mRNA levels against the reference gene were calculated as 
2−ΔCt, as previously described in (Kondaveeti, Reed et al. 2015). The primer pairs were 
purchased from Thermo Scientific, and GAPDH was used as a reference gene. Table 
2-9 indicates the sequence of the forward and reverse primers used.   
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Primer sequence (5’-3’) 
(Forward and Reverse) 
IGF-IR 
Target 86.78 130 F: AGCCGATGTGTGAGAAGACC 
R: TGGCAGCACTCATTGTTCTC 
IR-A 
Target 85.15 120 F: TTCGGCCGGCGAATGCTGCT 
R: CCGAGTGGCCTGGGGACGA 
IR-B 
Target 87.70 122 F: AAAACCTCTTCAGGCACTGG 
R: GAGGAAGTGTTGGGGAAAGC 
IR 
Target 83.96 154 F: TGACAACGACCAGTGTGGAG 
R: GCAGCCGTGTGACTTACAGA 
PPARγ 
Target 81 143 F: GGTGGCCATCCGCATCT 
R: TGCTTTTGGCATACTCTGTGATCT 
Adiponectin 
Target 86 200 F: TCAGCATTCAGTGTGGGATTG 
R: GGTAAAGCGAATGGGCATGT 
GLUT-4 
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2.7 Glucose uptake assay 
 
2.7.1 Principle  
 
Cellular metabolic activity and glucose uptake can be measured in cultured cells 
through the use of radiolabelled glucose analogue 2-deoxyglucose (2DG). When the 
2DG is transferred into the cells it is phosphorylated by hexokinase (HK) to 2-
deoxyglucose 6-phosphate (DG6P), which is a stable metabolite that is trapped and 
accumulated inside of the cell (Yamamoto, Ueda et al. 2011). 
2.7.2 Buffers/reagents 
 
10× calcium-free KREBS salts stock 500ml 
1.36M NaCl 39.7g 
47mM KCl 1.75g 
125mM MgSO4.6H2O 12.7g 
 
2× sodium phosphate buffer stock (stored in fridge) 
10mM NaH2PO4 0.78g in 500ml 
10mM Na2HPO4 0.71g in 500ml 
Add 387ml of Na2HPO4 to 113ml NaH2PO4 (will give a pH of 7.4, total of 500ml solution)  
 
50mM glucose: 0.180 of glucose in 10ml water 
 
125mM CaCl2 (fresh): 0.28g in 20ml H2O 
 
200mM NaHCO3 (fresh): 0.168g in 10ml H2O 
 
25mM HEPES: Dissolve 1M stock solution 1 in 40 with sterile water.  
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Krebs–Ringer phosphate (KRP) buffer 
solution  
25ml 
10× Ca-free KREBS stock 2.5ml  
125mM CaCl2 (fresh) 0.25ml 
2× sodium phosphate stock 12.5ml 
200mM NaHCO3 stock 0.25ml 
HEPES 25mM 0.625ml  
(adjust pH to 7.4 to make up to 25ml) 
 
Radiolabelled glucose (for 1ml in KRP buffer) 1ml 
50mM glucose  10µl 
Tritiated 2 deoxyglucose (Amersham Pharmacia 
Biotech, Little Chalfont, UK) 
5µCi 




Cells were washed three times with PBS (room temperature), and then 900µl of 
glucose-free KRP buffer was added to each well and incubated for 15 minutes at 37oC. 
Following this incubation, the plate was transferred into a 37oC water bath so that the 
bases of the wells were submerged. The assay can be performed at room temperature, 
but the changes in glucose uptake observed will be much smaller and slower to occur. 
After 15 minutes’ incubation with KRP buffer, the stimulus was added (e.g. 100nM 
insulin). Then, 100µl of radiolabelled 2-deoxyglucose (0.5µCi per well) was added to 
each well for 10 minutes. 
Glucose transport was terminated by transferring the plate, removing the KRP buffer 
and washing the cells gently with ice-cold PBS. The cells were solubilised in 0.5ml 
1% Triton X 100/PBS. Each solubilised cell suspension was mixed with 2ml of 
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scintillation fluid and counted on a β-Scintillation Counter (Beckman, High 
Wycombe, UK). Data were recorded as disintegrations per minute (DPM). Basal 
glucose uptake was measured without insulin or IGF-II stimulation. 
 
2.8 Radioimmunoassay (RIA) 
 
2.8.1 Principle   
 
This competition assay uses radioactively-labelled peptide for detection. It measures 
radioactivity associated with immune complexes. Ligand in the samples (i.e. IGF-II) 
competes with iodinated tracer (IGF-II antigen) for binding to the antibody (anti-IGF-
II). After excess tracer was washed away, γ-radiation emitted from the tracer bound to 
the antibody was detected and the concentration of the ligand in the samples was 
calculated from the standard curve. The principle is illustrated in Figure 2-9. 
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• Gamma Counter (BERTHOLD, LB 2111) 
• Vortexer (POTAMIXER DELUXE, Hook & Tucker Ltd.) 
• Test tubes (11 x 64mm) (Alpha Laboratories, DA 3510) 
2.8.3 Reagents 
 
Table 2-10 Reagents used for radioimmunoassay.  
Reagent Description 
Assay buffer Formed by 0.2g Protamine sulphate 
(Sigma – P4020), 3.6g (0.03M) sodium 
dihydrogen phosphate (BDH – 
301324Q), 0.2g (3mM) sodium azide 
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(Sigma – S2002), 3.72g (10mM) EDTA 
(Sigma – E5134), and 500µl (0.05%)                                
TWEEN 20 (Sigma – P5927).  Added 
to 1L dH2O, adjusted to pH 7.5 and 
stored at 4°C.                                          
Acetic acid solution 0.2875ml glacial acetic acid (BDH – 
27013), 0.01g (0.01%) BSA (Sigma – 
A7888), and 50µl (0.05%) TWEEN 20 
(Sigma – P5927). Added to 100ml of 
dH2O, aliquoted into 30ml and stored at 
-20°C.                                                     
8M formic acid  Formed by 33.92ml of neat formic acid 
added to 100ml of ddH2O, and 3–4 
drops of TWEEN 20 were added to give 
approximately 0.05% TWEEN (stored 
at room temperature). 
1M Tris base  Formed by adding 12.11g of Tris base 
to 100ml of ddH20, stored at room 
temperature. 
Acetone (BDH, Poole, UK) 
 
 
2.8.4  Procedure 
 
An extraction procedure is performed for IGF-I and -II measurements to release the 
ligands from their endogenous binding proteins. This step must proceed the RIA assay. 
It will help to avoid the reduction in the detection of IGF levels due to the competition 
of the binding proteins with the IGF antibody. 50µl of the sample (including the NHS 
control) were aliquoted into a 1.5ml Eppendorf. 25µl of the formic acid/TWEEN 
solution were added to each sample and vortexed. Using an acetone primed pipette 
tip, 175l of acetone were added to each sample, remembering to prime the tip 
between each sample. The samples were immediately capped, vortexed and 
centrifuged for 30 minutes at 4oC at an rcf of 3000g. In a fresh Eppendorf tube, 100µl 
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of supernatant were added and mixed with 100l of Tris base. The serum samples 
were further diluted to 1:10 with assay buffer (30µl into 270µl). The conditioned 
media when analysed did not need dilution, so standards were supplemented with 50µl 
of acid/acetone/Tris base solution, in addition to 50µl of the unconditioned media to 
ensure that all conditions were maintained. Normal human serum (NHS) at a dilution 
of 1:80 (in assay buffer) was used as a positive control.  
Recombinant human IGF standards were prepared with assay buffer to generate a 
standard curve with the following dilutions for IGF-I: 0, 0.25, 0.5, 1.0, 2.5, 5, 10, 25 
& 50ng/ml, and for IGF-II: 0, 0.5, 1.0, 2.5, 5, 10, 25 & 50ng/ml. 
Freshly made radioactive tracer with I-125 labelled IGF-I and IGF-II was prepared by 
adding 50μl of the labelled tracer to 25ml of the assay buffer. 50μl of the solution were 
added to a test tube and the number of counts was measured using a bench-top gamma 
counter. The number of counts needs to be between 10,000 and 15,000. 
IGF-I RIA antiserum was a monoclonal antibody (Clone M23/ILG1-001, 5345-0304) 
diluted with assay buffer at 1:2000, and for IGF-II (W5D2) an in-house antibody was 
used at a 1:25,000 dilution. 
Because RIA is very sensitive to residual binding protein, excess 500ng/ml IGF-I or 
200ng/ml IGF-II was added to the assay respectively (i.e. IGF-I for the IGF-II assay, 
and vice versa) to completely remove any interference from residual binding proteins 
remaining after the extraction procedure.  The peptides will not affect the levels of the 
measured IGFs because they will not be identified by the antibodies.  
Tubes were labelled in duplicates for TC (total counts of the tracer), NSB (non-specific 
binding, which determines the level of iodinated peptide binding to the tube, usually 
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less than 3% of TC), maximum binding (around 40% of TC), and each assay standard. 
Tubes were labelled in triplicate for the samples and were set up as indicated in Table 
2-15 for IGF-I and Table 2-16 for IGF-II.  
Each tube was vortexed (except for TC tubes), covered with cling film and incubated 
at 4°C (in the fridge) overnight. 50l of anti-mouse SAC-CEL (IDS Ltd., Bolden, UK) 
were added to each tube (except for the TC tubes) for IGF-I and -II RIA. All tubes 
were vortexed, covered with cling film and incubated for 30 minutes at 4°C.  SAC-
CEL is a solid-phase (covalent-coupled) secondary antibody coated cellulose 
suspension that enables the pull-down of primary antibodies in solution after 
centrifugation and was used with continuous stirring. 1ml of distilled water was added 
to each tube and tubes were centrifuged at 2000g at 4°C for 30 minutes (except for the 
TC tubes). The generated supernatant was aspirated and, finally, each tube was 
counted using the Gamma Counter. The concentration of IGF-I and IGF-II ligand was 
calculated automatically from the standard curve by a pre-set computer program. 
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2.8.5 IGFBP-3 radioimmunoassay 
 
The method for IGFBP-3 quantification in conditioned media is identical to IGF-I and 
IGF-II RIA quantification, as explained previously (2.8.4). Standards were prepared 
from normal human serum diluted in 100mM acetic acid to generate a standard curve 
of 0, 6.6, 13, 33, 66, 131, 312 and 624ng/ml. Acetic acid is helpful in keeping IGFBP-
3 from sticking to the plastic tubes. 50µl unconditioned medium were added to the 
standards (except for TC tubes), whereas a 50mM acetic acid solution (described in 
Table 2-10) was added to the samples to allow for continuity between standards and 
samples.  
Non-glycosylated I-125 labelled IGFBP-3 tracer was used and diluted in assay buffer to 
give a reading of 15,000cpm/50µl. In-house antiserum (SCH5) was used and diluted 
at 1:2000 in assay buffer. The tubes were set-up in a similar manner to those in the 
IGF-I/IGF-II assay, and samples were arranged in triplicate and prepared as indicated 
in Table 2-13. NHS was used as a positive control at 1:100 and 1:80 dilutions in assay 
buffer. 
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Tubes were vortexed, incubated at 4°C overnight, and 50µl of anti-rabbit SAC-CEL 
(IDS Ltd., AASAC1, UK) were added to each tube (except for the TC tubes). Tubes 
were vortexed, covered with cling film and incubated at 40°C for 30 minutes. 1ml of 
distilled water was added to each tube (except for the TC tubes), and the tubes were 
centrifuged at an rcf of 2000g at 4°C for 30 minutes.  
The resulting supernatant was aspirated and the radioactive pellets were counted on a 
gamma counter. IGFBP-3 levels in the samples were automatically calculated from 
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2.9 Microscopy  
 
Inverted microscopes (Nikon Eclipse TS 100 and Zeiss AXiO Vert A1) were used for 
counting and imaging cells. Motic Image and Q-Capture Pro7 software were used for 
capturing images.   
 
2.10 Statistical analysis  
 
SPSS 12.0.1 (SPSS Inc., Chicago, USA) for Windows was used for statistical analysis. 
Results were represented as the mean ± standard error (SEM). The number of biopsies 
used was indicated for each experiment. Analysis of variance (ANOVA) was used for 
multiple comparisons, followed by a least significant differences (LSD) post-hoc test. 
Pearson’s correlation coefficients (and subsequent linear regression) were used to 
assess IGF-II correlations with fat mass in the ALSPAC data. Non-parametric data 
were log-transformed to remove any skew.  
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Obesity is a health concern of epidemic proportions that is increasing worldwide. The 
negative consequences of obesity on health have mainly been reported in studies of 
adults: however, during recent years, it is clear that childhood obesity is markedly 
increasing and is also associated with a rise in morbidity and mortality (Lobstein, 
Jackson-Leach et al. 2015). An excess accumulation of adipose tissue results in 
obesity. The adipocyte has a critical role, normally functioning to buffer changes in 
availability of metabolic fuels, storing energy in the form of lipid at times of plenty 
and then providing a source of free fatty acids (FFA) to supply energy during times 
when food is limited (Frayn 2002). It is now clear that adipose tissue is also a very 
active endocrine organ, secreting and responding to many hormones and cytokines 
that play an important role in the regulation of appetite, fuel partitioning and 
utilization. The distribution of body fat has greater importance for the development of 
obesity-related morbidities than the simple extent of excess adipose tissue. 
Elimination of a large proportion of subcutaneous fat by liposuction has little effect 
on insulin sensitivity (Klein, Fontana et al. 2004), whereas removal of visceral fat by 
omentectomy significantly improves insulin sensitivity independent of change in total 
body weight (Thörne, Lönnqvist et al. 2002). It has also become apparent that 
adipocytes from different anatomical sites serve distinct functional roles. The visceral 
adipocytes have a specialized function due to their anatomical location with venous 
drainage via the portal system; they are more metabolically active and rapidly release 
nutrients during conditions of stress, directly providing FFA as substrates for hepatic 
glucose production and lipoprotein metabolism. This evolved specialist function for 
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providing alternative metabolic fuel at times of stress may however be maladaptive 
during times of prolonged positive energy balance, which throughout most of 
evolution would have been extremely rare. A western lifestyle with regular snacks and 
energy-dense foods however results in humans being in a postprandial state for 16-18 
hours per day (Parks 2002). In line with this specialized function, a number of distinct 
characteristics have been described for visceral adipocytes including higher rates of 
catecholamine-induced lipolysis (Rebuffe-Scrive, Andersson et al. 1989) and higher 
levels of β–adrenergic receptors (Arner, Hellström et al. 1990). In addition, regional 
differences have been reported for IGF production and receptor distribution in animal 
studies (Tchoukalova, Nathanielsz et al. 2009). Interestingly, changes in the IGF 
system have been described in obese children (Saitoh, Kamoda et al. 1998, Ballerini, 
Ropelato et al. 2004) although far less is known about site-specific differences in 
adipocytes in children.  
Experimental adipocyte models are very limited; there are no available human 
adipocyte cell lines and the majority of work to date has been undertaken in a murine 
cell line, 3T3-L1. While preadipocytes can proliferate in culture, those derived from 
adult humans will no longer differentiate into mature adipocytes following just one or 
two passages in culture ex vivo. The depot-specific differences in adipocyte function, 
that are so significant for human morbidities are very different and much less marked 
in rodents (Arner 2005), and the functional distinctions of visceral adipocytes 
therefore cannot be examined in murine cell lines. In our laboratory, we have 
overcome these limitations and are able to show that in contrast to cells from adult 
subjects, preadipocytes from children retain the ability to effectively differentiate 
following several passages in culture ex vivo enabling significant numbers of cells to 
be grown for experimentation (Grohmann, Sabin et al. 2005). We hypothesis that IGF-
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II is predominantly secreted by adipose cells, and IGFs receptor levels will differ 
between visceral and subcutaneous preadipocytes and differentiated adipocytes; 
showing a higher level of insulin receptor isoform A in visceral cells in comparison to 
subcutaneous cells. 
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3.2 Aims and objectives 
 
In this chapter, we aim to highlight the characteristic differences in subcutaneous and 
visceral preadipocytes and adipocytes from children to establish a fundamental 
foundation for future understanding and experimentation. This will be conducted by: 
 
• Culture and differentiate subcutaneous and visceral fat biopsies taken from 
pre-pubertal children 
• Characterize fat-depot differences between subcutaneous and visceral 
preadipocytes in terms of:  
a. Secretory levels of IGFs 
b. Genetic expression and protein abundance of glucose transporters (GLUT1, 
GLUT4) in preadipocytes and adipocytes 
c. Basal- and insulin-stimulated glucose uptake 
d. IGF receptor expression (IGF-IR, IR, insulin receptor isoforms) 
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3.3 Material and methods 
3.3.1 3T3-L1 cell line culture and differentiation 
3T3-L1 preadipocytes were grown in T75 flasks to 70% confluency, and then plated 
into 6-well plates and induced to differentiate over 7 days using differentiation media, 
as described in section (2.2.4) 
3.3.2 Child fat biopsy preparation, culture and differentiation 
Paired biopsies from subcutaneous and visceral fat were prepared as described in the 
methods section (2.2.5). Briefly, fat biopsies were washed with 10ml of HBSS, 
dissected into small pieces (1mm3) and digested using type II collagenase (1 mg/ml) 
in HBSS at 37°C using a shaking water bath for 1 hour.  Preadipocytes were separated 
from the stromal vascular compartment by centrifuging for 3 minutes at 80g. The 
sedimented cells were cultured in a gelatin-coated T75 flask after resuspension with 
10 ml of DMEM/Ham’s F12 medium (1:1, v/v) supplemented with 20% FBS, 2 mM 
glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin. Cells were incubated at 
37°C in a humidified atmosphere of 5% CO2, and the medium was changed every 2 
days until confluency was reached (7-14 days).  Cells were washed with PBS and 
detached from flasks using 1 ml trypsin and incubated for 5 minutes. Following 
incubation, trypsin was deactivated using 5 ml of growth media and the cell suspension 
was centrifuged at 80g for 5 minutes. For differentiation, cells were plated on a gelatin-
coated 6-well plate with a seeding density of 0.2 X 106 and were differentiated for 14 
days using the differentiation media described in the methods section (2.2.2). To 
maintain consistency, experiments were only performed using cell passages 3–5. 
3.3.3 Western immunoblotting  
Preadipocyte differentiation markers, glucose transporters and receptor protein 
abundance were visualized using SDS-PAGE and western blotting. Protocol and 
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antibody concentrations are described in section (2.4). GAPDH was used as a 
reference protein. Quantification of band intensities was determined by Image Lab 
1.46r software. 
3.3.4 RNA extraction and RNA- cDNA reverse transcription 
RNA was extracted by Trizol reagent (Invitrogen) as outlined in section (2.6.2) and 1 
µg of RNA was reversed to cDNA using a high capacity RNA-to-cDNA kit (Applied 
Biosystems) as described in section (2.6.5)   
3.3.5 Quantitative Polymerase Chain Reaction (qPCR) 
mRNA genetic expression of differentiation markers, glucose transporters, insulin and 
IGF-I receptors and insulin receptor isoforms were performed using SYBR green-
based qPCR. The PCR reaction was analysed using StepOnePlus and relative mRNA 
levels were determined using the 2−ΔCt method after normalization to the GAPDH 
reference gene. For protocol details and primer sequencing refer to section (2.6.6)  
3.3.6 Glucose uptake  
[3H]2-deoxyglucose uptake was performed for basal- and insulin-stimulated glucose 
uptake, ten µg of insulin (100nM) was added for 15 minutes and glucose uptake was 
quantified using a β-Scintillation Counter. Data are presented as disintegrations per 
minute (DPM).  Further protocol details are mentioned in section (2.7) 
3.3.7 Oil red O Triglyceride staining 
Cultured preadipocytes were washed twice by PBS before being fixed in 10% 
formalin, with Oil red O (ORO) staining being performed on day 0 and day 7 post-
differentiation for the 3T3-L1 cell line and on day 0 and day 14 post differentiation 
for human cultures; further details of ORO is described in section (2.3). Quantification 
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of the ORO stain was carried out using spectrophotometry (FLUOstar OPTIMA, 
BMG LABTECH) at 490nm. 
3.3.8 Radioimmunoassay (RIA) 
Conditioned media levels of IGF-I and IGF-II were assessed using a 
radioimmunoassay as described in section (2.8). 
3.3.9 Statistical analysis  
Student’s t-tests were used for 3T3-L1cells analysis (at day 0 and 7 of differentiation). 
One-way ANOVA followed by a least significant difference (LSD) post-hoc test was 
used for multiple group comparisons (subcutaneous and visceral) pre and post- 
differentiation (day 14). SPSS 12.0.1 for Windows were used for analysing data with 
a significant statistical difference at P<0.05.    
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3.4 Results  
3.4.1 Optimizing of preadipocyte differentiation using 3T3-L1 cell lines 
The process of preadipocyte differentiation has been studied in detail for the past 20 
years. It can be described as the ability of committed preadipocytes to change into 
adipocytes by undergoing growth arrest and is followed by terminal differentiation. 
This process is associated with an increase in specific mature adipocyte genes and 
lipid-processing enzymes and it is controlled by many transcription factors such as 
PPAR-γ and C/EBP (Altiok, Xu et al. 1997). The most extensively used experimental 
model to study fat cells is the 3T3-L1 murine cell line, which we decided to use to 
master the cell culture and differentiation techniques. Figure (3-1) illustrates the 
morphological changes of the 3T3-L1 preadipocytes from fibroblast-like cells to 
adipocytes containing spherical shaped lipid droplets. At 72 hours, the cells were 70-
80 % confluent, and 100% confluent at 96 hours. Following the introduction of 
differentiation media two days post-confluency, morphological changes from 
fibroblastic cells to rounded adipocytes appeared to start from day 2 of differentiation.  
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Figure 3-1 Phase contrast microscopy showing the preadipocyte growth and 
differentiation process in 3T3-L1 cell lines.   
Morphological change of preadipocytes from fibroblastic cell to adipocyte fat-containing cells 
(arrows); 3T3-L1 confluency was achieved after 96 hours and fat accumulation started at day 
2 post-differentiation. Magnification X10.  
 
With adipocyte maturation, triglycerides start to accumulate within the cells. This 
adipogenic potential can be assessed using Oil red O staining to confirm the 
morphological changes and evaluate the differentiation process (Ramirez-Zacarias, 
Castro-Munozledo et al. 1992). Figure (3-2-a) shows the morphological changes of 
preadipocytes (day 0) and the increase in Oil red O stain deposition after 
differentiation (day 7). There is a 40-fold increase in Oil red O spectrophotometry 
absorbance (490nm) in comparison to preadipocytes (adipocytes 40.35, preadipocytes 
0.335; P<0.01), Figure (3-2-b). 




Figure 3-2 3T3-L1 cell line differentiation assessment using Oil red O stain.   
(a) Oil red O staining of 3T3-L1 preadipocytes at experimental day 0 and day 7 showing red 
colour triglycerides accumulation at day 7 (Magnification X10) (b) Oil red O 
spectrophotometry absorbance analysis indicating an increased fat deposition with 
differentiation. Data is presented as mean ± SEM of two experimental repeats performed in 
triplicate.  
 
To further confirm 3T3-L1 preadipocyte differentiation protein abundance of 
peroxisome proliferator-activated receptor gamma (PPAR-γ), which is known to 
increase with differentiation, was determined using western blotting. This marker acts 
as a trans-activator of adipocyte genes and is involved in the cell growth arrest that is 
needed to start differentiation. The protein abundance of PPAR-γ increased gradually 
with differentiation; in comparison to day 0 of differentiation there was a 6.2-fold 
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increase in PPAR-γ at day 5 (p<0.01) and a 12-fold increase at day 7 of differentiation 
(p<0.001). illustrated in (Figure 3-3).  
 
Figure 3-3 PPAR-γ differentiation marker protein abundance in 3T3-L1 cell lines 
at day 0, 2, 5 and 7 of differentiation.  
(a) Western immunoblot illustrating PPAR-γ expression increase with differentiation; 
GAPDH was used as a loading control protein (b) image J analysis of the western blot (a) The 
graphs represent the mean ± SEM of two independent repeats each conducted in triplicate.  
 
3.4.2. Data relating to the prepubertal children that participated in subcutaneous 
and visceral fat biopsy collections 
Samples were obtained from young children admitted to a regional children’s hospital 
for elective surgery. The study was approved by the NRES Committee South West – 
Exeter (REC reference: 14/SW/0109). An invitation to the study and a written 
information sheet was sent by post along with the surgery admission letter to all 
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potential subjects. Parents/legal guardians were offered a verbal explanation of the 
study on the morning of admission for surgery and consent was obtained from the 
families of 20 participants. Further details about ethical approval, information sheets 
and consent forms are provided in the appendix section (9.1-9.4). 
Children recruited were of normal weight, and were admitted to the Bristol Royal 
Hospital for Children for routine renal surgery (non-malignant, non-septic operations). 
Fat tissue samples were collected by two Consultant Paediatric Surgeons during the 
operation. Subcutaneous and intra-abdominal peri-nephric (visceral) fat biopsies (0.2-
0.5g) were collected and transferred immediately to the laboratory. Clinical data for 
the participants are shown in Table 3-1.  














1 Male 6 Pyeloplasty 16.1 -0.2 
2 Male <1 Pyeloplasty 14.1 -1.6 
3 Female 4 Hemi-nephrectomy 16.7 +0.14 
4 Female 2 Pyeloplasty 15.3 -0.8 
5 Male 3 Pyeloplasty 15.1 -0.9 
6 Male 1 Pyeloplasty 16.6 +0.07 
7 Male 3 Nephrectomy 16.2 -0.2 
8 Female <1 Hemi-nephrectomy 18.3 +1.2 
9 Male <1 Pyeloplasty 16.6 +0.07 
10 Female <1 Pyeloplasty 18.9 +1.6 
11 Male 4 Pyeloplasty 16 -0.3 
12 Male 5 Pyeloplasty 16.5 0 
13 Male 7 Pyeloplasty 16.5 0 
14 Female 2 Hemi-nephrectomy 17.2 +0.4 
15 Male 2 Pyeloplasty 15.2 -0.9 
16 Female 7 Hemi-nephrectomy 17.2 +0.4 
17 Male 2 Nephrectomy 16.7 +0.1 
18 Female <1 Nephrectomy 18.8 +1.4 
19 Male 3 Pyeloplasty 17 +0.3 
20 Female 1 Nephrectomy 18.4 +1.3 
 
3.4.3 Differentiation of human subcutaneous and visceral fat biopsies  
Regional, depot-specific differences in adipocyte function are likely significant for 
human metabolic health. As these functional distinctions cannot be examined in 
murine cell lines we used a culturing system of preadipocytes obtained from children. 
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Paired subcutaneous and visceral fat biopsies were cultured and differentiated for 14 
days using the methods described in section (2.2.5). 
3.4.3.1 Assessment of human subcutaneous and visceral fat culture differentiation 
using Oil red O staining 
After optimization of adipocyte Oil red O staining using the 3T3-L1 cell line, we used 
Oil red O staining to evaluate the differentiation of children’s subcutaneous and 
visceral fat cultures. Following fat biopsy preparation, culture and differentiation as 
described in the methods section, Oil red O stain assessment was performed on 
preadipocytes (day 0) and adipocytes (day 14) post differentiation. Figure (3-4 a) 
illustrates the morphological changes observed in subcutaneous and visceral 
preadipocytes from fibroblastic-like cells to fat-containing differentiated adipocytes 
stained with Oil red O triglycerides. Figure (3-4 b) represents the spectrophotometry 
absorbance quantification; Oil red O stain was undetectable for subcutaneous and 
visceral preadipocytes but there was a 18.5-fold increase for subcutaneous adipocytes 
(P<0.001) and a 16.5-fold increase for visceral adipocytes (P<0.001) in Oil red O 
staining absorbance in comparison to preadipocytes: however there were no 
significant differences in fat deposition between the two fat depots.  
 




Figure 3-4 Characterization of subcutaneous and visceral preadipocyte fat 
biopsies from prepubertal children.  
(a) Photomicrographs of human subcutaneous and visceral preadipocytes (day 0) displaying a 
fibroblastic morphology and differentiated adipocytes (day 14) stained with Oil red O. 
Magnification at (X10). (b) Quantitative absorbance analysis of Oil red O staining showing a 
significant increase in fat deposition in mature adipocytes in comparison with preadipocytes. 
The data are represented as mean ± SEM from 4 biopsies conducted in triplicate.   
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3.4.3.2 Assessment of subcutaneous and visceral differentiation markers using 
quantitative polymerase chain reaction (qPCR) 
To further confirm the preadipocyte differentiation process, mRNA expression of the 
preadipocyte differentiation markers PPAR-γ and adiponectin, were analyzed. Trizol 
RNA extraction of preadipocytes (day 0) and adipocytes (day 14) was performed 
followed by qPCR as described in the methods section (2.6). The mRNA expression 
of both differentiation markers significantly increased in mature adipocytes (day 14) 
in comparison to preadipocytes (day 0) in both fat depots. Figure (3-5a) shows the 
increase in PPAR-γ in subcutaneous adipocytes (20.2 vs.1; p<0.001) and in visceral 
adipocytes (37.7 vs.2. 1; P<0.001) in comparison to preadipocytes. Figure (3-5b) 
shows the mRNA expression of adiponectin in subcutaneous adipocytes (14533 Vs.1; 
P<0.001) and in visceral adipocytes (23575 vs.1.8; P<0.001) vs. preadipocytes. A 
difference in PPAR-γ and adiponectin mRNA expression in visceral adipocytes in 
comparison to subcutaneous adipocytes was seen at day 14 of differentiation. 
 




Figure 3-5 Relative mRNA expression of preadipocyte differentiation markers in 
subcutaneous and visceral preadipocytes and adipocytes obtained from pre-
pubertal children. 
mRNA expression of (A) PPAR-γ and (B) adiponectin quantified using SYBR green-based 
qPCR indicating an increase of mRNA expression with differentiation. (C) melting curves for 
PPAR-γ and adiponectin. GAPDH was used as reference gene. Data are expressed as mean ± 
SEM of duplicate runs (N=4). 
 
 3.4.3.3 Assessment of subcutaneous and visceral differentiation markers using 
western immunoblotting 
This assessment determined whether the protein abundance of preadipocyte 
differentiation markers corresponded to mRNA expression. Western blotting was 
performed using specific PPAR-γ and adiponectin antibodies. At day 0 and 14 post-
differentiation adipocyte whole cell lysate extracts were collected. As anticipated, a 
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significant increase in the differentiation marker PPAR-γ (Figure 3-6 b) in 
subcutaneous (adipocytes 2.7 Vs. 1 preadipocytes; p<0.01) and visceral (adipocytes 
2.1 Vs.0.8 preadipocytes; P<0.01) was found. A similar increase was seen in 
adiponectin protein abundance (Figure 3-6c) with differentiation in subcutaneous (3.4 
Vs. 1; P<0.001) and visceral (4.1 vs. 0.9; P<0.001).  
 
Figure 3-6 Protein abundance of preadipocyte differentiation markers in 
subcutaneous and visceral cutures obtained from pre-pubertal children.    
Densitometry of the differentiation marker PPAR-γ (b) showing increase in protein abundance 
with differentiation in subcutaneous and visceral preadipocytes and adipocytes (day 14) (c) 
Densitometry qualification of adiponectin protein abundance with differentiation. β-action 
was used as a loading control. Data are expressed as mean ± SEM (N=4). 
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3.4.4 Fat depot differences in IGF-I and IGF-II local tissue production 
Active adipocytes, in addition to their role in fat storage, are a secretory endocrine cell 
producing many hormones. To further asses the functionality of our fat cultures and 
address our future aim to study the role of IGFs in adipocyte regulation, we examined 
basal secretory levels of IGF-I and IGF-II from subcutaneous and visceral adipocytes. 
The levels of IGF-I and IGF-II in the media were measured after 24 hrs of culture in 
5mM glucose-containing serum-free media using radioimmunoassay. Our results 
showed a significant predominance in IGF-II secretion over IGF-I from the two fat 
depots; almost a five-fold increase of IGF-II (4.86) secreted from visceral adipocytes 
in comparison to IGF-I (1.079) (p<0.001) and a 4.6-fold significant increase in 
subcutaneous IGF-II secretion in comparison to IGF-I (1.2) (p<0.001). There was no 
significant difference between the two-fat depot in IGF-II or IGF-I secretion (Figure 
3-7).  
 
Figure 3-7 Secretory media levels of IGF-II and IGF-I from visceral and 
subcutaneous primary cell cultures obtained from pre-pubertal children. 
Chapter 3: Characterization of adipose tissue 
 
 108 
IGF-II is predominantly secreted by mature adipocytes from children’s primary cultures. IGF-
II was measured using radioimmunoassay. Preadipocytes were cultured and differentiated into 
mature adipocytes for 14 days in normal glucose differentiation media (5mM). Data are 
presented as mean ± SEM of 3 repeats in triplicate and ANOVA was used to verify statistical 
significance (N=3). 
 
3.4.5 Effect of hyperglycaemia on fat depot differences in IGF-I and IGF-II 
secretion 
IGFs are nutritionally regulated and IGF secretory levels can be influenced by glucose 
concentrations (D’Esposito, Passaretti et al. 2012). To determine whether this applies 
to our model and to examine this phenomenon in a fat-depot context, we studied 
changes in adipocyte secretory levels of IGF-I and IGF-II. Media were collected after 
24 hours’ culture in 5mM or 25mM glucose-containing serum-free media. There was 
no significant difference between subcutaneous or visceral IGF-I secretion in normal 
and high glucose media (Figure 3-8). 
 




Figure 3-8 IGF-I secretion from subcutaneous and visceral adipocytes in 
different glucose conditions. 
Preadipocytes were differentiated for 14 days then serum starved for 24 hours in normal 
(5mM) or high (25mM) glucose serum-free media. Media were collected, and RIA was 
performed using 3 different biopsies run in triplicate. Data are presented as mean ± SEM and 
ANOVA were used to verify statistical significance (N=3). 
 
Similarly, there was no significant change in IGF-II secretion in high glucose (25mM) 
from visceral and subcutaneous adipocytes in comparison to normal glucose (5mM). 
Also, there was no difference in IGF-II production between the fat depots in high 
glucose conditions. (Figure 3-9).  




Figure 3-9 Effect of glucose concentration on IGF-II secretion from visceral and 
subcutaneous adipocytes. 
IGF-II secretory levels were measured using radioimmunoassay (RIA). Media were collected 
after 24 hours’ culture in normal (5mM) or high glucose (25mM) serum-free media. Data are 
presented as mean ± SEM of 3 experimental repeats in triplicate. ANOVA was used to verify 
statistical significance (N=3). 
 
 
3.4.6 Characterisation of glucose transporters 1 and 4 (GLUT1, GLUT4) with 
differentiation in subcutaneous and visceral fat 
The process of preadipocyte differentiation requires increased transcription of certain 
genes and expression of specific proteins such as the insulin-sensitive glucose 
transporter GLUT4. We investigated the change in glucose transporter expression and 
protein abundance in subcutaneous and visceral preadipocytes and differentiated 
adipocytes collected on day 14 post differentiation. Figure (3-10) illustrates the change 
in protein abundance of GLUT4; there was a significant increase in GLUT4 abundance 
with differentiation for both fat depots. Subcutaneous adipocytes have higher 
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expression of GLUT4 in comparison to preadipocytes (1.73 to 1; P<0.001). Also, 
visceral adipocytes have a significantly higher abundance than preadipocytes (2.8 to 
1.3: P<0.001).  However, there was no significant difference between subcutaneous 
and visceral GLUT4 expression in preadipocytes. The depot differences in GLUT4 
abundance become more obvious with differentiation, with visceral adipocytes found 
to have a significantly higher expression in comparison to subcutaneous adipocytes 
(P<0.01).  
 
Figure 3-10 Fat depot protein abundance of GLUT4 in preadipocytes and 
adipocytes. 
(a) Western blot of subcutaneous and visceral preadipocytes and adipocytes showing the 
increase of GLUT4 abundance with differentiation. (b) Semi-dosimetry quantification of 
western blot (a) The data represent mean ± SEM of 3 experimental repeats in triplicate (N=3). 
 




In contrast to GLUT4, GLUT1 abundance decreased with differentiation as expected 
because adipocytes are more insulin dependent.  Visceral preadipocyte abundance was 
(1.5 vs. 0.5: P<0.05) in comparison to adipocytes. Subcutaneous adipocytes also 
showed a decrease in GLUT1 abundance, but this did not reach statistical significance 
(Figure 3-11).  A similar pattern of genetic expression of GLUT4 and GLUT1 was 
also seen and confirmed using qPCR (Figure 3-12). 
 
 
Figure 3-11 Characterization of GLUT1 protein abundance with differentiation. 
(a) Western blot of GLUT1 in subcutaneous and visceral preadipocytes and adipocytes (b) 
Semi-quantitative analysis of (a) showing a decrease of GLUT1 abundance with 
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differentiation. GAPDH was used as a reference protein. Data are expressed as mean ± SEM 
of three experimental repeats in triplicate.  (N=3) 
 
 
Figure 3-12  mRNA expression of glucose transporters 1 and 4 with 
differentiation. 
Preadipocytes and differentiated adipocytes (day14) from subcutaneous and visceral fat from 
pre-pubertal children (who were serum starved for 24 hours) in 5mM serum-free media 
followed by RNA extraction and quantified using SYBR green-based qPCR (A) mRNA 
expression of GLUT4 (B) GLUT1 (C) Melt curve of GLUT4, GLUT1. GAPDH was used as 
a house keeping gene.   
 
3.4.7 Basal glucose uptake by human subcutaneous and visceral preadipocytes 
To observe whether a difference in glucose transporters reflected changes in glucose 
uptake ability, we assessed basal 2-deoxy-[3H] d-glucose uptake of preadipocytes and 
differentiated adipocytes. Preadipocytes were cultured for 24 hours in normal glucose 
growth media and then changed to normal (5mM/L) or high glucose (25mM/L)-
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containing serum-free media for an additional 24 hours and then a non-insulin 
stimulated glucose uptake assay was performed. 
Subcutaneous and visceral preadipocytes have similar basal glucose uptake (3641.3 
disintegrations per minute (DPM) vs 4261.33 DPM) when cultured in normal glucose. 
In high glucose (25mM/L) there was a minor reduction in the uptake levels of both fat 
depots (3358 DPM vs. 2928.5 DPM), respectively, in comparison to normal glucose 
(Figure 3-13).  
 
Figure 3-13 Basal glucose transport in human subcutaneous and visceral 
preadipocytes. 
Non-insulin stimulated 2-deoxy-[3H] d-glucose uptake transport was measured in 
subcutaneous and visceral preadipocytes in two different glucose conditions – 5mM and 
25mM. The data represent the basal glucose uptake ± SEM (N=2). 
 
With differentiation, the level of basal glucose uptake was reduced in comparison to 
preadipocytes for visceral and subcutaneous adipocytes, respectively (3.99 and 
3.81fold reduction), and this was expected because glucose uptake by adipocytes is 
more insulin dependent. Visceral adipocytes also had a significant reduction in 
glucose uptake (P<0.05) when cultured in high glucose media (Figure 3-14).  




Figure 3-14 Basal glucose transport in human subcutaneous and visceral 
adipocytes. 
Non-insulin stimulated 2-deoxy-[3H] d-glucose uptake transport was measured in 
subcutaneous (open bars) and visceral (closed bars) adipocytes in high glucose (25mM) and 
low glucose (5mM). The data represent the basal glucose uptake mean ± SEM (N=2). 
 
To test for adipocyte functionality, insulin-stimulated radioactive glucose uptake was 
performed for subcutaneous and visceral adipocytes. As predicted, glucose uptake for 
both subcutaneous and visceral adipocytes was increased after insulin treatment; 
subcutaneous glucose uptake in comparison to control was (3197vs.1985; P<0.001) 
and visceral glucose uptake was (3513vs.2194; P<0.001). There was a significant 
increase in visceral glucose uptake in comparison to subcutaneous glucose uptake 
(P<0.05) (Figure 3-15). 




Figure 3-15 Insulin stimulate 2-deoxy-[3H] d-glucose uptake in subcutaneous and 
visceral adipocytes. 
Subcutaneous and visceral adipocytes were serum starved in 5mM glucose-containing serum 
free media for 24 hours followed by the presence or absence of insulin (100 nM) for 15 
minutes. Data is presented as mean ± SEM (N=2).   
 
3.4.8 Characterization of insulin and insulin-like growth factor receptors in 
subcutaneous and visceral preadipocytes 
 
In 3T3-L1 cell lines, there was a clear shift in IGF-IR and IR receptor distribution with 
differentiation; preadipocytes expressed higher IGF-IR in comparison to IR (41.9 Vs 
1; P<0.001). When the cells differentiate the insulin, receptor is predominant (3.9 
Vs.48.5; P<0.001) and levels of the IGF-IR are negligible (Figure 3-16). 
 




Figure 3-16 Insulin receptor (IR) and insulin-like growth factor I receptor (IGF-
IR) abundance in 3T3-L1 cell line in preadipocytes and adipocytes. 
(a) Western blot of 3T3-L1 pre-adipocyte cells and differentiated adipocytes (day 7) whole 
cell lysate extract, showing IR and IGF-IR protein abundance. MCF7 breast cancer cells were 
used as a positive control and GAPDH worked as loading control. (b) Quantitative 
densitometry analysis; the data are expressed as mean ± SEM from two experimental repeats 
and P<0.05 was considered as significant. 
 
 
In human cells, we found that the expression of the IGF-IR receptor decreased with 
differentiation for subcutaneous (P<0.01) and visceral preadipocytes (P<0.05). 
Interestingly, the IGF-IR was significantly higher in subcutaneous preadipocytes in 
comparison to visceral preadipocytes (P<0.05) (Figure 3-17). We then examined 
protein abundance of the IGF-IR (Figure 3-18) before and after differentiation in 
subcutaneous and visceral cultures, and a similar pattern was seen; however, 
subcutaneous preadipocyte predominance in comparison to visceral preadipocytes did 
not reach statistical significance (P= 0.082). 




Figure 3-17 mRNA expression of insulin-like growth factor I receptor (IGF-IR) 
with differentiation in subcutaneous and visceral cultures. 
A.IGF-IR mRNA expression was quantified using SYBR green-based qPCR indicating a 
reduction of expression with differentiation. B.IGF-IR melting curve. Data are expressed as 
mean ± SEM of duplicate runs (N=3). GAPDH was used as reference gene. 
 




Figure 3-18 Protein abundance of IGF-IR with differentiation in subcutaneous 
and visceral cultures. 
(a) Western blot of IGF-IR indicating decrease abundance with differentiation (b) Semi-
quantitative analysis of the western blot (a) Normalized to GAPDH reference protein. Data 
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Insulin receptor mRNA expression seems to increase with differentiation (Figure 3-
19) for subcutaneous and visceral adipocytes, as cells become more insulin dependent. 
The mRNA expression of total insulin receptor was higher in visceral preadipocytes 




Figure 3-19 Genetic expression of insulin receptor (IR) with differentiation in 
subcutaneous and visceral cultures. 
A. Relative mRNA expression was quantified using SYBR green-based qPCR indicating an 
increase of expression with differentiation. B. Insulin receptor qPCR melting curve. Data are 
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3.4.9 Insulin receptor isoform expression with differentiation in subcutaneous 
and visceral tissue cultures 
The insulin receptor has two isoforms due to the alternative splicing of exon 11. IR-B 
which has exon 11 and IR-A which lacks this exon. A main functional difference 
between the two isoforms is their affinity for IGF-II. In the previous results section 
(3.4.8), we indicated that preadipocytes express both the IR and the IGF-IR, and the 
IR is expressed more with differentiation together with a reduction in the IGF-IR. We 
examined the distribution of IR-A and IR-B in both preadipocytes and adipocytes. In 
preadipocytes, visceral preadipocytes have a higher ratio of insulin receptor isoform 
A in comparison to insulin receptor isoform B (28.2 Vs. 1.5; P<0.001) and 
subcutaneous preadipocytes have a higher ratio of IR-B compared with IR-A (8.9 Vs. 
1.0: P<0.05). Looking further into the difference between subcutaneous and visceral 
fat depots, there was a significant higher expression of IR-A in visceral preadipocytes, 
with a more than 30-fold (P<0.001) higher expression in comparison to subcutaneous 
preadipocytes (Figure 3-20). 




Figure 3-20 Relative genetic mRNA expression of insulin receptor isoforms in 
preadipocytes from prepubertal children. 
Subcutaneous and visceral preadipocytes were serum starved for 24 hours in 5mM/l serum 
free media followed by RNA extraction and quantified using SYBR green-based qPCR. Data 
are expressed as mean ± SEM of experiments run in duplicate (N=4). GAPDH was used as 
reference gene.  
 
In terms of differentiation, the mRNA expression ratio of IR-B significantly increased 
compared to that of IR-A in subcutaneous and visceral adipocytes (22.4 Vs. 1.0: 
P<0.05) and (45.6 Vs. 33.7; P<0.05), respectively. This ratio is a feature of insulin-
sensitive tissues. However, visceral adipocytes still maintained a higher ratio of IR-A 
in comparison to subcutaneous adipocytes (P<0.01) (Figure 3-21). 




Figure 3-21 mRNA expression of insulin receptor isoforms in differentiated 
adipocytes from prepubertal children. 
Subcutaneous and visceral adipocytes on day 14 of differentiation were serum starved for 24 
hours in 5mM/L serum-free media followed by RNA extraction and quantified using SYBR 
green-based qPCR. GAPDH was used as reference gene. Data are expressed as mean ± SEM 










This chapter focused on the differences between visceral and subcutaneous 
preadipocytes derived from prepuberal children in terms of levels and distribution of 
IGF receptors, uptake of glucose and levels of GLUT 1 and 4 transporters and we also 
measured tissue production of IGFs.   
The importance of using prepubertal adipose tissue is related to the need to understand 
adipose tissue distribution during childhood, which is a critical time in the 
development of childhood obesity. The majority of tissue characterisation studies are 
based on adult samples, which might be influenced by the pubertal surge of growth 
hormone, insulin-like growth factors and sex-steroids.  
We examined the differences in local production of insulin-like growth factors, and 
consistent with other studies, IGF-II was predominantly secreted in comparison to 
IGF-I (Hauner, Röhrig et al. 1998, Gude, Frystyk et al. 2012). Our data indicate that 
this substantial increase in production of IGF-II was from both subcutaneous and 
visceral cultures. However, there was no marked depot-specific difference in IGF-II 
secretion when cultures were subjected to hyperglycaemia. It was previously reported 
that the metabolic environment could influence the secretion of IGFs (Bäck and 
Arnqvist 2009) and that intra-uterine hyperglycaemia alters IGF-II gene expression 
(Ding, Wang et al. 2012). Furthermore, IGF-II production with increased secretion 
from visceral cultures in comparison to subcutaneous has been observed in cultures 
obtained from middle-aged obese females (Gude, Frystyk et al. 2012) . 
We showed that GLUT1 expression decreased with preadipocyte differentiation, 
whereas GLUT4 increased: a similar pattern of expression was also reported in 
cultures obtained from young females (Hauner, Röhrig et al. 1998); however, in older 
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women a similar increase in GLUT4 was reported with no change in GLUT1 (Perrini, 
Laviola et al. 2008, Bäck and Arnqvist 2009). Our results indicate that glucose 
transporter 1 which is an insulin independent transporter was more abundant in 
preadipocytes in comparison to adipocytes this being reflected in  elevated basal levels 
of glucose uptake (Ebeling, Koistinen et al. 1998), in preadipocytes in comparison to 
adipocytes. However with differentiation, adipocytes became more insulin dependent 
and a significant increase in glucose uptake was seen and these related to associated 
increases in GLUT4. We also observed increased insulin-stimulated glucose uptake 
and increased GLUT4 levels in visceral adipocytes, compared to subcutaneous 
adipocytes, which is consistent with findings reported in children (Grohmann, Stewart 
et al. 2005) and have also been observed in primary cultures of visceral adipocytes 
from adults (Lundgren, Burén et al. 2004). 
Receptors are an important regulator of physiological functions. In adipose tissue, 
receptor distribution varies with the status of preadipocyte differentiation, with the 
IGF-IR being expressed in preadipocytes, as seen in the 3T3L1 cell line (Shimizu, 
Torti et al. 1986, Smith, Wise et al. 1988), and in cultures obtained from mammals 
(Nouguès, Reyne et al. 1993, Gerfault, Louveau et al. 1999). However, whether or not 
IGF-IR receptor expression persists in adipocytes is still controversial. We have 
shown that the IGF-IR significantly decreases with differentiation; however, it was 
still detected in mRNA expression and protein abundance but at minimal levels. In 
cultures obtained from middle-aged adults, the expression of the IGF-IR was also 
detected (Shimizu, Torti et al. 1986) and this was accompanied by increased levels of 
the insulin receptor (Kern, Svoboda et al. 1989, Bäck and Arnqvist 2009). In contrast, 
the IGF-IR was not detected in primary cultures obtained from pigs (Richardson, 
Hausman et al. 1994). Other studies also indicated an increase of insulin receptor 
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expression with differentiation (Shimizu, Torti et al. 1986, Bäck and Arnqvist 2009).  
The fat-depot differences in insulin receptor expression showed an increase in insulin 
receptor expression being observed in visceral fat in comparison to subcutaneous fat 
in adult subjects of normal weight  (Laviola, Perrini et al. 2006) and in the obese  
(Lefebvre, Laville et al. 1998). As all our data was obtained from samples taken from 
normal weight children, it might be interesting in future studies to consider comparing 
biopsies from lean and obese children. Other adults studies however, have reported no 
fat-depot differences in insulin receptor expression  (Bolinder, Kager et al. 1983).  
Insulin receptor isoforms have a tissue-specific manner of expression and this 
expression also varies between species. This indicates that insulin receptor isoforms 
may serve different physiological functions. For instance, in pigs IR-A is the dominant 
isoform in subcutaneous and retroperitoneal fat, whereas IR-B predominates in 
muscles. However, in rodents, IR-A is more expressed in muscles and IR-B is the 
dominant isoform in epididymal fat, and both IR-A and IR-B are expressed in 
retroperitoneal fat (Vienberg, Bouman et al. 2011). In humans, studies investigating 
insulin receptor isoforms are limited and controversial. Although similar IR-B 
predominance was reported in insulin-sensitive adipocytes (Moller, Yokota et al. 
1989), a conflicting study reported that IR-A is predominant in adipocytes in middle-
aged overweight female subcutaneous fat (Bäck and Arnqvist 2009). The literature is 
extremely limited with respect to children; only one study discussed childhood insulin 
receptor isoforms, examining perirenal fat from a single, 9-month-old female infant 
and reporting higher expression of IR-A. Although this is consistent with our results, 
this study was from one individual only and no mention was made regarding the 
differentiation status of the cells (Seino and Bell 1989). Our data indicate that in 
children, IR-A is more predominant in visceral preadipocytes, whereas IR-B is 
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significantly expressed in subcutaneous fat; however, as the cells differentiate into 
adipocytes, IR-B becomes more prominent. However, visceral adipocytes still 
maintained a higher expression of IR-A in comparison to subcutaneous adipocytes. As 
far as we know, this is the only study that has analyzed fat depot differences in insulin 
receptor isoforms in children. The role of these isoforms is currently of growing 
interest. Although the literature indicates that IR-A is more involved in prenatal 
growth and IR-B is linked to metabolism, recent studies suggest a new metabolic 
function for IR-A promoting glucose uptake and glycogen synthesis in muscle and 
murine hepatocytes (Diaz-Castroverde, Baos et al. 2016, Lopez-Pastor, Gomez-
Hernandez et al. 2019), and that insulin-like growth factor differences in receptor 
affinity may play an important role in this context.  
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3.6 Conclusion  
 
Adipose tissue is uniquely distributed throughout the human body, that allows for 
biological differences in cellular metabolism and endocrine function between fat 
depots. In this chapter we examined differences in IGF-IR, insulin and insulin receptor 
isoforms A and B in subcutaneous and visceral preadipocytes and post differentiation 
adipocytes. IGF-IR levels were higher in preadipocytes and decreased with 
differentiation, while the insulin receptor showed an increased expression. In 
agreement with our hypothesis, insulin receptor isoforms showed a predominance of 
IR-A in visceral cells in comparison to subcutaneous. As insulin like growth factor II 
is known to have a higher affinity to insulin receptor isoform A, this encourages us 
next to examine how IGF-II regulates preadipocyte physiological growth and 
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4.1. Introduction  
 
The IGF system has an established role in adipose tissue growth and metabolism.  The 
system consists of insulin-like growth factor I (IGF-I), insulin-like growth factor II 
(IGF-II), surface receptors (IGF-IR, IR and IGF-IIR/M6P) and six regulatory binding 
proteins (IGFBPs 1-6). The IGFs promote the growth of many tissues like muscle and 
bone (Zapf and Froesch 1986) and adipose tissue is considered a major target of IGF 
hormones. IGF-I is a potent promoter of preadipocyte proliferation and differentiation 
(Wright and Hausman 1995, Gregoire, Smas et al. 1998) and fat-depot differences in 
IGF-I responses have been reported (Grohmann, Sabin et al. 2005). IGF-I regulates 
preadipocytes directly or indirectly by facilitating the actions of growth hormone (GH) 
on adipose tissue (Berryman, Glad et al. 2013). In addition to adipose tissue growth, 
IGF-I acts as a metabolic regulator of glucose uptake, lipogenesis and lipolysis 
(Berneis, Vosmeer et al. 1996). 
Dysregulation of IGF binding proteins and ultimately IGF-I bioavailability is seen in 
obesity and metabolic syndrome (McMillen, MacLaughlin et al. 2008, Saydah, 
Ballard-Barbash et al. 2009). 
IGF-II is recognized for being an embryonic and placental growth factor, but its 
physiological role postnatally is still to be determined. The reason for this might be 
because IGF-II is not expressed postnatally in mouse or rat models, whereas humans 
maintain extremely high levels of IGF-II throughout life with concentrations 
considerably higher than those of IGF-I (Birnie, Ben-Shlomo et al. 2012). 
IGF-II expression has been strongly related to weight and adiposity; the level of IGF-
II gene methylation is associated with birth weight (Bennett, Wilson et al. 1983) and 
the expression of IGF-II in utero promotes adipogenesis and fat storage during 
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pregnancy (Whitaker and Dietz 1998). Additionally, the methylation status of the IGF-
II gene at birth has been linked to early childhood weight, (Le Stunff, Fallin et al. 
2001) and the level of IGF-II in the circulation during childhood has been closely 
related to fat mass (Ong, Kratzsch et al. 2002). In adults, polymorphic genetic 
differences in IGF-II expression correlated with weight gain; homozygous individuals 
with Apal AA had significantly higher IGF-II levels and this was associated with less 
body weight and lower risk of pathological body mass index (BMI) in comparison to 
those with Apal GG who had lower levels of IGF-II (O'Dell, Miller et al. 1997, Gaunt, 
Cooper et al. 2001). Furthermore, IGF-II levels have been proposed as a prognostic 
marker to predict future weight gain because lower baseline circulating levels of IGF-
II were associated with a higher risk of obesity and future weight gain (Sandhu, Gibson 
et al. 2003). Despite these strong suggestions of a role for IGF-II in adipose tissue 
growth and metabolism, a regulatory role is still largely unknown.  Using matched 
pairs of subcutaneous and visceral adipocyte cultures from children we investigated 
the physiological role of IGF-II in adipose tissue growth, and we speculated a distinct 
effect on subcutaneous and visceral cell growth, due to differences in the differential 
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4.2. Aims and objectives 
Our aim is to study if IGF-II has a physiological regulatory role on adipose tissue 
directly effecting preadipocytes number and their ability to differentiate and mature, 
this will be assessed by:  
A) Examine the proliferative effect of IGF-I, IGF-II and insulin on 
preadipocytes using subcutaneous and visceral human cultures. 
B) Study the role of IGF-II in subcutaneous and visceral preadipocyte 
differentiation using:   
1. Oil red O staining triglyceride staining 
2. Changes in the genetic expression and protein abundance of differentiation 
markers 
C) Examine the effect of IGF-II on preadipocyte maturation by the assessment 
of terminal differentiation markers like; insulin receptor, glucose 
transporter 4 and fatty acid synthase. 
D) Examine the acute effects of IGF-II treatment on adipocytes; the effect on 
receptor expression of IGF-IR, IR, IR isoforms and the subsequent 
metabolic consequences. 
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4.3. Materials and methods  
4.3.1. 3T3-L1 cell line culture. 
3T3-L1 preadipocytes were used for optimization purposes. Preadipocytes were 
grown in T75 flasks to 70% confluency and then plated into 24 well plates with a 
seeding density of 0.03 X106 with proliferation being assessed using a tritiated 
thymidine incorporation assay as described in section (2.2.4). 
4.3.2. Child fat biopsy preparation, culture and differentiation 
Paired biopsies from subcutaneous and visceral fat were prepared and cultured as 
described in the methods section (2.2.5). For differentiation experiments, 
preadipocytes were differentiated with or without continuous exposure to IGF-II at 
different concentrations. 
4.3.3. Tritiated thymidine incorporation Assay (TTI) 
A tritiated thymidine incorporation assay (TTI) was used to monitor proliferation in 
primary human preadipocytes, Cells were seeded into 24 well plates with a seeding 
density of 0.017 X 106 in growth media and allowed to attach for at least 12 hours. 
Complete media was replaced with SFM for 24 hours to allow the cells to become 
quiescent and were dosed the following day. After 48 hours 0.1µCi of [3H] thymidine 
per well was added for the last 4 hours at 37oC. Media was removed, and cells were 
incubated with 5% trichloroacetic acid (TCA) at 4oC for 10 minutes. The TCA was 
removed, and the cells were lysed in 1M sodium hydroxide for 1 hour at room 
temperature. The incorporation of [3H] thymidine into DNA was determined by 
scintillation counting; a sample (300µl) was mixed with 2ml of scintillation fluid and 
counted on a β-Scintillation Counter. Data was recorded as disintegration per minute 
(DPM). Further description of the equipment and protocol is described in section (2.5).  
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4.3.4. Trypan blue dye exclusion assay 
0.4% Trypan blue dye was used for preadipocyte cell counting; cells were harvested 
from culture plates and mixed with trypan blue dye in a 1:1 ratio. Cell number was 
determined using a haemocytometer slide and bright white cells were counted as 
viable cells. Protocol is described in section (2.2.3.2).  
4.3.5. Western immunoblotting  
Preadipocyte differentiation markers, glucose transporter 4, insulin receptor protein 
abundance and fatty acid synthase (FASN) were visualized using SDS-PAGE and 
western blotting. Protocol and antibody concentrations are described in section (2.4). 
Quantification of band intensities was determined by Image Lab 1.46r software. 
4.3.6. RNA extraction and RNA- cDNA reverse transcription 
RNA was extracted using Trizol reagent (Invitrogen) as outlined in section (2.6.2): 
one µg of RNA was reverse transcribed to cDNA using a high capacity RNA-to-cDNA 
kit (Applied Biosystems) as described in section (2.6.5).   
4.3.7. Quantitative Polymerase Chain Reaction (qPCR) 
mRNA expression was assessed using SYBR green-based qPCR. The PCR reaction 
was analyzed using StepOnePlus and relative mRNA levels were determined using 
the 2−ΔCt method after normalization to the GAPDH reference gene. For protocol 
details and primer sequencing refer to section (2.6.6)  
4.3.8. Glucose uptake  
[3H]2-deoxyglucose uptake was performed for IGF-II and insulin-stimulated cells: the 
stimulus was added for 15 minutes and glucose uptake was quantified using a β- 
Scintillation Counter. Data are presented as disintegrations per minute (DPM).  
Further protocol details are described in section (2.7) 
Chapter 4: the role of IGF-II in preadipocyte regulation 
 135 
4.3.9. Oil red O Triglyceride staining 
Oil red O (ORO) staining being performed on day 14 post differentiation for human 
cultures; further details of ORO is described in section (2.3). Quantification of the 
ORO stain was carried out using spectrophotometry (FLUOstar OPTIMA, BMG 
LABTECH) at 490nm. 
4.3.10. Statistical analysis  
One-way ANOVA followed by a least significant difference (LSD) post-hoc test was 
used for multiple comparisons (subcutaneous and visceral) at day 0 and day 14 post 
differentiation. The software used for analysis was SPSS 12.0.1 for Windows. A 
statistically significant difference was considered to be present at p< 0.05. 
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4.4. Results 
4.4.1. Optimization of a proliferation assay for the 3T3-L1 cell line using a 
tritiated thymidine incorporation (TTI) assay 
Because children’s biopsies are very precious, we first used the 3T3-lL cell line to 
optimize the assay. The tritiated thymidine incorporation  assay is one of the most 
accurate because it is directly measuring DNA synthesis (Madhavan 2007). 3T3-L1 
cells were treated with IGF-I ( 0-500 ng/ml)  (Boney, Smith et al. 1998). IGF-I induced 
a significant increase in proliferation from 31.25 ng/ml in comparison to control with 
a peak response observed at 125 ng/ml ; the fold change increase was respectively; 
(31.25 ng/ml 2.5; p<0.01), (62.5ng/ml 3.3, p<0.001), (125 ng/ml;4.8; p<0.01), (250 
ng/ml; 2.8; p<0.01), (500 ng/ml;2.4; p<0.05). 7.8 and 15.62ng/ml IGF-I were too low 
to elicit a significant response (Figure 4-1).  
 
Figure 4-1 Assessment of proliferation in 3T3-L1 cells using a tritiated thymidine 
incorporation assay (TTI) following IGF-I treatment  
3T3-L1 preadipocytes were seeded in 24 well plates at a density 0.03×106 per well. Following 
cell attachment, preadipocytes were serum starved for 24 hours and then dosed with IGF-I(0-
500ng/ml) for 48 hours. Cell proliferation was detected using a TTI assay. The graph 
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represents the mean ±SEM of three independent repeats each performed in duplicate (* 
P<0.05, ** P<0.01, *** P<0.001). 
 
To confirm the results obtained using the TTI assay, the effects of IGF-I on 3T3-L1 
cell growth was also assessed by cell counting using a trypan blue dye exclusion assay 
(Figure 4-2).  A similar pattern of proliferation was seen with a peak in cell growth 
observed at 125 ng/ml. 
 
Figure 4-2 Assessment of 3T3-L1 proliferation following IGF-I treatment using 
trypan blue dye exclusion assay. 
Preadipocytes were serum starved in 5mM glucose serum free media (24h) followed by IGF-
I treatment (0-500 ng/ml). Trypan blue cell counting was performed after 48 hours of 
treatment where bright cells were considered viable. The graph represents the mean ±SEM of 
two independent repeats each performed in duplicate (* p<0.05, ** p<0.01, *** p<0.001). 
 
IGF-II was less effective in inducing proliferation in 3T3-L1 cells than IGF-I: this 
probably being due to its lesser affinity to the IGF-IR. 62.5 ng/ml elicited a 3.4 fold 
increase  (p<0.01), 125 ng/ml a 2.8 fold increase (p<0.05) with the highest response 
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observed with 250 ng/ml is 3.6 fold increase in comparison to control (p<0.01). The 
other doses did not induce an effective proliferative response (Figure 4-3). 
 
Figure 4-3 Assessment of proliferation in 3T3-L1 cells using a tritiated thymidine 
incorporation assay (TTI) following IGF-II treatment.  
3T3-L1 preadipocytes were seeded in 24 well plates at a density 0.03×106 cells per well, 
followed by serum starvation for 24 hours. They were the dosed with IGF-II (0- 500ng/ml) 
for 48 hours. TTI assay was used to measure preadipocyte proliferation. The graph represents 
the mean ±SEM of three independent repeats each conducted in duplicate (* p<0.05, ** 
p<0.01, *** p<0.001). 
 
 
4.4.2. The effect of IGF-I on human subcutaneous and visceral preadipocyte 
proliferation. 
After optimization of the tritiated thymidine incorporation (TTI) assay using 3T3-L1 
cells, we investigated fat-depot differences in proliferation using human cultures.  
Paired subcutaneous and visceral preadipocytes were serum starved in normal glucose 
(5mM) serum free media for 24 hours followed by IGF-I treatment (0-500 ng/ml) for 
48 hours. IGF-I was more potent in stimulating growth in subcutaneous compared 
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with visceral preadipocytes. In comparison to control there was a (1.4; p<0.05), (1.7; 
p<0.05), (2.1; p<0.001), (1.8; p<0.05), (1.6; p<0.05) and (1.5; p<0.01) fold increase 
in proliferation for the following IGF-I doses 7.8, 15.6, 31.2, 62.5 ,125, 250 
respectively (Figure 4-4 A). Visceral preadipocytes were less responsive to IGF-I than 
subcutaneous at the higher doses and the fold of increase in comparison to control was 
1.4 (p<0.05) and 1.9 (p<0.001) for the doses 15.6 and 31.2 ng/ml with a diminution of 
proliferative responses with other doses (Figure 4-4 B). The IGF-I responses showed 
a bell-shaped curve, representative of a typical biological response.  
 
Figure 4-4 Effect of IGF-I treatment on subcutaneous and visceral preadipocyte 
proliferation. 
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Tritiated thymidine incorporation assay (TTI) was used to assess proliferation in. 
subcutaneous (A) and visceral (B) preadipocytes. Cells were seeded at 0.017x106 cells/well 
and treated with IGF-I (0 to 500 ng/ml) in 5mM glucose SFM. TTI was performed after 48h 
of treatment.  The graph represents the mean ±SEM of three independent repeats each 
performed in duplicate (n=3). 
(* p<0.05, ** p<0.01, *** p<0.001). 
4.4.3. Effect of IGF-II on human subcutaneous and visceral preadipocyte 
proliferation. 
A role for IGF-I in preadipocyte growth regulation is well established but less is 
known about the role of IGF-II. We investigated the effect of IGF-II treatment (0-500 
ng/ml) on subcutaneous and visceral preadipocytes proliferation using a TTI assay.  
IGF-II treatment induced subcutaneous preadipocytes proliferation in comparison to 
control with 15.6 ng/ml treatment (1.2 fold; p<0.05), 31.25 ng/ml (1.4 fold; p<0.05) 
and 62.5 ng/ml (1.5 fold; p<0.01) (figure 4-5 A). Interestingly, IGF-II elicited a greater 
proliferative effect in visceral preadipocytes in comparison to subcutaneous as the fold 
change increase in comparison to control was (1.3 fold; p<0.05), (1.7 fold; p<0.05), 
(1.8 fold; p<0.05), (2.0 fold; p<0.001) for the doses 7.8 ,15.6, 31.2, 62.5 ng/ml 
respectively.  The higher doses of IGF-II; 125 ng/ml induced lesser proliferative 
response (Figure 4-4 B).  
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Figure 4-5 Proliferative effect of IGF-II on human subcutaneous and visceral 
preadipocytes. 
The proliferation of A. Subcutaneous and B. visceral preadipocytes was determined using a 
TTI assay. Cells were seeded at 0.017x106 cells and were treated with multiple concentrations 
of IGF-II (0ng/ml to 500 ng/ml) in (5mM) glucose SFM. TTI was performed after 48hrs of 
treatment.  The graph represents the mean±SEM of three independent repeats each performed 
in duplicate (n=3). (* p<0.05, ** p<0.01, *** p<0.001). 
 
 
Chapter 4: the role of IGF-II in preadipocyte regulation 
 142 
4.4.4. Effect of insulin on human subcutaneous and visceral preadipocytes on 
proliferation. 
In comparison to IGFs, insulin has minimal effects on proliferation of subcutaneous 
or visceral preadipocytes. Preadipocytes were treated with insulin (0-500 ng/ml) and 
no significant increase in proliferation was detected in either fat depot. The highest 
fold change increase in comparison to control was 1.1 in subcutaneous preadipocytes 
and 1.05 in visceral preadipocytes (figure 4-6).  
 
Figure 4-6 Effect of insulin treatment on human subcutaneous and visceral 
preadipocyte proliferation. 
A. Subcutaneous preadipocytes and B. visceral preadipocytes were seeded at 
0.017x106cells and treated with different concentrations of insulin (0- 500 ng/ml) in 
5mM glucose SFM. Proliferation was determined using a TTI assay after 48h. The 
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graph represents the mean ±SEM of three independent repeats each performed in 
duplicate (n=3). Statistical significance was determined at (p<0.05). 
 
 
4.4.5. Effect of IGF-II treatment on human subcutaneous and visceral 
preadipocyte differentiation. 
Adipose tissue growth consists of an increase in cell number as well as size. After 
examining the effect of IGF-II on preadipocyte proliferation, we investigated the role 
of IGF-II in preadipocyte differentiation in a depot-specific manner. As illustrated 
previously in section (4.4.3), IGF-II is more effective at doses less than 100 ng/ml: for 
that reason, we chose the lowest dose that caused a significant proliferative effect (7.5 
ng/ml) and the dose with maximal effect on proliferation (62.5 ng/ml) to examine the 
role of IGF-II in preadipocyte differentiation (these doses are within the physiological 
concentration) (Philpott, Sanders et al. 1994). Visceral and subcutaneous 
preadipocytes were differentiated for 14 days with normal glucose (5mM/L) 
differentiation media or differentiation media supplemented with the stipulated 
concentrations of IGF-II concentrations. 
4.4.5.1. Assessment of IGF-II on preadipocyte differentiation using Oil red O triglyceride 
staining.  
Oil red O staining was performed on day 14 post differentiation. Spectrometry 
quantification of absorbance of the Oil red O indicated that IGF-II (62.5 ng/ml) 
enhanced fat deposition in subcutaneous fat in comparison to control; this was 
observed under the microscope (Figure 4-7 A) and by Oil red O staining analysis, as 
the absorbance quantification showed a significant increase in comparison to control 
(0.847 Vs. 0.3; p<0.01) (figure 4-7 B). In terms of visceral preadipocyte 
differentiation, interestingly IGF-II reduced the amount of preadipocyte 
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differentiation as seen under the microscope (Figure 4-7 A). Oil red O absorbance 
analysis showed a reduction in triglycerides with IGF-II treatment (62.5 ng/ml) in 
comparison to control (0.3 Vs. 0.5; P<0.05) (Figure 4-7 B) 
 
Figure 4-7 Effect of IGF-II treatment on subcutaneous and visceral preadipocyte 
differentiation.  
Subcutaneous and visceral preadipocytes were differentiated for 14 days in the presence or 
absence of IGF-II at (7.5 ng/ml) or (62.5 ng/ml). (A) micrograph of differentiated 
preadipocytes stained with Oil red O at day 14 of differentiation. Magnification at (X10). (B) 
Quantitative Oil red O staining absorbance analysis of (A) showing a reduction in Oil red O 
absorbance in visceral adipocytes (p<0.05) and an increase in the absorbance in subcutaneous 
differentiated adipocytes (p<0.01) with IGF-II treatment (62.5 ng/ml). The data are expressed 
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as the mean ± SEM of duplicate runs from three individual biopsies (n=3). Statistical analysis 
was performed using one-way ANOVA on day 14 of differentiation. 
 
4.4.5.2. Assessment of IGF-II on markers of differentiation in subcutaneous and visceral 
cultures. 
 
To further confirm the effect of IGF-II on preadipocyte differentiation, subcutaneous 
and visceral preadipocytes were differentiated for 14 days with normal glucose 
differentiation media (control) or differentiation media supplemented with the IGF-II 
(7.5 ng/ml, 62.5 ng/ml). Whole cell lysate was extracted on day 14 post differentiation 
for western blotting analysis for assessment of peroxisome proliferator-activated 
receptor gamma (PPARγ) and adiponectin which are known to be increased with 
adipogenesis, as we previously showed in section (3.4.3.3) and illustrated in figure (4-
8). The protein abundance of the differentiation markers PPARγ and adiponectin 
showed a significant increase in relative fold-change in comparison to control (1.86 
vs.1.0 for adiponectin; p<0.05) and (3.8 vs. 1.0 for PPARγ; p<0.01) in subcutaneous 
adipocytes when treated with 62.5 ng/ml IGF-II. This IGF-II induced increase in 
PPARγ was mainly due to an increase in PPARγ2.  In contrast, a decrease in the 
relative fold-change of protein abundance of the differentiation markers in comparison 
to control was observed for adiponectin (0.4 vs. 0.9; P<0.05) and PPARγ (0.3 vs. 1.2; 
P<0.05) for visceral adipocytes when treated with the same dose of IGF-II. IGF-II at 
7.5ng/ml was not sufficient to induce significant changes. The changes are illustrated 
in (Figure 4-9). 
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Figure 4-8 Illustration of preadipocyte early and late differentiation markers. The 
figure is adapted from (Ràfols 2014). 
 
 
Figure 4-9 IGF-II promoted differentiation of subcutaneous but not visceral 
preadipocytes.  
Subcutaneous and visceral preadipocytes were differentiated for 14 days in the presence or 
absence of IGF-II at (7.5 ng/ml) or (62.5 ng/ml). (A) Western immunoblotting of the 
differentiation markers PPARγ and adiponectin. (B) Densitometry of the western blot showing 
protein abundance of adiponectin after normalization to the reference protein β-actin. (C) 
Densitometry quantification of the differentiation marker PPARγ after normalization to β-
actin.  The data are expressed as the mean ± SEM of and each western blot densitometry is 
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representative of experiments performed in triplicate from three individual biopsies (n=3). 
Statistical analysis was performed using one-way ANOVA on day 14 of differentiation. 
 
4.4.6. Effect of differentiation with IGF-II on fat metabolism in subcutaneous and 
visceral cultures. 
Insulin receptor signaling is known to activate the genetic transcription of fatty acid 
synthase (FASN), lipoprotein lipase (LPL) and glucose transporter 4 (GLUT4). 
Insulin will also cause GLUT4 translocation to the cell membrane that induces glucose 
uptake to the fat cell (Czech, Tencerova et al. 2013). In addition, these genes are also 
known to increase with differentiation (Moseti, Regassa et al. 2016). To further 
confirm that IGF-II reduced differentiation and fat deposition in visceral 
preadipocytes whilst enhancing it in subcutaneous preadipocytes, we examined the 
protein abundance of the insulin receptor, GLUT4 and FASN using western blotting 
after 14 days of differentiation of paired subcutaneous and visceral preadipocytes with 
IGF-II at two doses (7.5 ng/ml and 65.5 ng/ml).  
 
4.4.6.1. Effect of IGF-II on insulin receptor abundance with differentiation.  
 
IGF-II enhanced insulin receptor protein abundance in subcutaneous adipocytes and 
the relative fold change in comparison to control was 2.2 vs.1.0 fold (p<0.001) for 
7.5ng/ml IGF-II and 3.1 vs.1.0 fold (p<0.001) for 62.5 ng/ml IGF-II. In contrast, with 
visceral adipocytes there was an IGF-II-induced, significant reduction in insulin 
receptor abundance in comparison to control; the relative fold change reduction was 
significant for both doses 7.5 ng/ml (1.0vs. 1.4; P<0.05) and 62.5 ng/ml (0.9vs.1.4; 
P<0.01). When comparing fat depots, there was a significant difference in insulin 
receptor protein abundance with IGF-II (62.5 ng/ml) increasing insulin receptor 
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abundance 2.2-fold in subcutaneous adipocytes in comparison to visceral (P<0.001) 
(Figure 4-10).  
 
 
Figure 4-10 Effect of IGF-II on insulin receptor protein abundance with 
differentiation.  
(A)Western blotting of paired subcutaneous and visceral preadipocytes differentiated for 14 
days with IGF-II (7.5 ng/ml or 62.5 ng/ml) showing insulin receptor protein abundance.  (B) 
Densitometry western blot analysis of (A). β-actin was used to ensure equal loading of 
samples. Densitometry represents the mean ± SEM of three experimental repeats from three 
individual biopsies (n=3). Statistical analysis was performed using one-way ANOVA on day 
14 of differentiation.  
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4.4.6.2. Effect of IGF-II treatment on the abundance of the glucose transporter 4 (GLUT4) 
and consequent glucose uptake with differentiation in subcutaneous and visceral 
cultures. 
A consistent decrease in GLUT4 protein abundance was seen in visceral adipocytes 
when differentiated with IGF-II at 7.5 ng/ml (0.8vs.1.4; p<0.01) and at 62.5 ng/ml 
(0.7vs. 1.4; p<0.01) (Figure 4-11). This was also reflected by a 16% reduction in 
insulin-stimulated radioactive 2DG glucose uptake by visceral adipocytes in 
comparison to control (p<0.01) (Figure 4-12) following IGF-II (62.5ng/ml) treatment. 
GLUT4 relative protein abundance increased in subcutaneous adipocytes with IGF-II 
(62.5 ng/ml) (1.5vs.1.0; P<0.05) in comparison to control, However, the increase in 
abundance of GLUT4 at 7.5 ng/ml IGF-II was insignificant (Figure 4-11). Insulin-
stimulated glucose uptake was also significantly increased in subcutaneous adipocytes 
using the higher dose of IGF-II in comparison to control (2019 DPM vs.1678 DPM; 
P<0.01) as seen in figure (4-12).  
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Figure 4-11 Effect of IGF-II on the abundance of the glucose transporter 4 
(GLUT4) with differentiation.  
(A) Western blotting of paired subcutaneous and visceral preadipocytes differentiated for 14 
days with IGF-II (7.5 ng/ml or 62.5 ng/ml) showing GLUT4 protein abundance.  (B) 
Densitometry western blot analysis of (A). β-actin was used to ensure equal loading of 
samples. Densitometry represents the mean ± SEM of three experimental repeats from three 
individual biopsies (n=3). Statistical analysis was performed using one-way ANOVA on day 
14 of differentiation. 
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Figure 4-12 Effect of differentiation with IGF-II (7.5 ng/ml, 62.5 ng/ml) on 
radioactive insulin stimulated glucose uptake. 
Subcutaneous and visceral preadipocytes were differentiated in the presence or absence of 
IGF-II at (7.5 ng/ml) or (62.5 ng/ml), at day 14 of differentiation for 15 minutes. Insulin 
stimulated H3 -2deoxy glucose was performed. Data represents the mean ± SEM of three 
experimental repeats from three individual biopsies (n=3). Statistical analysis was performed 
using one-way ANOVA on day 14 of differentiation. 
 
4.4.6.3. Effect of IGF-II treatment on fatty acid synthase (FASN) with differentiation in 
subcutaneous and visceral cultures. 
Fatty acid synthase protein abundance was also reduced in visceral adipocytes when 
differentiated with 7.5 ng/ml IGF-II (0.9vs.1.8; p<0.001) and 62.5 ng/ml IGF-II (0.5 
vs. 1.8; p<0.001) and similarly FASN protein abundance was enhanced in 
subcutaneous adipocytes with both doses of IGF-II; 7.5ng/ml (2.7vs.1.0; P<0.001) and 
62.5ng/ml (4.5 vs.1.0; P<0.001) as demonstrated in (Figure 4-13). 
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Figure 4-13 Effect of IGF-II on fatty acid synthase (FASN) abundance with 
differentiation.  
Western blotting of paired subcutaneous and visceral preadipocytes differentiated for 14 days 
with IGF-II (7.5 ng/ml or 62.5 ng/ml) (A) Western blot illustrates FASN protein abundance.  
(B) Densitometry western blot analysis of (A). β-actin was used as a loading control. 
Densitometry represents the mean ± SEM of three experimental repeats from three individual 
biopsies (n=3). Statistical analysis was performed using one-way ANOVA on day 14 of 
differentiation. 
 
4.4.7. The Effect of acute IGF-II treatment on the expression of insulin receptor 
and the IGF-IR in subcutaneous and visceral adipocytes.  
After investigating IGF-II’s role in preadipocyte proliferation and differentiation, we 
further examined the acute effect of IGF-II on mature differentiated adipocytes to 
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understand IGF-II actions at the receptor level, these cells being differentiated with 
normal glucose (5mM/L) differentiation media and collected on day 14. The 
adipocytes were serum starved for 24 hours followed by 24 hours’ treatment with IGF-
II (62.5 ng/ml). IGF-II treatment down regulated the mRNA expression of total insulin 
receptor levels in visceral adipocytes; the expression was normalized to GAPDH 
reference gene and the relative fold change vs. control was (16.5 vs. 42.07; p<0.01). 
Furthermore, there was also a reduction in total levels of insulin receptor mRNA in 
subcutaneous adipocytes (15.9 vs.1.0; P<0.05) (Figure 4-14). 
 
 
Figure 4-14 :Effect of IGF-II treatment on receptor expression in subcutaneous 
and visceral differentiated adipocytes.  
Relative mRNA expression of the insulin receptor following 24 hours treatment with IGF-II 
(62.5 ng/ml) was performed using qPCR showing down regulation of the IR in visceral 
adipocytes. The expression was normalized to the reference gene GAPDH and data are 
represented as the mean ± SEM of experiments performed in duplicate runs from six 
individual biopsies (n=6). Statistical analysis was performed using one-way ANOVA. 
Chapter 4: the role of IGF-II in preadipocyte regulation 
 154 
 In terms of the IGF-IR, there were no significant changes in IGF-IR mRNA 
expression after IGF-II treatment for subcutaneous adipocytes (P=0.098) or visceral 
adipocytes (p=0.71) (Figure4-15). This was expected as IGF-IR abundance decreased 
in adipocytes as we showed previously in section (3.4.8). 
 
 
Figure 4-15: Effect of IGF-II treatment on IGFIR receptor expression in 
differentiated adipocytes.  
Relative mRNA expression of the IGF-IR following 24 hours IGF-II (62.5 ng/ml) treatment 
was performed using qPCR showing no significant changes in receptor expression in 
subcutaneous and visceral adipocytes. In all experiments, expression was normalized to the 
reference gene GAPDH and data are represented as the mean ± SEM of experiments 
performed in duplicate runs from six individual biopsies (n=6). Statistical analysis was 
performed using one-way ANOVA.  
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4.4.8. The effect of IGF-II treatment for 24hours on the distribution of insulin 
receptor isoforms in subcutaneous and visceral adipocytes. 
When looking specifically at the insulin receptor isoforms, there was an IGF-II 
induced down regulation of insulin receptor isoform B in both visceral adipocytes vs. 
control (5.5 vs. 18.7: P<0.05) (Figure 4-16 B) and subcutaneous adipocytes 
(2.1vs.14.0: p<00.1) (Figure 4-16 A). However, insulin receptor isoform A was only 
significantly down regulated in visceral adipocytes (1.4 vs.12.8: P<0.05) consistent 
with the maintenance of IR-A and maintained sensitivity to IGF-II.  
 
 
Figure 4-16: Effect of IGF-II treatment on the expression of insulin receptor 
isoforms in differentiated adipocytes.  
Relative mRNA expression following 24 hours treatment with IGF-II (62.5 ng/ml) was 
performed using qPCR.  mRNA expression of the insulin receptor isoforms IR-A and IR-B in 
(A) subcutaneous and (B) visceral adipocytes showing down regulation of IR-A and IR-B 
with IGF-II treatment in visceral adipocytes and in IR-B expression in subcutaneous 
adipocytes. In all experiments, expression was normalized to the reference gene GAPDH and 
Chapter 4: the role of IGF-II in preadipocyte regulation 
 156 
data are represented as the mean ± SEM of experiments performed in duplicate runs from six 
individual biopsies (n=6). Statistical analysis was performed using one-way ANOVA.  
 
4.4.9. The effect of 24hours of IGF-II treatment on glucose transporter 4 and 
glucose uptake in differentiated subcutaneous and visceral adipocytes. 
IGF-II treatment markedly down regulated GLUT4 mRNA expression in visceral  
adipocytes as the fold change in comparison to control was (0.66 vs 8.13; P<0.001). 
In contrast, IGF-II had a minimal effect on GLUT4 expression in subcutaneous 
adipocytes (P=0.592) (Figure 4-17). 
 
 
Figure 4-17: Effect of IGF-II treatment on GLUT4 expression in differentiated 
adipocytes.  
Relative mRNA expression of GLUT4 in subcutaneous and visceral adipocytes following 
24hours treatment with IGF-II (62.5 ng/ml) measured by qPCR and normalized to GAPDH 
reference gene. Data are expressed as the mean ± SEM of duplicate runs from three individual 
biopsies (n=3). Statistical analysis was performed using one-way ANOVA. 
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To examine if the mRNA expression changes corresponded with protein abundance, 
we also examined GLUT4 protein abundance for subcutaneous and visceral 
adipocytes. Visceral GLUT4 protein abundance was also reduced in comparison to 
control (0.4 vs. 0.8: P<0.05) and no significant changes in GLUT4 protein abundance 
were observed in subcutaneous adipocytes (P=0.369) (Figure 4-18) 
 
Figure 4-18: Effect of IGF-II on GLUT4 protein abundance in differentiated 
adipocytes. 
(A) Western blot showing GLUT4 abundance; GAPDH was used a loading control. (B) 
Densitometry analysis of (A) indicating a reduction in GLUT4 protein abundance in visceral 
adipocytes. Data are expressed as the mean ± SEM and each western blot densitometry is 
representative of experiments performed in triplicate from three individual biopsies (n=3). (* 
P<0.05, ** P<0.01, *** P<0.001). 
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The down regulation of GLUT4 in visceral adipocytes was associated with a 33.8 % 
reduction in 2DG glucose uptake (1580.5 DPM vs 2388.8 DPM; P<0.05). There were 
no significant changes in glucose uptake with IGF-II treatment in subcutaneous 
adipocytes (1904.4 DPM vs 1656.3 DPM; P=0.855) (Figure 4-19) 
 
 
Figure 4-19: Effect of IGF-II treatment on glucose uptake in subcutaneous and 
visceral differentiated adipocytes.  
[3H]2-Deoxy glucose uptake following IGF-II treatment (60 ng/ml) in visceral and 
subcutaneous adipocytes. Data are expressed as the mean ± SEM of duplicate runs from three 
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4.5. Discussion   
 
The post-natal role of IGF-II has been poorly investigated, despite its abundance in 
the human circulation where it exceeds that of IGF-I and its predominant local 
production from adipose tissue (Gude, Frystyk et al. 2012). Being a fetal growth 
promoter, IGF-II in utero expression promotes adipogenesis and fat storage during 
pregnancy (Whitaker and Dietz 1998). Additionally, methylation status of the IGF-II 
gene at birth has been linked to early childhood weight (Le Stunff, Fallin et al. 2001), 
and the level of IGF-II in the circulation during childhood has been closely related to 
fat mass (Ong, Kratzsch et al. 2002). Together these reports indicate a possible 
regulatory role of IGF-II in adipose tissue. 
We investigated IGF-II’s actions using paired visceral and subcutaneous fat biopsies 
and the data suggested that at physiological concentrations, IGF-II has depot-specific 
actions in terms of promoting preadipocyte growth; IGF-II enhances subcutaneous 
preadipocyte growth to mature adipocytes and fat deposition but in contrast has a 
restricting effect on visceral preadipocyte maturation.  
IGFs are known mitogenic factors (Jones and Clemmons 1995) , the proliferative 
effect of IGF-I on preadipocytes is well- established in the 3T3-L1 cell line (Boney, 
Smith et al. 1998) and in mammalian primary cultures (Wright and Hausman 1995). 
These studies are consistent with our findings supporting this proliferative effect on 
3T3-L1 cell lines.  IGF-I also promoted subcutaneous and visceral preadipocyte 
proliferation with a higher increase in subcutaneous preadipocytes. This might be due 
to the mitogenic actions of IGF-I  reported to be mediated through the IGF-IR (Bäck, 
Brännmark et al. 2011). Furthermore, a higher level of the IGF-IR was detected in 
subcutaneous preadipocytes than visceral preadipocytes, section (3.4.8).   
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IGF-II was also shown to stimulate proliferation in the 3T3-L1 cell line (Siddals, 
Westwood et al. 2002). However, IGF-II was less effective than IGF-I in promoting 
3T3-L1 proliferation. This can be explained since 3T3-L1 preadipocytes almost 
exclusively express the IGF-IR and IGF-I affinity for IGF-IR is known to be higher 
than IGF-II and insulin (Varewijck and Janssen 2012).  Unlike the 3T3-L1 cell line, 
studies have indicated that human preadipocytes express both IGF-IR and IR (Bäck, 
Brännmark et al. 2011).  In humans, IGF-II preadipocytes proliferation might also be 
mediated through the insulin receptor (Morrione, Valentinis et al. 1997), and that IGF-
II can stimulates different responses than insulin through the insulin receptor 
(Morcavallo, Gaspari et al. 2011). Furthermore, insulin receptor isoform expression is 
different between the two fat depots with the isoform B (IR-B) being predominant in 
subcutaneous preadipocytes, and the visceral expressing mainly the IR-A form.  This 
might contribute to the proliferative effect of IGF-II as IR-A has a more potent  
mitogenic effect  than IR-B  (Belfiore, Malaguarnera et al. 2017). Our findings also 
indicate and are consistent with other studies that suggest that insulin has less of a 
mitogenic effect in comparison to IGFs and is more responsible for metabolic action 
(Siddals, Westwood et al. 2002).  
In terms of preadipocyte differentiation , IGF-II stimulated differentiation of adipose 
tissue isolated from eyelids in humans (Kang, Park et al. 2011) but no human studies 
focused on the fat-depot specific IGF-II effects. In mammals, similar findings on fat 
depot differences due to the actions of IGF-II have been reported in fetal baboons, 
with higher lipid deposition being seen in subcutaneous in comparison to visceral fat 
(Tchoukalova, Nathanielsz et al. 2009).  
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The depot-specific pattern of differences in IGF-II has been described more frequently 
in human genetic studies, with higher methylation of IGF2/H19 imprinting control 
region (ICR) in young adults at the age of 17 being associated with higher IGF-II 
expression and increases in subcutaneous fat but not increased waist circumference or 
visceral fat accumulation (Huang, Galati et al. 2012). Furthermore, analysis of the East 
Hertfordshire cohort study reported that individual variance in the genetic region 
IGF2-INS-TH is related to body weight. Individuals with an IGF2-INS-TH 5* 
haplotype that involves the IGF2 Apal A allele together with allele 9 of TH01 and a 
subset of class I alleles of INS VNTR as a gene cluster, and who are known to have 
higher IGF-II levels, (O'Dell, Miller et al. 1997) had lower associated waist 
circumference, hip-to-waist ratio and BMI in comparison to non *5 haplotype 
individuals (Rodríguez, Gaunt et al. 2004, Rodríguez, Gaunt et al. 2006). 
Controversially, other studies have suggested that increased IGF-II levels are 
positively associated with central adiposity (Martin, Holly et al. 2006) and overall 
weight gain (Roth, Schrager et al. 2002). However, ethnic differences may be 
important in IGF-II weight-related effects (Fowke, Matthews et al. 2010, Perkins, 
Murphy et al. 2012).  Interestingly, IGF-II regulation of the differentiation markers 
showed a  particular regulation of PPARγ2 , which unlike PPARγ1 is very specific to 
adipose tissue (Mukherjee, Jow et al. 1997) functioning as an early regulator of the 
transcription genes  needed for adipocytes differentiation (Tontonoz, Hu et al. 1994). 
This might suggest that IGF-II can regulate preadipocyte growth by influencing the 
splice variance of PPAR early in the differentiation process. We further investigated 
how IGF-II treatment affected mRNA expression of the IGF-IR, insulin receptor and 
its isoforms in adipocytes. Because IGF-IR abundance reduces with differentiation, 
IGF-II exposure showed a non-significant effect on the IGF-IR in adipocytes. whereas, 
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IGF-II caused down regulation of total insulin receptor mRNA levels, particularly 
with respect to IR-A in visceral adipocytes. This was associated with downregulation 
of GLUT4.  IGF-II was reported to activate insulin receptor in adipose cells (Bäck, 
Brännmark et al. 2011) and with higher affinity to IR-A (Lefebvre, Laville et al. 1998). 
Furthermore, a supporting report  also indicated that IGF-II regulates glucose uptake 
through the insulin receptor in isolated adipocytes obtained from adult subjects  
(Sinha, Buchanan et al. 1990) and through IR-A in neonatal hepatocytes (Nevado, 
Valverde et al. 2006).  Because of the higher expression of IR-A in visceral adipocytes 
in comparison to subcutaneous, this might explain the profound action of IGF-II on 
visceral in comparison to subcutaneous adipocytes which have less IR-A (Frasca, 
Pandini et al. 2008). In addition, IGF-II depot-specific actions may be explained by 
the differences in IGF-II tissue availability. This is regulated by IGF binding proteins 
(IGFBPs) and the IGF-II receptor (IGF-IIR/M6P) an IGF-II clearance receptor that 
together regulate IGF-II levels. A difference in IGFBP production between 
subcutaneous and visceral fat (Gude, Hjortebjerg et al. 2016) has been reported,  and 
a fat-depot difference in IGF-IIR/M6P abundance was also seen in mammals 
(Tchoukalova, Nathanielsz et al. 2009). Furthermore, fat depot variances in the 
protease enzymes e.g. the protease pregnancy associated plasma protein-A (PAPP-A)  
which can regulate IGF binding to the binding proteins  (Conover, Harstad et al. 2013) 
has been indicated to influence fat, as interestingly knocking down PAPP-A in high 
fat fed mice showed a reduction in visceral fat. Another study indicated that high-fat 
consumption in PAPP-A knock-down female mice showed an increase in 
subcutaneous fat and a reduction in retroperitoneal fat (Hill, Arum et al. 2015), 
however a contrary study also showed no effect (Christians, Bath et al. 2015). This 
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highlights the importance of investigating IGFs in a fat depot specific manner which 
can highly affect adipose tissue development.  
Overall, our results indicate that IGF-II might have a role as a physiological regulator 
of preadipocyte growth and metabolism and may play a fat-depot specific role in 
regulating body fat composition possibly by increasing subcutaneous and reducing 
visceral fat differentiation.  
 
  





Insulin like growth factor -II is an important fetal growth regulator, however little is 
known about its role after birth.  The genetic associations of IGF-II expression and 
circulating levels with body weight and obesity indicate a regulatory role for IGF-II 
in adipose tissue. In support of our hypothesis, the results indicate that IGF-II can 
promote adipose tissue proliferation and differentiation. However, IGF-II acts in a 
depot-specific manner causing an increase in differentiation of subcutaneous 
preadipocytes and limiting that in visceral preadipocytes. This was shown by 
assessment of the differentiation markers PPAR-γ and adiponectin and evaluation of 
adipocyte maturation indicators (FAS, IR, GLUT4). Furthermore, IGF-II regulated the 
expression of insulin receptor isoforms in adipocytes and had a more pronounced 
effect on visceral cells, most likely due to the higher predominance of IR-A in 
comparison to subcutaneous. In the next chapter, we want to explore if these fat-depot 













Chapter 5 : Fat-depot differences in insulin-like 
growth factor-II (IGF-II) regulation: role of the 
IGF-II/ mannose-6-phosphate receptor (IGF-
IIR/M6P).





The IGF-IIR/M6P receptor is a multifunctional transmembrane glycoprotein that has 
a unique structure consisting of a large extracellular domain of 2,264 residues and a 
small intracellular domain consisting of 23 transmembrane residues and a 164-residue 
cytoplasmic domain (Lemamy, Ndeboko et al. 2016). The binding of IGF-II to the 
IGF-IIR/M6P receptor does not induce tyrosine kinase activity, but it induces the 
internalization and lysosomal degradation of the hormone inside the cell (Oka, Rozek 
et al. 1985). In addition to IGF-II binding, IGF-IIR/M6P has an M6P-bearing site that 
binds to other ligands including transforming growth factor-β (TGF- β) and 
plasminogen (Dennis and Rifkin 1991, Leksa, Pfisterer et al. 2012). Human IGF-IIR 
(IGF-IIR/M6P) has been shown to exhibit bi-allelic expression (Kalscheuer, Mariman 
et al. 1993, Xu, Goodyer et al. 1993), unlike in rodents where it is only maternally 
expressed; however, some controversial studies have suggested a similar maternal 
expression in humans as well (Xu, Goodyer et al. 1993). 
Tight maintenance of IGF-II levels is important because dysregulation is not only 
associated with growth disturbance (Kalscheuer, Mariman et al. 1993) and malignancy 
(Yamada, De Souza et al. 1997, Oates, Schumaker et al. 1998) but also with metabolic 
diseases such as diabetes (Jeyaratnaganthan, Højlund et al. 2010). The IGF-IIR/M6P  
has been shown to act as a growth suppressor and IGF-IIR/M6P gene mutation has 
been associated with tumour progression, thus the receptor was targeted as a 
therapeutic approach to treating cancer (Chen, Ge et al. 2002, Hébert 2006, Hu, 
McCall et al. 2006). However, the roles of both IGF-II and the IGF-IIR/M6P in 
metabolic regulation are not definitive. Although the IGF-IIR/M6P has a well-
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established role as a clearance receptor for IGF-II, it has a less well established role in 
signalling, but it may facilitate signal transduction in muscle to promote amino acid 
uptake (Shimizu, Webster et al. 1986) and in pancreatic tissue by affecting insulin 
exocytosis (Zhang, Tally et al. 1997). However, it still remains to be determined 
whether IGF-II can induce biological signalling through the IGF-IIR/M6P. IGF-
IIR/M6P expression has been identified in adipose tissue in the 3T3-L1 mouse cell 
line (Shimizu, Torti et al. 1986) and in mammalian tissue (Gardan, Mourot et al. 2008). 
Nevertheless, limited and conflicting studies have examined IGF-IIR/M6P  expression 
in human adipose tissue (DiGirolamo, Eden et al. 1986, Sinha, Buchanan et al. 1990), 
mainly focusing on adult adipose tissue with no reports of fat depot-specific 
comparisons. 
Interestingly, circulating IGF-IIR/M6P  levels were related to body weight, showing 
an increase with obesity and a reverse downregulation after weight loss (Oka, Rozek 
et al. 1985). Furthermore, similar to IGF-II genetic polymorphisms, IGF-IIR/M6P  
genetic variation has also shown to be related to type 2 diabetes (Chanprasertyothin, 
Jongjaroenprasert et al. 2015). The association of IGF-IIR/M6P with weight might be 
due to its role as a regulator of IGF-II, although one study reported no association 
between variations in IGF-II and IGF-IIR/M6P levels in relation to body weight 
(Jeyaratnaganthan, Højlund et al. 2010). Furthermore, the IGF-IIR/M6P was shown to 
be epigenetically regulated as maternal diet altered the expression of the IGF-IIR/M6P  
in fetal peri-renal adipose tissue, which suggests that the IGF-IIR might have a fat 
depot-related regulation (Lan, Cretney et al. 2013). This chapter focuses on the 
regulation of the IGF-IIR/M6P in different fat depots. We hypothesize that IGF-
IIR/M6P receptor will show depot-specific differences in abundance and expression 
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levels, and IGF-IIR/M6P receptor abundance (and subsequent IGF-II secretory levels) 
will be influenced by insulin treatment.   
Chapter 5: IGF-II regulation in adipose tissue 
 169 
 
5.2 Aims and objectives 
 
• Characterise the differences in the expression and abundance of the IGF-
IIR/M6P receptor in visceral and subcutaneous preadipocytes and 
differentiated adipocytes. 
• Study the effect of IGF-II treatment on IGF-IIR/M6P abundance in 
preadipocytes and adipocytes from visceral and subcutaneous fat.  
• Study the effect of insulin treatment and different glucose conditions on IGF-
IIR/M6P protein abundance in fat depots. 
• Examine the impact of altered levels of the IGF-IIR/M6P receptor on secreted 
levels of IGF-II. 
• Study the effect of IGF-II and insulin on IGFBP-3 abundance and secretion 
from subcutaneous and visceral adipocytes in different glucose conditions.   
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5.3 Materials and methods 
 
5.3.1 Cell culture  
Paired biopsies from subcutaneous and visceral fat were prepared and cultured as 
described in the methods section (2.2.5). For glucose experiments, preadipocytes and 
differentiated adipocytes (day 14) were exposed to either high (25 mM/L) or normal 
glucose (5 mM/L)-containing serum-free media for 24 hours followed by IGF-II 
(Gropep) or insulin (Novo Nordisk) treatment.  
5.3.2. RNA extraction and RNA-cDNA reverse transcription 
Total RNA was extracted using Trizol RNA extraction reagent (Invitrogen) as detailed 
in section (2.6.2): one µg of RNA was reversed transcribed into cDNA using a high 
capacity RNA-to-cDNA kit (Applied Biosystems) as described in section (2.6.5).   
5.3.2 Quantitative PCR (qPCR) 
SYBR Green JumpStart Tag ReadyMix (Sigma) was used to perform qPCR using an 
ABI StepOne Plus Realtime PCR System (Applied Biosystems, 4376600) and 
following the manufacturer’s protocol. Relative mRNA expression was calculated 
using the 2−ΔCt method. IGF-IIR/M6P and GAPDH (reference gene) forward and 
reverse primer sequences are listed in Table (2.6.6).  
5.3.3 Western blotting  
Western blotting was performed as previously described in section (2.4). Briefly, 
proteins were run on a 10% SDS-PAGE gel followed by transfer to a nitrocellulose 
membrane (BioRad) and immunoblotting was performed with the following 
antibodies: IGF-II receptor was visualised using the IGF-II Receptor/CI-M6PR 
(D3V8C) from Cell Signaling Technology (1:1000), IGFBP-3 (1:1000, Santa Cruz), 
GAPDH (1:5000, Millipore) and β-actin (1:10000, Sigma) following the 
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manufacturer’s instructions. The membranes were then incubated with peroxidase-
conjugated secondary antibodies (Sigma). Visualization was achieved using 
SuperSignal West-Dura substrate and Chemidoc XRS + system (BioRad) and 
quantification using Image J software.  
5.3.4. Radioimmunoassay (RIA)   
Radioimmunoassays were used to assess IGF-II levels in preadipocytes and 
adipocytes (at day 14 of differentiation the levels were measured in culture media 
according to the protocol described in section (2.8)). 
5.3.5. Statistical analysis  
Data analysis was carried out with the IBM SPSS Statistics 12.0.1 software for 
Windows, using one-way ANOVA with LSD as a post-hoc test for multiple 
comparisons (subcutaneous and visceral) and experiments with different glucose 
conditions. Statistical significance was considered at a p-value of 0.05.  
  




5.4.1.1 Characterisation of the expression of the IGF-IIR/M6P in subcutaneous 
and visceral fat depots with differentiation. 
First, we investigated IGF-IIR/M6P expression in subcutaneous and visceral 
preadipocytes and whether receptor expression changed with differentiation. Visceral 
preadipocytes showed a higher fold change expression of the IGF-IIR/M6P in 
comparison to subcutaneous preadipocytes (visceral 16.1 vs. 7.7 for subcutaneous; P 
< 0.05). Furthermore, IGF-IIR/M6P mRNA expression decreased with differentiation 
indicating a higher expression in preadipocytes than adipocytes. These results were 
observed for both visceral (P < 0.01) and subcutaneous (P < 0.05) fat depots, as shown 
in Figure (5-1 A). 
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Figure 5-1 Expression of the IGF-IIR/M6P with differentiation in visceral and 
subcutaneous fat.   
A. Relative mRNA expression of the IGF-IIR/M6P in subcutaneous and visceral 
preadipocytes and differentiated adipocytes. SYBR green-based qPCR was used normalized 
to the GAPDH reference gene. B. Melting curves of the IGF-IIR/M6P and GAPDH generated 
during qPCR. Data represent the mean ± SEM of three independent experiments each 
performed in duplicate. (N = 3)  
 
 
5.4.1.2 IGF-IIR/M6P protein abundance in subcutaneous and visceral 
preadipocytes and differentiated adipocytes. 
To investigate whether IGF-IIR/M6P protein abundance was comparable to the 
associated mRNA expression levels, Western blotting was carried out on protein 
extracts from preadipocytes and differentiated adipocytes (day 14) as indicated in 
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Figure (5-2 A). IGF-IIR/M6P abundance decreased with differentiation, and the fold 
change from preadipocytes to adipocytes was 1 vs. 0.44 (P < 0.05) in subcutaneous 
cells and 1.73 vs. 0.48 (P < 0.001) in visceral cells. Furthermore, there was a persistent 
predominance of the IGF-IIR/M6P in visceral preadipocytes in comparison to 
subcutaneous preadipocytes (P < 0.05). There were no fat depot differences in receptor 
abundance detected in adipocytes. 
 
Figure 5-2 Protein abundance of IGF-IIR/M6P in subcutaneous and visceral 
preadipocytes and adipocytes.  
A. Western immunoblot illustrating IGF-IIR/M6P protein abundance. B. Quantification 
analysis of the Western blot indicating a decrease of IGF-IIR/M6P protein abundance with 
differentiation in both fat depots. β-actin was used as a reference protein. The 3T3-L1 cell line 
was used as a positive control.  Data are represented as the mean ± SEM. (N=3) 
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5.4.3 Effect of IGF-II and insulin treatment on the IGF-IIR/M6P in 
preadipocytes in normal (5 mM/L) and high (25 mM/L) glucose  
Preadipocytes were initially used to examine the depot-specific differences in IGF-II 
on IGF-IIR/M6P levels given the high expression of the latter in these cells. In 
addition, the effects of insulin on total IGF-IIR/M6P  protein abundance was examined 
in subcutaneous and visceral cells based on previous reports that insulin might 
influence the distribution of the IGF-IIR/M6P on the cell surface (Sinha, Buchanan et 
al. 1990) and influence total IGF-IIR/M6P  levels assessed by western blotting (Oka, 
Rozek et al. 1985). Preadipocytes were seeded in normal or high glucose media and 
serum starved for 24 hrs prior to IGF-II or insulin treatment (60 ng/ml). In normal 
glucose conditions, IGF-II and insulin had minimal effects on IGF-IIR/M6P 
abundance in subcutaneous preadipocytes (Figures 5-3 A–B). However, IGF-II 
treatment in visceral preadipocytes maintained IGF-IIR/M6P abundance whereas 
insulin showed a downregulation in the IGF-IIR/M6P  in comparison (Oka, Rozek et 
al. 1985). Glucose has been shown previously to regulate the mRNA expression levels 
of the IGF-IIR/M6P  receptor in insulin secreting pancreatic cell lines (Raile, Klammt 
et al. 2005). Therefore, we examined whether hyperglycaemia alters IGF-II receptor 
abundance in subcutaneous and visceral cells. Interestingly, high glucose treatment 
induced an upregulation in IGF-IIR/M6P fold change abundance in subcutaneous 
preadipocytes in comparison to normal glucose controls (2.6 vs. 1; P < 0.05) (Figures 
5-3 A–B). IGF-IIR/M6P abundance was persistently high in visceral preadipocytes in 
both glucose conditions (Figures 5-3 C–D). After IGF-II and insulin treatment, 
subcutaneous preadipocytes maintained the increased receptor abundance under high 
glucose conditions in comparison to low glucose. There was also an increase in IGF-
IIR/M6P abundance in visceral preadipocytes in high glucose after insulin treatment 
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(p < 0.05). These results suggest that high glucose treatment maintains a high IGF-
IIR/M6P receptor abundance in both subcutaneous and visceral preadipocytes.  
 
 
Figure 5-3 Protein abundance of the IGF-IIR/M6P in subcutaneous and visceral 
preadipocytes in different glucose conditions. 
Western blot of A. subcutaneous preadipocytes and C. visceral preadipocytes showing IGF-
IIR/M6P abundance. Semi-qualitative densitometry analysis of B. subcutaneous and D. 
visceral preadipocytes. GAPDH was used as a reference protein. Data are represented as the 
mean ± SEM, and statistical significance was obtained when p < 0.05 (N = 3). 
 
5.4.4. Levels of secreted IGF-II from preadipocytes after 24 hours’ treatment with 
insulin in different glucose conditions using radioimmunoassay (RIA) 
 
To determine whether the changes in the levels of the IGF-IIR/M6P receptor will alter 
IGF-II degradation rates and affect the actual levels of IGF-II in the media, IGF-II 
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levels were measured using radioimmunoassays in normal glucose (5 mM/L) and high 
glucose (25 mM/l) conditions. The data indicated no significant difference in IGF-II 
media levels in either cell type. In subcutaneous preadipocytes, the levels of IGF-II in 
control vs. after insulin treatment were 5.0 ng/ml vs. 4.1ng/ml, respectively (p = 
0.121), whereas in visceral preadipocytes secreted IGF-II levels were 5.1ng/ml vs. 4.4 
ng/ml, respectively (p = 0.257). Figure 5-4 illustrates the changes in secreted IGF-II 
levels in normal glucose conditions following insulin treatment.  
 
Figure 5-4  Radioimmunoassay measurements of IGF-II levels in subcutaneous and 
visceral preadipocyte culture media following insulin treatment in normal glucose 
conditions (5 mM/L).   
Conditioned media was obtained from visceral and subcutaneous preadipocytes seeded at 
0.2X106 and serum starved for 24 hours followed by insulin treatment. IGF-II levels were 
measured using radioimmunoassays from three individual experiments performed in 
duplicate. Data are expressed as the mean ± SEM, and statistical significance was obtained 
when p < 0.05. (N=3)  
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As IGF-IIR/M6P  levels were upregulated in high glucose conditions, we anticipated 
a corresponding decrease in IGF-II levels due to increased clearance however there 
were no significant changes in secreted levels of IGF-II levels in subcutaneous 
preadipocytes (3.4 ng/ml vs. 4.3 ng/ml; P = 0.3) or in visceral preadipocytes (5.03 
ng/ml vs. 4.6 ng/ml; P = 0.6) in comparison to controls. These results suggest that 
changes in IGF-II receptor abundance are not necessarily accompanied by direct 
changes in IGF-II secreted levels, as illustrated in Figure 5-5. 
 
Figure 5-5 Radioimmunoassay measurements of secreted IGF-II in culture media of 
subcutaneous and visceral preadipocytes in high glucose conditions (25 mM/L).   
Conditioned media were obtained from visceral and subcutaneous preadipocytes seeded at 
0.2X106 and serum starved for 24 hours followed by insulin treatment in high glucose 
conditions (25 mM/L). IGF-II levels were measured using radioimmunoassays from three 
individual biopsies (N=3) run in duplicate. Data are expressed as the mean ± SEM, and 
statistical significance was obtained when p < 0.05. 
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5.4.5 Effects of IGF-II and insulin treatment on IGF-IIR/M6P levels in 
adipocytes in different glucose conditions. 
 
The IGF-IIR/M6P receptor was detected at low levels in adipocytes in comparison to 
preadipocytes under basal stimulation in our model, as indicated in section (5.3.1-2). 
Given that human studies on isolated adipocytes have shown alterations in IGF-
IIR/M6P  levels in response to ligand stimulation (Sinha, Buchanan et al. 1990), we 
further investigated IGF-IIR/M6P  levels after IGF-II treatment and whether changes 
in the physiological environment with high glucose and insulin stimulation will also 
affect IGF-IIR/M6P levels. As demonstrated in Figure 5-6, insulin was associated with 
increased IGF-IIR/M6P levels in subcutaneous (2.4 vs. 1.0; p < 0.01) and visceral 
adipocytes (3.3 vs. 1.0; p < 0.05) in normal glucose conditions in comparison to 
controls. Furthermore, IGF-II enhanced IGF-IIR/M6P abundance in visceral 
adipocytes (3.4 vs. 1.0; p < 0.05) with no detectable change in subcutaneous 
adipocytes. High glucose stimulation was associated with a significant increase in the 
IGF-IIR/M6P in both fat depots (subcutaneous (p < 0.01) and visceral (p < 0.05)) in 
comparison to normal glucose. In subcutaneous adipocytes, hyperglycaemia along 
with IGF-II treatment (Figures 5-6 A–B) was associated with increased levels of the 
IGF-IIR/M6P (P < 0.01) and insulin treatment maintained this increase.  However, 
IGF-II and insulin treatments had no significant further effect on the increased levels 
of the IGF-IIR/M6P in hyperglycaemic visceral adipocytes (Figures 5-6 C–D). 
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Figure 5-6 Protein abundance of the IGF-IIR/M6P in visceral and subcutaneous 
adipocytes in different glucose conditions.  
Adipocytes at day 14 of differentiation were serum starved for 24 hrs followed by 60 ng/ml 
of IGF-II or insulin. Western blot of A. subcutaneous adipocytes and C. visceral adipocytes 
showing IGF-IIR/M6P abundance. Semi-qualitative densitometry analysis of B. subcutaneous 
and D. visceral adipocyte western blots. GAPDH was used as a reference protein. Data are 
represented as the mean ± SEM, and statistical significance was obtained when p < 0.05 (N = 
4). 
 
5.4.6. Levels of secreted IGF-II in adipocytes following insulin treatment in 
different glucose conditions using radioimmunoassays (RIAs). 
We further measured IGF-II secretory levels from subcutaneous and visceral 
adipocytes following insulin treatment in normal and high glucose conditions. IGF-II 
levels were not significantly altered after insulin treatment in comparison to controls 
(2.7ng/ml vs. 3.1ng/ml; p = 0.90) in subcutaneous adipocytes and visceral adipocytes 
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(1.8 ng/ml vs. 2.5 ng/ml; p = 0.22) in normal glucose conditions, as indicated in Figure 
5-7. In hyperglycaemic conditions, the levels of IGF-II after insulin treatment also did 
not show a statistically significant change either in subcutaneous adipocytes (2.8 
ng/ml vs. 3.0 ng/ml; p = 0.40) or in visceral adipocytes (4.2 ng/ml vs. 3.9 ng/ml; p = 
0.54), as demonstrated in Figure 5-8.  
 
 
Figure 5-7  IGF-II levels secreted from adipocytes following insulin treatment in 
normal glucose conditions as determined by RIA.  
Subcutaneous and visceral adipocytes at day 14 of differentiation were serum starved for 24 
hrs followed by insulin treatment. Conditioned media was subjected to radioimmunoassays in 
duplicate runs. Result are shown as the mean ± SEM. P-values less than 0.05 were considered 
statistically significant (N = 4). 
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Figure 5-8 IGF-II levels secreted from adipocytes following insulin treatment in high 
glucose conditions.  
Subcutaneous and visceral adipocytes were differentiated in normal glucose for 14 days, cells 
were serum starved for 24 hrs in high glucose serum-free media followed by insulin treatment. 
Conditioned media were subjected to radioimmunoassays in duplicate runs. The results are 
shown as the mean ± SEM. P-values of less than 0.05 were considered statistically significant 
(N = 4). 
 
5.4.7 Effect of IGF-II and insulin treatment on the level of endogenous IGFBP-3 
in visceral and subcutaneous adipocytes.  
 
Since secreted levels of IGF-II were not influenced by altered levels of the IGF-
IIR/M6P, we further investigated the effect of insulin and IGF-II treatment on IGFBP-
3 abundance in visceral and subcutaneous adipocytes. IGFBP-3 is the most abundant 
IGF transporter, and it contributes significantly to the regulation of IGFs bioactivities 
(Baxter 2000). IGFBPs have a higher affinity for IGFs that do the IGF receptors, which 
may result in the inhibition of IGF receptor activation. Assessment of IGFBP-3 levels 
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was conducted using western immunoblotting of protein extracts from subcutaneous 
and visceral adipocytes; intact and fragmented forms of IGFBP-3 were examined in 
both normal and high glucose conditions. In subcutaneous adipocytes with normal 
glucose conditions, insulin treatment decreased total endogenous IGFBP-3 levels by 
reducing intact IGFBP-3 (0.27 vs. 1; p < 0.01) and with no change in fragmented 
IGFBP-3, leading to a decrease in total IGFBP-3 (0.52 vs. 1; p < 0.01). The high 
glucose conditions increased the fragmentation of IGFBP-3 (1.99 vs. 1; p < 0.05) and 
reduced the total IGFBP-3 levels in comparison to high glucose in combination with 
IGF-II (0.2 vs.1.2; p < 0.001) and with insulin treatments (0.1 vs. 1.2; p < 0.001), as 
illustrated in Figure 5-9.  The increase in IGFBP-3 fragments in high glucose 
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Figure 5-9 Protein abundance of IGFBP-3 in subcutaneous adipocytes in different 
glucose conditions using Western immunoblotting.   
A. Western immunoblot of IGFBP-3 abundance after IGF-II and insulin treatment in normal 
(5 mM/L) and high glucose (25 mM/L) conditions. Semi-quantitative densitometry analysis 
of Western blots showing B. intact IGFBP-3 C. fragmented IGFBP-3 and D. total IGFBP-3 
protein abundance, normalized to the GAPDH reference protein. The graph represents the 
mean ± SEM of three independent repeats (N = 3). Statistical analysis was considered 
significant at P < 0.05. 
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In visceral adipocytes, there was no change in intact IGFBP-3 after IGF-II (1.5 vs. 1; 
p = 0.10) and insulin (1.4 vs. 1; p = 0.23) treatments in normal glucose conditions. 
However, there was a significant increase in fragmented IGFBP-3 following treatment 
with IGF-II (1.3 vs. 0.4; P < 0.01) and insulin (0.84 vs. 0.4; p < 0.05), and a small 
increase in total IGFBP-3, as indicated in Figures (5-10 A–D). In high glucose 
conditions, intact IGFBP-3 was reduced in comparison to that in normal glucose 
conditions (0.04 vs. 1, respectively; p < 0.01) and following IGF-II (0.3 vs. 1.5, 
respectively; P < 0.01) and insulin (0.2 vs. 1.4, respectively; P < 0.01) treatments. 
IGFBP-3 proteolysis increased after IGF-II (0.9 vs. 0.3; p < 0.05) and insulin (1.0 vs. 
0.3; p < 0.01) treatments in comparison to controls in high glucose, which might cause 
an increase in local IGF tissue availability. Total IGFBP-3 was also increased in high 
glucose after IGF-II and insulin treatments (p < 0.05), and interestingly total IGFBP-
3 was reduced in comparison to that in normal glucose conditions (0.3 vs.1.3; p < 0.05) 
as shown in Figure (5-10 D). 
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Figure 5-10 Protein abundance of IGFBP-3 in visceral adipocytes following IGF-II, 
insulin and high glucose treatments.  
A. Immunoblot of IGFBP-3 showing intact and fragmented BP-3. Semi-quantitative 
densitometry analysis in normal (5 mM/L) and high (25 mM/L) glucose conditions after 24 
hrs IGF-II and insulin treatment of B. intact IGFBP-3 C. fragmented IGFBP-3 and C. total 
IGFBP-3. Normalized to reference protein GAPDH. The graph represents the mean ± SEM 
from three individual biopsies (N=3). A P-value of less than 0.05 was considered significant.  
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IGFBP-3 levels were also measured using radioimmunoassay in subcutaneous and 
visceral adipocytes in conditioned media to confirm IGFBP-3 production levels. It is 
important to note that the IGFBP-3 radioimmunoassay detects both intact and 
fragmented IGFBP-3.  
In subcutaneous adipocytes, IGF-II had a minimal effect on IGFBP-3 levels in normal 
glucose conditions. There were no changes in the pattern of IGFBP-3 secretion in 
normal and high glucose conditions after insulin treatment, as shown in Figure (5-11 
A). In visceral adipocytes, there were no significant changes in IGFBP-3 secretion in 
normal glucose conditions after IGF-II (p = 0.9) and insulin (p = 0.5) treatments in 
comparison to controls. There was a 1.5-fold decrease in IGFBP-3 secretion after 
exposure to high glucose (p < 0.05). Furthermore, IGF-II treatment significantly 
increased IGFBP-3 secretion in high glucose (p < 0.05) in comparison to high glucose 
controls, as demonstrated in Figure (5-11 B). In high glucose, this reduction was 
mainly due to intact IGFBP-3 rather than fragmented IGFBP-3 which might increase 
the availability of IGF-II. 
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Figure 5-11 Secreted levels of IGFBP- from subcutaneous and visceral adipocytes 
measured by radioimmunoassay (RIA).  
Supernatants obtained from subcutaneous and visceral adipocytes were subjected to 
radioimmunoassays from three individual biopsies performed in duplicate. Data are expressed 
as the mean ± SEM. Results from statistical analysis were considered significant at P < 0.05. 
(N =3)  





This chapter focused on the regulation of IGF-IIR/M6P  in adipose tissue, particularly 
investigating any fat depot differences in IGF-IIR/M6P  levels that act as an important 
regulator of IGF-II availability and function in multiple tissues (Hari, Pierce et al. 
1987, Han, Luan et al. 2011). Given the limited literature investigating IGF-IIR/M6P 
levels in adipose tissue, our data indicate that the IGF-IIR/M6P was detected in 
preadipocytes and decreased in abundance during differentiation. This expression 
pattern was consistent with that described in previous studies using 3T3-L1 cell lines 
(Shimizu, Torti et al. 1986) and from mammalian studies examining the subcutaneous 
fat obtained from porcine samples (Gardan, Mourot et al. 2008). In humans however, 
IGF-IIR/M6P  expression and protein abundance were reported in cultured fibroblast 
cells (Ryu, Hwang et al. 2007) but studies were more controversial in detecting the 
IGF-IIR/M6P in mature adipocytes. The IGF-IIR/M6P was found in isolated 
subcutaneous adipocytes obtained from adult individuals (Shimizu, Torti et al. 1986) 
however others failed to detect the IGF-IIR/M6P in adipocytes from murine cells 
(Ryu, Hwang et al. 2007) and adult human fat cells (Gardan, Mourot et al. 2008). Our 
results indicated that IGF-IIR/M6P expression and abundance was minimally detected 
in adipocytes and was less than that in preadipocytes. 
Further comparisons of IGF-IIR/M6P fat-depot levels showed a predominance of the 
IGF-IIR/M6P in visceral preadipocytes in comparison to subcutaneous as indicated by 
mRNA expression and protein abundance. This pattern was not maintained in 
adipocytes, mostly due to the lower levels of the IGF-IIR/M6P with differentiation. 
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As far as we know, there are no studies comparing the levels of the IGF-IIR/M6P 
levels between human fat-depots. However, higher levels of the IGF-IIR/M6P were 
identified in visceral than in subcutaneous fat depots of fetal baboon adipose tissue 
(Tchoukalova, Nathanielsz et al. 2009). The higher IGF-IIR/M6P  levels in 
preadipocytes would suggest a role in regulating preadipocyte differentiation; 
however, IGF-IIR/M6P  knockdown in preadipocytes did not affect the differentiation 
process (Kang, Park et al. 2011).  
Following IGF-IIR/M6P characterization, we investigated whether IGF-IIR/M6P 
levels were affected by insulin stimulation. Our results indicate that insulin induced 
an increase in IGF-IIR/M6P  abundance and this is consistent with previous studies in 
murine adipocytes (Appell, Simpson et al. 1988) and in humans tissue using 
subcutaneous isolated adipocytes (Sinha, Buchanan et al. 1990). The mechanism by 
which insulin affects the redistribution of the IGF-IIR/M6P  is still not clear, and the 
involvement of multiple kinases has been suggested (Kiess, Yang et al. 1994). Our 
results showed a more predominant change in receptor distribution due to insulin 
treatment in adipocytes with a minimal effect on preadipocytes. This may synchronize 
with the suggestion that IGF-IIR/M6P  is recycled with GLUT4 ‘which is found in 
higher abundance in mature cells’ and they traffic together in sequestered vesicles that 
fuse to the plasma membrane after insulin stimulation (Wabitsch, Heinze et al. 2000, 
Slomiany and Rosenzweig 2004). In contrast, this study suggested that insulin 
administration did not affect IGF-IIR/M6P levels however, methodological 
differences may have accounted for this discrepancy as the soluble IGF-IIR/M6P was 
measured in the circulation and not in an in vitro setting (Jeyaratnaganthan, Højlund 
et al. 2010). 
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Our data showed that hyperglycaemia also caused an increase in IGF-IIR/M6P 
abundance basally and with ligand stimulation. This is consistent with other studies 
indicating that glucose can stimulate phosphorylation, which enhances IGF-IIR/M6P 
receptor levels (Scharf, Schmidt-Sandte et al. 1995). Effects of glucose on the IGF-
IIR/M6P were also previously reported using RINm5F and HIT insulin-secreting 
pancreatic and leukaemia cell lines (Yandell, Dunbar et al. 1999).  
As a lysosomal clearance receptor, the IGF-IIR/M6P regulates circulating IGF-II 
levels. In genetic modulation studies, mice lacking the IGF-IIR/M6P had high 
circulating levels of IGF-II due to the reduction in the clearance receptor, and this was 
associated with fetal over-growth (Lau, Stewart et al. 1994). Therefore, we further 
evaluated secreted levels of IGF-II and explored whether alterations in IGF-IIR/M6P 
abundance would subsequently affect IGF-II levels. Our data indicated that insulin-
induced changes in IGF-IIR/M6P levels were not directly associated with changes in 
IGF-II media levels over the timeframe of our study. It is possible that although insulin 
induced the translocation of IGF-IIR/M6P to the cell surface, this might not be 
associated with an increase in IGF-II clearance via its own receptor  (Oka, Mottola et 
al. 1984, Wardzala, Simpson et al. 1984). However, insulin treatment has been 
reported to cause an increase in the binding of IGF-II to its conjugate receptor in 
adipocytes (King, Rechler et al. 1982). 
To further investigate IGF-II tissue availability, we examined IGFBP-3 as a major 
regulator of IGF-II activity. In addition, to being the most abundant circulating binding 
protein with effects on mediating IGF access to the targeted tissue, IGFBP-3 is also 
secreted locally by many cells (Scharf, Schmidt-Sandte et al. 1995, Wabitsch, Heinze 
et al. 2000, Slomiany and Rosenzweig 2004).  IGFBP-3 has been strongly associated 
with adipogenesis (Chan, Schedlich et al. 2009, Baxter 2013). IGFBP-3 is minimally 
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secreted by preadipocytes (Grohmann, Sabin et al. 2005); however, its levels increase 
in human adipocytes as the cells differentiate (Wabitsch, Heinze et al. 2000). 
Therefore, we further investigated the role of IGFBP-3 in adipocyte regulation in a 
depot-specific manner and whether exogenous treatment of IGF-II and insulin or a 
change in glucose conditions may alter IGFBP-3 production or fragmentation.  
In normal glucose, our results showed a decrease in intact IGFBP-3 in subcutaneous 
adipocytes with insulin treatment, and this was associated with a subsequent decrease 
in total IGFBP-3. In high glucose, there was an associated increase in fragments of 
IGFBP-3 with no change in intact IGFBP-3, suggesting that high glucose by itself 
seems to increase the fragmentation of IGFBP-3. Insulin treatment still reduced total 
levels of IGFBP-3 in high glucose. 
In visceral adipocytes, normal glucose was associated with an increase in 
fragmentation of IGFBP-3 with no significant change in intact IGFBP-3. In high 
glucose, intact IGFBP-3 levels were reduced compared with normal glucose with only 
an increase in fragmentation leading to a reduction in total IGFBP-3 in comparison to 
normal glucose. Increased fragmentation of IGFBP-3 has been associated with an 
exposed NH2 terminal in IGFBP-3, which leads to a reduced affinity for IGF-II. Such 
fragmentation will affect IGF-II availability and could cause a dysregulation in insulin 
receptor signalling making it more predisposed to metabolic disturbances associated 
with obesity and diabetes (Kim 2013). Intact IGFBP-3 has an unexposed NH2 terminal 
with an increased affinity for IGFs, and interestingly, intact IGFBP-3 has been 
associated with an IGF-independent anti-inflammatory action (Mohanraj, Kim et al. 
2013).   
 As our data indicate that fragmented IGFBP-3, which has less affinity for IGF 
binding, was higher in visceral than in subcutaneous adipocytes with IGF-II treatment. 
Chapter 5: IGF-II regulation in adipose tissue 
 193 
The increase in cleavage might be associated with increased bioavailability of IGF-II 
due to less binding to IGFBP-3 (Baxter 2000). Furthermore, hyperglycaemia seems to 
increase the protease activity acting on IGFBP-3 leading to altered availability of IGF-
II. (Conover 1991). Interestingly, an increase in IGFBP-3 protease activity and a 
corresponding reduction in intact IGFBP-3 was correlated with obesity and waist 
circumference, as observed in our study after culturing cells in high glucose conditions 
in visceral cells (Mohanraj, Kim et al. 2013).  The reduction in IGFBP-3 secretory 
levels was observed in visceral adipocytes after high glucose treatment with no evident 
changes in subcutaneous adipocytes.  Only subcutaneous IGFBP-3 production was 
measured in other studies: they showed an increase in IGFBP-3 with insulin treatment, 
however in contrast to our study this was performed using adult samples (Wabitsch, 
Heinze et al. 2000) . Measuring intact and fragmented IGFBP-3 separately may be 
interesting and could provide additional understanding to the role of IGFBP-3 in the 
bioavailability of IGF-II.  
In summary fat depot differences in IGFBP-3 were observed that may influence the 
bioavailability of IGF-II. This provides evidence suggesting other members of the 
IGFBP family and secreted proteases may play a role in a fat-depot specific manner. 
In fact, recent reports have shown that IGFBP-4 and its specific protease, pregnancy 
associated plasma protein–A (PAPP-A), were differentially secreted between 
subcutaneous and visceral fat that may influence the tissues’ response to the growth 
factors (Gude, Hjortebjerg et al. 2016, Hjortebjerg, Berryman et al. 2018).  
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5.6 Conclusion  
 
IGF-II bio-availability is precisely regulated and an important IGF-II regulator is the 
IGF-IIR/M6P clearance receptor. In this chapter we investigated IGF-IIR/M6P 
receptor abundance in subcutaneous and visceral preadipocytes and adipocytes and 
examined factors that might alter IGF-IIR/M6P levels in a fat-depot specific manner. 
Our data indicate that IGF-IIR/M6P abundance decreases with differentiation and also 
differs in abundance between subcutaneous and visceral preadipocytes. Although 
insulin treatment affected the abundance of the IGF-IIR/M6P, this did not alter the 
clearance of secreted IGF-II. Hyperglycaemia increased IGF-IIR/M6P receptor 
abundance in subcutaneous and visceral cells, and increased IGFBP-3 fragmentation 
causing a potential increase in IGF-II tissue availability. Future research is required to 
further understand fat-depot specific differences in IGF tissue bioavailability and 
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6.1 Introduction  
 
Circulating levels of IGFs are related to many physiological and pathological 
conditions in relation to tissue growth (Johansson, Baglietto et al. 2004, Clemmons 
2012). The biological effects of IGFs are tightly regulated in the circulation and, in 
the case of IGF-I is hormonally regulated by growth hormone (GH). The GH–IGF-I 
axis has an established role in the development of specific tissues and body 
composition; for example, reduced GH levels are associated with increased body fat 
and reduced lean mass (Veldhuis, Liem et al. 1995). GH indirectly acts via IGF-I to 
promote preadipocyte proliferation and differentiation (Smith, Wise et al. 1988). and  
circulating IGF-I levels are associated with body weight (Merimee, Zapf et al. 1982, 
Yamamoto and Kato 1993), and dysregulation of GH–IGF-I levels are linked with 
obesity (Maccario, Ramunni et al. 1999). IGF-I levels were also shown to be related 
to the arrangement of body fat deposition in obese individuals (Rasmussen, Frystyk et 
al. 1994).  
The relationship between postnatal circulating IGF-II levels and body composition has 
not been extensively described in the literature, presumably because IGF-II is 
considered to be a prenatal growth factor with sustained, high levels throughout 
pregnancy (Constância, Hemberger et al. 2002). However, IGF-II is also maintained 
postnatally and remains high throughout adult life, while IGF-I peaks in puberty and  
reduces with ageing (Zapf and Froesch 1986). IGF-II is not regulated by GH; however, 
it has a restricted genetic expression which regulates the level of IGF-II in the 
circulation (Giannoukakis, Deal et al. 1993). Polymorphisms in IGF-II are associated 
with differences in circulating IGF-II levels; for example, individuals with the IGF-II 
Apal AA genotype have higher circulating IGF-II levels than those with the IGF-II 
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Apal GG genotype. Intriguingly, Apal AA individuals have a lower weight than those 
with the Apal GG genotype (O'Dell, Miller et al. 1997). Baseline circulating levels of 
IGF-II in the blood predict, future weight gain (Sandhu, Gibson et al. 2003), and IGF-
II levels are reversible following weight loss. The role of IGF-II in regulating body 
weight is not clear; however, these findings indicate that circulating IGF-II levels may 
be a prognostic biomarker for obesity. 
The metabolic risk of obesity is not necessarily related to overall body weight, as this 
measurement encompasses lean mass and subcutaneous fat that may be protective 
against metabolic disease (Münzer, Harman et al. 2001). Most IGF-II studies so far 
have focused on correlations with  BMI or body weight, however a more recent report 
suggested more fat-depot specific associations with IGF-II in adults (Song, Ernst et al. 
2018). Dual-energy X-ray absorptiometry (DXA) scans measure body fat 
compartments in a cost-effective and non-invasive manner, thus making this approach 
suitable for large population studies (Lee and Gallagher 2008, Shepherd, Ng et al. 
2017). The Avon Longitudinal Study of Parents and Children (ALSPAC) is a large 
longitudinal study that performed DXA scans and measured IGF-II plasma levels at 
several time points, thus making it a valuable source in which to investigate the 
correlation between IGF-II plasma levels in early life and the distribution of body fat 
at puberty (Fraser, Macdonald-Wallis et al. 2012).  
 
  





Using the ALSPAC cohort, this study examined the association between prepubertal 
serum IGF-II levels and pubertal fat distribution using DXA scan measurements, 
particularly the levels of trunk and peripheral fat mass at age 15 and 17. We 
hypothesised, based on the laboratory work in this thesis, that prepubertal serum IGF-
II levels would associate with body fat distribution, negatively correlating with 
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6.3  Study methods 
6.3.1 Study subjects 
ALSPAC is a prospective observational study conducted in Bristol, United Kingdom. 
The main aim of this trans-generational study is to explore how the environment and 
genetics impact on health and growth of  individuals (Fraser, Macdonald-Wallis et al. 
2012). The ALSPAC study recruited 14,541 pregnant women who were expected to 
give birth between April 1991 and December 1992. The number of children born was 
14,062, out of which 13,988 were alive at 1 year of age. A group of children who were 
born in the last 6 months of the study (approximately 10% of the cohort), were invited 
to participate in an ALSPAC sub-study called ‘Children in Focus’. This sub-cohort 
comprised 1,432 children who were brought to the research clinics by their parents 
and were evaluated from between 4 months and 5 years old. By the age of 7, all 
children from the cohort had been invited to the clinics. An additional invitation was 
sent out to all eligible participants who failed to join the initial study, which added an 
extra 713 children to the study and enhanced the total number of children who were 
alive at age 1 to 14,701. Further details of the sample size are provided on the study 
website (www.bristol.ac.uk/alspac) (Golding, Pembrey et al. 2001, Boyd, Golding et 
al. 2013).  
Extensive follow-up was performed at birth, yearly from age 7–13 and then at age 15 
and 17. Data were collected in the form of questionnaires, clinical assessments, 
biological samples and DNA.  
6.3.2 Ethics 
Ethical approval was gained from the ALSPAC Ethics and Law Committee and the 
local research ethics committees. This study proposal approval number was B2840. 
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6.3.3 Exposures 
IGF-II measured in the cord blood and at 61 months of age (~5 years) was used for 
analysis. Cord blood was collected by an assigned midwife and a non-fasting venous 
blood sample was obtained by a research nurse at the 61 month’s clinic. The blood 
samples were centrifuged and stored at −70ºC. IGF-II levels were determined using 
the direct enzyme-linked immunosorbent assay (Diagnostic Systems Laboratories, 
Inc., Sinsheim, Germany) technique, following the separation of IGF-II from its 
binding complexes. The lower limit of detection of the assay was 40 ng/ml, the inter- 
and intra-assay coefficients of variation were 10% and the average detection was 
300–1200 ng/ml.  
6.3.4 Outcomes 
Post-pubertal body fat distribution data at age 15 were obtained from teen focus 3 
(TF3) research clinic participants who attended between October 2006 and November 
2008. Data at age 17 were obtained from teen focus 4 (F17) research clinic participants 
attending between December 2008 and June 2011. Fat mass was measured using DXA 
scan data. DXA scan measurements (Lunar Prodigy DXA scanner; GE Medical 
Systems, Madison, WI, USA) in TF3 (mean age = 15.5 years) and F17 (mean age = 
17.8 years) participants were performed during research clinic visits. DXA uses two 
X-ray beams of different energies that pass through tissue and are attenuated to 
different degrees according to the nature of the tissue (Rothney, Brychta et al. 2009). 
It provides detailed measures of total body fat, trunk body fat, peripheral body fat 
(arms, legs, android and gynoid) and lean mass. Figure 6-1 shows a flowchart of the 
participants from the ALSPAC study involved in the analysis.  
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Figure 6-1: Illustration of ALSPAC study numbers included in the final analyses. 
Flowchart showing the core sample, singletons or first-born twins, respondents with cord 
blood samples, respondents with blood samples obtained at 61 months, respondents with DXA 




• Anthropometric measurements: infant weight was measured immediately 
after birth by the assigned midwife and recorded in the hospital notes. Height 
and weight were measured when the child was 7 years old during their annual 
visit to the research clinics. A Harpenden Stadiometer was used to record 
standing height to the last complete mm, and a Tanita body fat analyser (model 
TBF 305) was used to record weight to the nearest 0.1 kg. Body mass index 
(BMI) was calculated as weight (kg) divided by height (m2). 
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• Maternal education: this parameter was obtained from a questionnaire 
completed by the mother at 32 weeks gestation. Education level was 
determined using a five-point scale including no academic qualifications; 
vocational training; at least one O-level academic qualification, or equivalent, 
usually taken at age 16; at least one A-level academic qualification, or 
equivalent, usually taken at age 18 and a university degree.  
• Maternal social class: measurement of the household social class was 
obtained from a questionnaire completed by the mother at 32 weeks gestation. 
Data regarding occupational title, the mother’s job and her partner’s job were 
collected to identify the highest occupational social class. The standard 
occupational classification (SOC) codes established by the United Kingdom 
Office of Population Census and Surveys were used to classify social class as 
I, professional; II, managerial and technical; III, non-manual (i.e. non-manual 
skilled occupations); III, manual (i.e. manual skilled occupations); IV, part-
skilled occupations and V, unskilled occupations.  
• Gestational age: this parameter was recorded using paediatric and obstetric 
assessments, the date of the mother’s last menstrual period (LMP) and 
ultrasound measurements. In brief, the date of the LMP was considered if the 
mother was certain and there were no other clinical suggestions that it was 
inaccurate. If the LMP date was not certain, then the earliest ultrasound 
measurement was most likely to be used. 
• Maternal BMI: maternal height and pre-pregnancy weight were self-reported 
in a questionnaire completed at 12 weeks gestation, and BMI was calculated 
accordingly.  
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• Pubertal stage: this parameter was self-reported by the child or their parent 
in a questionnaire using illustrated drawings following the Tanner staging. 
Tanner staging describes maturation levels of pubic hair and genital size and 
is categorised into five stages, with one being the least mature (Marshall and 
Tanner 1970). 
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6.3.6 Statistical analysis 
Descriptive analysis of continuous variables that were normally distributed was 
performed using mean and SD, while skewed variables were described using medians 
and interquartile ranges. Frequencies were used to describe categorical variables (i.e. 
maternal education, maternal social class and pubertal staging). 
Regression coefficient comparison between the outcome measures was performed 
using z-scores for total fat mass, trunk fat mass, lean fat mass, peripheral fat mass 
(arms, legs, android and gynoid) and BMI. These variables were not normally 
distributed and were therefore logged, z-scores were calculated by subtracting the 
mean from the individual value and then dividing this by the standard deviation.  
Three models of regression were used: model 1 included an adjustment for sex and 
age; model 2 included an adjustment for sex, age, height at the time of the DXA scan, 
maternal height, maternal BMI, maternal social class, maternal education, gestational 
age and birth weight and model 3 was similar to model 2 but also included an 
adjustment for the pubertal stage. Model 1 was also analysed using data only from 
those for whom complete confounder information was available (model 1*) to 
evaluate whether changes in effect size were due to missing data bias. Data analysis 
was conducted using IBM SPSS statistics version 12.0.1. 
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6.4 Results  
6.4.1 Description of ALSPAC sample data  
A total of 631 children recruited in the ALSPAC study had complete data available 
for use in this study. These participants were singletons and had at least one IGF-II 
measurement and one total fat mass measurement. Of these, 305 (48.3%) were male 
and 326 (51.7%) were female. As shown in Table 6.1, 366 participants had IGF-II 
cord blood measurements (mean ± SD: 263.1 ± 83.9 ng/ml), and 365 participants had 
IGF-II measurements at 61 months old, with a range of 165–695 ng/ml and a mean 
(±SD) value of 395.7 (±107.5) ng/ml, participants who provided cord blood samples  
were similar to those collected at 61 months of age. 
At the TF3 time point, the mean age of participants was 15.3 ± 0.17 years, the mean 
height was 169.5 ± 7.9 cm and the average total fat mass measured by DXA was 15.6 
± 9.5 kg. At the F17 time point, the mean age of the participants was 17.6 ± 0.33 years, 
the average height was 171.7 ± 9.1 cm (range: 149.60–196.30) and the average total 
fat mass was 17.9 ± 9.9 kg. Further descriptive details of the respondent’s fat mass 
(i.e. trunk, arms, legs, android and gynoid) and lean mass variables are also 
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Table 6-1: Sample size description of IGF-II levels, age, height, body fat mass and 
lean mass in ALSPAC respondents included in the final analyses at different time 
points. 
Variable Time point N Mean SD 
IGF-II (ng/ml) 
  
 Birth (cord blood) 366 263.06 83.9 
61 months 365 395.7 107.47 
Age (years) TF3 552 15.3 0.17 
F17 539 17.6 0.33 
Height (cm) TF3 544 169.5 7.9 
F17 523 171.7 9.1 
Total fat mass 
(kg)a 
TF3 528 15.6 9.53 
F17 505 17.9 9.94 
Trunk fat 
mass (kg)a 
TF3 528 7.3 5.07 
F17 508 9.1 5.51 
Arm fat mass 
(kg)a 
TF3 528 1.2 0.81 
F17 508 1.4 0.83 
Leg fat mass 
(kg)a 
TF3 528 6.4 3.59 
F17 508 6.6 3.59 
Android fat 
mass (kg)a 
TF3 528 1.08 0.82 
F17 508 1.29 0.89 
Gynoid fat 
mass (kg)a 
TF3 528 3.16 1.60 
F17 508 3.58 1.69 
Lean mass 
(kg)a 
TF3 528 43.42 8.16 
F17 505 46.17 9.96 
F17, 17 years; SD, standard deviation; TF3, 15 years.  
a median and interquartile ranges. 
 
 
In addition to age and sex adjustments, maternal factors were also considered in the 
model 2 regression analysis. The average maternal height was 164.1 ± 6.0 cm (range: 
146.4–183.4), and the average maternal BMI was 26.8 ± 5.5 (range: 17.4–52.6). The 
mean reported length of pregnancy was 39.7 ± 1.4 weeks, and the average birth weight 
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Table 6-2: Description of maternal continuous confounders (i.e. height, BMI, 
pregnancy length and birth weight) in ALSPAC respondents included in the 
final analyses. 
Variable N Mean SD 
Maternal height (cm) 465 164.11 6.00 
Maternal BMI 465 26.76 5.48 
Pregnancy length (weeks) 631 39.66 1.42 
Birth weight (kg) 624 3.49 0.48 
BMI, body mass index; SD, standard deviation. 
In terms of the maternal education status, most participants had O-level qualifications 
(38.2%) or A-level qualifications (26.9%). Maternal social class was also considered 
according to the SOC codes of the Office of Population Census and Surveys. Most 
mothers had class III skilled non-manual occupations (38.4%) or class II managerial 
and technical occupations (30.7%). The maternal educational level and social class 
classification are summarised in Table 6-3. 
Table 6-3: Frequency and percentage of maternal education levels and social 
class of ALSPAC respondents included in the final analysis. 
 
CSE, certificate of secondary education 
 





(n = 620) 
CSE 57 9.2 
Vocational 49 7.9 
O level 241 38.9 
A level 170 27.4 




social class  
(n = 547) 
I 36 6.6 
II 194 35.5 
III (nonmanual) 242 44.2 
III (manual) 31 5.7 
IV 40 7.3 
V 4 0.7 
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In the model 3 regression analysis, further adjustments were required for the pubertal 
staging as assessed by Tanner staging (described in Section 6.3.5). At the TF3 time 
point, 222 of the respondents involved in the final analyses had provided pubertal stage 
information and 409 participants had not. Of these, 120 (19%) were at stage 4 of 
Tanner’s classification and 90 (14.3%) were at stage 5. By F17, the majority had 
reached stage 5 (83.4%). Details of the pubertal staging frequencies at different time 
points are described in Table 6-4. 
 
Table 6-4: Frequencies and percentage of pubertal staging categories at TF3 
and F17 in the ALSPAC respondents included in the final analyses. 
  Frequency Percent 




 Stage 1–3 12 0 5.4 0 
Stage 4 120 61 54.1 16.6 
Stage 5 90 307 40.5 83.4 
 Total 222 368 100 100 
F17, 17 years; TF3, 15 years.  
 
6.4.2 Association between IGF-II levels and total body fat distribution  
To overcome the skewed nature of the fat mass data, z-scores were used and calculated 
as described in Section 6.3.6. Ten-unit block increases in IGF-II was used for analysis, 
and z-scores of fat mass (total, trunk and peripheral), lean mass and BMI were 
associated with cord blood IGF-II and IGF-II at 61 months using the three statistical 
models. Further analysis of model 1 was restricted to participants who had complete 
data for all variables (model 1*). 
Table 6-5 indicates the associations between IGF-II (cord blood and 61 months) and 
total body fat at TF3 and F17. Cord blood IGF-II was strongly and inversely correlated 
with total body fat at F17 following adjustment for sex and age (P = 0.017). The 
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correlation also persisted when analysis model 1* was used, thus ruling out attrition 
bias; however, this association was attenuated when further adjusting for confounders 
in models 2 and 3. IGF-II levels at 61 months were weakly and positively correlated 
with total body fat (P = 0.045) at TF3; however, this correlation was not seen at F17 
and did not persist when more confounders were adjusted for or when model 1* 
restricted analysis was performed. There was no evidence of an association between 
cord IGF-II and total body fat at TF3. 
 
Table 6-5 : Regression between IGF-II levels (cord blood and 61 months) and 
total body fat at TF3 and F17 in the ALSPAC cohort. 
 IGF-II cord blood IGF-II 61 months 
 N β SE P-
value 






Model 1a 303 −0.002 0.006 0.684 309 0.010 0.005 0.045 
Model 2 204 −0.006 0.007 0.350 202 0.006 0.006 0.261 
Model 3 177 −0.006 0.007 0.408 178 0.006 0.006 0.332 





Model 1 292 −0.014 0.006 0.017 286 0.006 0.005 0.253 
Model 2 210 −0.012 0.007 0.067 199 0.005 0.006 0.393 
Model 3 135 −0.009 0.008 0.306 138 0.004 0.007 0.599 
Model 1* 210 −0.014 0.007 0.046 199 0.004 0.006 0.470 
F17, 17 years; SE, standard error; TF3, 15 years. 
aModel definitions are provided in Section 6.3.6. 
 
 
6.4.3 Correlation between IGF-II and trunk fat mass at TF3 and F17. 
To further determine the correlation between total body fat and IGF-II, and because 
central fat deposition is more related to metabolic risk than overall fat (Nguyen-Duy, 
Nichaman et al. 2003), the association between IGF-II levels (in cord blood and at 61 
months) and trunk fat was determined at TF3 and F17. Table 6-6 shows evidence of a 
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strong negative correlation between IGF-II cord blood levels and trunk fat mass at F17 
(P = 0.011) in the minimally-adjusted model and a persisting association between 
these variables when using the restricted model 1* (P = 0.036). However, this 
association was attenuated with adjustment for additional confounders. Conversely, 
there was no evidence of any association between IGF-II cord blood and trunk fat 
mass when measured at TF3. Furthermore, IGF-II levels at 61 months were not 
associated with trunk fat at either TF3 or F17.  
 
Table 6-6 : Regression between IGF-II levels (cord blood and 61 months) and 
trunk body fat at age TF3 and F17 in the ALSPAC cohort. 
 IGF-II cord blood IGF-II 61 months 
 N β SE P-
value 






Model 1a 303 −0.005 0.006 0.419 309 0.009 0.005 0.056 
Model 2 204 −0.007 0.007 0.297 202 0.005 0.006 0.360 
Model 3 177 −0.007 0.007 0.313 178 0.006 0.061 0.320 





Model 1 294 −0.016 0.006 0.011 289 0.006 0.005 0.224 
Model 2 211 −0.013 0.007 0.059 201 0.005 0.006 0.400 
Model 3 136 −0.008 0.009 0.356 140 0.003 0.007 0.703 
Model 1* 211 −0.015 0.007 0.036 201 0.004 0.006 0.507 
F17, 17 years; SE, standard error; TF3, 15 years. 
aModel definitions are provided in Section 6.3.6. 
 
 
6.4.4. Correlation between IGF-II and peripheral fat mass. 
6.4.4.1 Correlation between IGF-II and arms and legs fat mass at TF3 and F17. 
The relationship between IGF-II and body fat distribution was further analysed by 
correlating IGF-II levels (cord blood and at 61 months) and peripheral fat in the legs 
and arms at TF3 and F17 (Table 6-7). The analysis showed strong evidence of an 
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association between IGF-II at 61 months and arm fat mass at TF3 (P = 0.016); 
however, the association did not persist when using additional analysis models or 
when fat mass was measured at F17. In addition, weak evidence of an inverse 
correlation between cord blood IGF-II and arm fat mass at F17 was seen using the 
minimally-adjusted model (P = 0.039); however, this association was weakened when 
adjusting for further confounders and when using model 1*. No evidence of 
association was seen for IGF-II at 61 months and arm fat mass at F17. 
 
Table 6-7: Regression analysis between IGF-II levels (cord blood and 61 
months) and arm fat mass at TF3 and F17 in the ALSPAC cohort. 
 IGF-II cord blood IGF-II 61 months 
 N β SE P-
value 







Model 1 a 303 −0.003 0.005 0.640 309 0.012 0.005 0.016 
Model 2 204 −0.006 0.006 0.297 202 0.007 0.006 0.237 
Model 3 177 −0.005 0.006 0.391 178 0.006 0.006 0.290 





Model 1 294 −0.012 0.006 0.039 289 0.004 0.005 0.376 
Model 2 211 −0.011 0.007 0.091 201 0.004 0.006 0.528 
Model 3 136 −0.009 0.008 0.306 140 0.002 0.007 0.796 
Model 1* 211 −0.013 0.007 0.061 201 0.003 0.006 0.656 
F17, 17 years; SE, standard error; TF3, 15 years. 
aModel definitions are provided in Section 6.3.6. 
 
Table 6-8 shows evidence of a strong positive correlation between IGF-II at 6 months 
and leg fat mass at TF3 when minimally adjusted for age and gender (P = 0.011); 
however, this correlation did not persist when adjusting for further confounders, when 
the restricted model 1* was used or at F17. Furthermore, no evidence of correlation 
between cord blood IGF-II and leg fat mass was detected at TF3 or F17. 
Chapter 6: IGF-II and pubertal fat distribution in ALSPAC cohort 
 212 
 
Table 6-8 : Regression analysis between IGF-II levels (cord blood and 61 
months) and leg fat mass in the ALSPAC cohort study. 
 IGF-II cord blood IGF-II 61 months 
 N β SE P-
value 






Model 1a 303 −0.001 0.006 0.890 309 0.014 0.005 0.011 
Model 2 204 −0.006 0.006 0.343 202 0.009 0.006 0.138 
Model 3 177 −0.005 0.007 0.439 178 0.007 0.006 0.242 





Model 1 294 −0.011 0.006 0.053 289 0.005 0.005 0.331 
Model 2 211 −0.009 0.006 0.152 201 0.005 0.006 0.361 
Model 3 136 −0.006 0.008 0.482 140 0.006 0.007 0.426 
Model 1* 211 −0.011 0.007 0.107 201 0.004 0.006 0.479 
F17, 17 years; SE, standard error; TF3, 15 years. 
aModel definitions are provided in Section 6.3.6. 
 
  




6.4.4.2 Correlation between IGF-II and android and gynoid fat mass at TF3 and F17 
Android and gynoid distribution were previously shown to relate to insulin resistance 
and metabolic risk (Samsell, Regier et al. 2014), therefore the correlation between 
IGF-II levels and android and gynoid fat mass was measured at TF3 and F17. Table 
6-9 shows that cord blood IGF-II was weakly and negatively correlated with android 
fat at F17 in model 1 (P = 0.027); however, this correlation did not persist when 
restricted model 1* was used. Cord blood IGF-II was not correlated with android fat 
mass at TF3. Examining IGF-II levels at 61 months showed no evidence of correlation 
with android fat mass at puberty.  
 
Table 6-9 : Regression analysis between IGF-II levels (cord blood and 61 
months) and android fat mass at TF3 and F17 in the ALSPAC study. 
 IGF-II cord blood IGF-II 61 months 
 N β SE P-
value 






Model 1a 303 −0.004 0.006 0.463 309 0.009 0.005 0.088 
Model 2 204 −0.006 0.007 0.374 202 0.004 0.006 0.503 
Model 3 177 −0.006 0.007 0.359 178 0.004 0.006 0.504 





Model 1 294 −0.014 0.006 0.027 289 0.004 0.005 0.414 
Model 2 211 −0.010 0.007 0.147 201 0.003 0.006 0.609 
Model 3 136 −0.007 0.009 0.457 140 0.000 0.008 0.959 
Model 1* 211 −0.013 0.007 0.084 201 0.002 0.006 0.746 
F17, 17 years; SE, standard error; TF3, 15 years. 




Table 6-10 shows a similar weak association between cord blood IGF-II and gynoid 
fat mass at F17 (P = 0.027) when adjusting for age and sex. No correlation was 
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detected between cord blood IGF-II and gynoid fat mass at TF3, and no correlation 
was seen between IGF-II at 61 months and gynoid fat mass at either time point. 
 
Table 6-10 : Regression analysis between IGF-II levels (cord blood and 61 
months) and gynoid fat mass at TF3 and F17 in the ALSPAC cohort. 
 IGF-II cord blood IGF-II 61 months 
 N β SE P-
value 






Model 1 a 303 −0.001 0.005 0.784 309 0.009 0.005 0.059 
Model 2 204 −0.006 0.007 0.363 202 0.006 0.005 0.284 
Model 3 177 −0.006 0.007 0.395 178 0.005 0.006 0.353 





Model 1 294 −0.013 0.006 0.027 289 0.006 0.005 0.227 
Model 2 211 −0.011 0.006 0.091 201 0.006 0.006 0.323 
Model 3 136 −0.008 0.008 0.329 140 0.006 0.007 0.442 
Model 1* 211 −0.013 0.007 0.057 201 0.005 0.006 0.425 
F17, 17 years; SE, standard error; TF3, 15 years. 
aModel definitions are provided in Section 6.3.6. 
 
  




6.4.5 Correlation between IGF-II and lean mass fat at TF3 and F17 
To further understand the role of IGF-II plasma levels in the regulation of body 
composition, the correlation between IGF-II levels (cord blood and 61 months) and 
lean mass at age TF3 and F17 was investigated. No correlation between prepubertal 
IGF-II and post-pubertal lean mass was observed at TF3 or F17 (Table 6-11).  
 
Table 6-11: Regression analysis between IGF-II levels (cord blood and 61 
months) and postpubertal lean mass at TF3 and F17 in the ALSPAC cohort 
study. 
 IGF-II cord blood IGF-II 61 months 
 N β SE P-
value 






Model 1a 303 −0.004 0.003 0.126 309 0.002 0.002 0.417 
Model 2 204 −0.001 0.003 0.771 202 0.003 0.003 0.333 
Model 3 177 −0.002 0.003 0.537 178 0.005 0.003 0.112 





Model 1 292 −0.004 0.003 0.164 286 0.003 0.002 0.135 
Model 2 210 −0.004 0.003 0.133 199 0.002 0.003 0.351 
Model 3 135 −0.007 0.004 0.104 138 0.004 0.003 0.167 
Model 1* 210 −0.004 0.003 0.137 199 0.003 0.003 0.264 
F17, 17 years; SE, standard error; TF3, 15 years. 
aModel definitions are provided in Section 6.3.6. 
 
6.4.6 Correlation between IGF-II and BMI at TF3 and F17 
Table 6-12 illustrates the correlation between IGF-II and BMI at different time points. 
A strong positive correlation was seen between IGF-II levels at 61 months and BMI 
at TF3 using model 1; however, this correlation was lost when other models were used 
and when the analysis was restricted to participants with completed data (model 1*). 
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There was no correlation between IGF-II cord blood and BMI measured at either TF3 
or F17.  
Table 6-12: Regression analysis between IGF-II levels (cord blood and 61 
months) and postpubertal BMI at TF3 and F17 in the ALSPAC cohort. 
 IGF-II cord blood IGF-II 61 months 
 N β SE P-
value 






Model 1 a 320 −0.008 0.006 0.192 330 0.014 0.005 0.009 
Model 2 213 −0.007 0.007 0.256 209 0.009 0.006 0.137 
Model 3 184 −0.007 0.007 0.303 182 0.009 0.006 0.158 





Model 1 307 −0.012 0.006 0.054 304 0.005 0.006 0.333 
Model 2 218 −0.012 0.007 0.070 212 0.005 0.006 0.423 
Model 3 140 −0.010 0.009 0.231 144 0.007 0.007 0.374 
Model 1* 218 −0.014 0.007 0.051 212 0.004 0.006 0.517 
F17, 17 years; SE, standard error; TF3, 15 years. 
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6.5 Discussion  
 
The ALSPAC cohort study was used to examine the association between pre-pubertal 
IGF-II plasma levels (in cord blood and at 61 months old) and body fat composition 
at puberty measured by DXA scans at TF3 and F17 years. The findings indicate that 
cord blood IGF-II was strongly and negatively associated with pubertal fat mass at 
F17, particularly with total body fat and trunk fat mass. In addition, IGF-II levels at 
61 months were positively associated with BMI in puberty; however, this association 
was mainly due to increased peripheral fat mass measured in the legs and arms. These 
associations were seen when minimal adjustments for confounders (i.e. age and sex) 
were used.  
The correlation between IGF-II levels and body weight has been inconsistently 
reported in the literature; for example, cross-sectional studies reported that IGF-II 
levels were lower (Cruickshank, Heald et al. 2001), higher (Frystyk, Vestbo et al. 
1995) and similar in obese individuals (Chang, Wu et al. 2002) when compared to 
normal weight controls. The ALSPAC study previously showed a correlation between 
IGF-II at 61 months and current fat mass (Ong, Kratzsch et al. 2002), and our 
observations also indicate an association with fat mass at puberty and seems more 
related to arm and leg fat mass; however, this association did not persist when 
adjusting for additional confounders or when using restricted models. The same study 
also indicated that IGF-II levels in the cord blood were correlated to IGF-II levels at 
61 months, thus suggesting that IGF-II levels are genetically regulated (Ong, Kratzsch 
et al. 2002). Other studies have demonstrated that the methylation status of the IGF-II 
gene in cord blood was reflected in the circulating plasma levels of IGF-II, and higher 
circulation levels were associated with higher birth weight in the Newborn Epigenetics 
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Study cohort (Hoyo, Fortner et al. 2012). However, a contradictory study showed that 
IGF-I, and not IGF-II, was associated with birth weight (Reece, Wiznitzer et al. 1994).  
Interestingly, the time point of the IGF-II measurement and the outcome measurement 
appear to be important; for example, retrospective studies have reported a negative 
correlation between IGF-II and BMI. The Southern Community Cohort Study 
identified increasing IGF-II levels with BMI in middle age; however, IGF-II levels 
were negatively associated with BMI at 21 years of age (Fowke, Matthews et al. 2010). 
This was also reported in the Boyd Orr Cohort, which correlated IGF levels in old age 
(mean age: 71 years) with childhood BMI. Similarly, IGF-II correlated positively with 
BMI and waist–hip ratio at 71 years but showed a negative association with BMI at 6 
years of age (Martin, Holly et al. 2006). 
Nevertheless, prospective studies showed that low baseline IGF-II levels, may cause 
higher weight gain after 5 years in middle-aged, non-obese participants. This study 
reported that for every 100 ng/ml decrease in IGF-II, there is a 0.88 increase in the 
relative risk for weight gain (Sandhu, Gibson et al. 2003) and that a higher baseline 
level of IGF-II protected against weight gain. However, this study also indicated that 
there may be a threshold level for the association between IGF-II and weight. This 
was reported again in another prospective study in subjects with diabetes, where 
circulating levels of IGF-II were related to BMI in morbidly obese subjects and these 
IGF-II levels reduced with weight loss. However, this was not seen in subjects with 
moderate obesity, in whom IGF-II levels were similar to normal weight individuals 
(Heald, Kärvestedt et al. 2006). 
Whilst IGF-I serum levels having been associated with fat depots, few have examined 
the relationship between circulating IGF-II levels and fat distribution. IGF-II is known 
to be a fetal growth factor and has therefore been extensively studied at a genetic level, 
Chapter 6: IGF-II and pubertal fat distribution in ALSPAC cohort 
 219 
and evidence of IGF-II fat depot-specific action was revealed in these genetic studies 
(Mårin, Kvist et al. 1993). Similar to the results obtained in this study, IGF-II  
increased expression in young adults due to IGF2/H19 gene methylation showed a fat 
depot-specific effect, by increasing subcutaneous fat distribution but having no effect 
on visceral fat distribution (Huang, Galati et al. 2012). This was also seen in 
individuals with polymorphisms in IGF-II (i.e. Apal AA individuals), who exhibited 
higher circulating levels of IGF-II that were associated with lower waist–hip 
measurements (Tchoukalova, Nathanielsz et al. 2009). In post-menopausal women, 
body fat measured by DXA scan displayed a different association with IGF-II DMR2b 
methylation according to the location of body fat, preferring a more subcutaneous fat 
accumulation in comparison to visceral fat (Song, Ernst et al. 2018).   
 In vitro mammalian studies also showed a fat depot-specific action of IGF-II 
(Rodríguez, Gaunt et al. 2004), and this was demonstrated using subcutaneous and 
visceral preadipocytes from children (Chapter 4.4). This was also observed in this 
study with a positive association between IGF-II levels at 61 months and peripheral 
fat mass (i.e. arms, legs fat) at TF3 although this was not consistent though all 
peripheral body fat measurements (android and gynoid fat) and indicate a weak 
association with BMI at this age. However, the lack of association with lean mass and 
trunk fat mass indicates that the association with BMI is mainly due to an increase in 
peripheral fat.  
In vitro studies suggest IGF-II may have a regulatory role in myogenesis (Florini, 
Ewton et al. 1996, Carter, Cosgrove et al. 2009); however, our study indicated no 
association between circulating levels of IGF-II in early life and lean mass at puberty. 
This was also reported in later life, as no association was observed between baseline 
IGF-II and lean mass after 10 years (Bann, Holly et al. 2015). 
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The strength of this present study is its longitudinal nature as it allows IGF-II levels 
during early stages of life to be related to post-pubertal measurements. In addition, 
DXA scans gave detailed descriptions of fat distribution that provided a better idea of 
metabolic risk than BMI alone. This was clearly seen in this study, as an association 
between IGF-II and fat mass at T17, but not BMI, was determined. A weakness of the 
study lies in its lack of generalisability across ethnicities as the vast majority of 
participants were white (Fraser, Macdonald-Wallis et al. 2012), and evidence has 
indicated that the correlations between IGF-II levels and weight and BMI are affected 
by race (Fowke, Matthews et al. 2010). In fact, circulating levels of IGFs are related 
to genetic factors, and IGF-II levels are more heavily influenced by genes and race, 
than IGF-I (Harrela, Koistinen et al. 1996, Jernström, Chu et al. 2001).  
In conclusion, pre-pubertal circulating levels of IGF-II in early life were negatively 
associated with trunk fat mass, positively associated with peripheral fat mass (arms 
and legs) at puberty with adjustment for age and sex, but not associated with lean body 
mass. 
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6.6 Conclusion  
 
This study focused on examining the relationship between childhood IGF-II serum 
levels and body fat distribution at puberty using the ALSPAC cohort study data.  We 
had access to IGF-II levels measured in early life (birth and at 61 months) and DXA 
scan measurements of fat mass obtained from subcutaneous and visceral body regions 
at and after puberty (15 and 17 years). This was a logical extension of the laboratory 
study suggesting a role for IGF-II in fat deposition. The data indicate a fat-depot 
association between IGF-II and fat mass; a negative association with trunk body fat 
and a selective positive association with peripheral body fat mass. Furthermore, IGF-
II showed a weak positive association with BMI however this seems to be due to 
increased peripheral body fat as no associations with truncal fat and lean mass was 
seen. These associations were seen with the adjustments of age and sex and but were 
attenuated when further confounders were examined. 
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7.1 General discussion 
 
The IGF system has an established role in regulating many biological processes such 
as cell survival, growth, differentiation and cell metabolism. IGFs are secreted from 
most body tissues however, they are not stored within cells but are maintained at high 
levels in the circulation. Bioavailability is controlled by binding to IGFBPs; around 
80-90% of circulating IGF is kept in the vascular compartment by forming a ternary 
complex with ALS and IGFBP-3, and to a lesser extent IGFBP-5, that modulates tissue 
availability. The actions of IGFs are mediated through their corresponding receptors 
which are found in most tissues (Yakar, Liu et al. 1999, Duan, Ren et al. 2010, Werner 
and LeRoith 2014). An important target tissue for IGF action is adipose tissue, where 
the receptors are characteristically distributed, allowing a regulatory role for IGF in 
the growth and expansion of body fat. IGF-I was shown to promote pre-adipocyte 
proliferation and differentiation in the 3T3-L1 cell line (Humbel 1990) and in primary 
cultures (Birnie, Ben-Shlomo et al. 2012) and as previously reported, in primary 
cultures obtained from children (Grohmann, Sabin et al. 2005). IGF-II was recognised 
for years as a fetal tissue growth regulator, with less known about its postnatal role. 
One reason is because IGF-II expression is down-regulated postnatally in rodents, 
whereas humans maintain extremely high levels of IGF-II, with concentrations 
considerably higher than those of IGF-I (Humbel 1990, Birnie, Ben-Shlomo et al. 
2012). A potential role of IGF-II in adipose tissue regulation has emerged because of 
its association with weight, obesity, and a number of cancers (Feinberg, Koldobskiy 
et al. 2016). With the increasing epidemic of child and adult obesity and the 
association of IGF-II genetic variations with body weight and obesity (O'Dell, Miller 
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et al. 1997, Roth, Schrager et al. 2002, Faienza, Santoro et al. 2010), further 
understating of the role of IGF-II in adipose tissue is needed.  
In this study, we investigated the function of IGF-II as a regulator of adipose tissue 
growth and examined the fat depot differences in IGF-II actions using paired visceral 
and subcutaneous fat biopsies obtained from children. The use of paediatric samples 
was a strength of our study as pre-adipocytes obtained from children display greater 
viability and have the ability to differentiate for several passages in comparison to 
adult samples, as previously indicated (Grohmann, Sabin et al. 2005). Furthermore, 
using paediatric samples minimises the influence of sex-hormone augmentation which 
accompanies puberty (Sizonenko 1978). In addition, characteristic differences are 
reported for paediatric adipose tissue compared to that from adults (Rosenbaum, 
Presta et al. 1991).One of the study aims was to examine fat depot differences in IGF 
receptor levels, particularly insulin receptor isoforms. Reports have indicated that age 
can alter the IR-A/IR-B ratio causing an increase in the IR-A: using paediatric samples 
removes this potential confounder (Serrano, Villar et al. 2005).  A minor limitation is 
that paediatric fat samples are more difficult to obtain due to the existence of fewer 
operative indications, especially if malignant or inflammatory causes are excluded. As 
was the case with our sample group, this led to an extension of the sample collection 
period. 
As IGF-II has been described as a potent mitogenic factor (Forbes and Westwood 
2010), we investigated the effect of IGF-II on pre-adipocyte proliferation. As 
speculated, our results showed that IGF-II induced pre-adipocyte proliferation in 
subcutaneous and visceral pre-adipocytes. Interestingly, in terms of pre-adipocyte 
differentiation, our data suggest that IGF-II has depot-specific actions in terms of 
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promoting pre-adipocyte differentiation. IGF-II treatment at physiological 
concentrations enhances the growth of subcutaneous pre-adipocytes into mature 
adipocytes and fat deposition, but, in contrast, has a restrictive effect on visceral pre-
adipocyte maturation. This effect was associated with an increase in the differentiation 
markers PPARγ and adiponectin in subcutaneous pre-adipocytes. Interestingly, IGF-
II specifically increased PPARγ2 expression, one of the two alternatively spliced 
forms of PPARγ, indicating that IGF-II alters the splicing preferences of another key 
adipocyte protein. This may be important as, although PPARγ1 and PPARγ2 are 
involved in adipogenesis in vitro, PPARγ2 is more closely related to nutritional status 
and the maintenance of insulin sensitivity (Kilroy, Kirk-Ballard et al. 2012). It would 
be interesting to examine whether proteins involved in alternative splicing are 
differentially regulated in subcutaneous and visceral adipocytes. Differentiation with 
IGF-II also increased the levels of the insulin receptor, GLUT4, FASN, and insulin-
stimulated glucose uptake in subcutaneous pre-adipocytes with an opposing effect 
with visceral pre-adipocytes. Recently published supportive evidence also indicates 
that IGF-II can regulate metabolic in utero growth by modulating the genetic 
expression controlling nutritionally-regulated genes like FASN and PPAR in hepatic 
cells (Lopez, Zheng et al. 2018). 
Potential differences in the action of IGF-II on fat depots has been reported in a limited 
manner in in vitro studies, and only in mammalian experiments (Tchoukalova, 
Nathanielsz et al. 2009). IGF-II is a genetically highly regulated hormone with 
restricted imprinted expression and changes in IGF-II gene methylation have been 
associated with fat depot differences in adipose tissue growth, as seen in younger 
adults (Huang, Galati et al. 2012) and adults (Rodríguez, Gaunt et al. 2004, Rodríguez, 
Gaunt et al. 2006). Although those showed that higher IGF-II expression was 
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associated with less visceral fat accumulation, other studies reported contradictory 
actions of IGF-II (Roth, Schrager et al. 2002, Martin, Holly et al. 2006). The genetic 
expression of most imprinted genes is associated with differential methylation of one 
or multiple regions of the maternal or paternal alleles, with DNA methylation levels 
influencing the genetic expression of these genes. Interestingly, the methylation status 
of IGF-II differently methylated regions (DMRs), have been associated with the 
regulation of body weight and obesity (Murrell, Heeson et al. 2003, Hoyo, Fortner et 
al. 2012) , and is suggested to be influenced epigenetically. Parental weight peri-
conceptually seems to be an important epigenetic effector; obese mothers had reduced 
IGF-II methylation and increased fetal birth weight (Hoyo, Fortner et al. 2012), while 
paternal obesity was associated with hypomethylation of the DMRs, leading to altered 
levels of IGF-II and an increased risk of obesity in the offspring (Soubry, Schildkraut 
et al. 2013). However, whether the maintenance of normal weight before pregnancy 
will be protective against the risk of early life obesity in offspring is still to be 
determined in humans; in animal studies, paternal dietary control modulated the 
epigenetic expression of IGF-II (Tybl, Shi et al. 2011). Furthermore, in a study of 
normal weight pregnant women, maternal exercise during pregnancy was linked to a 
lower infant birth weight and lower IGF-II levels in cord blood (Hopkins, Baldi et al. 
2010). Lastly, another recognised postnatal epigenetic influencing factor is breast 
feeding status, which may modulate the differences in the magnitude of methylation 
and this has been suggested to relate to the risk associated with being overweight in 
early life (Perkins, Murphy et al. 2012) although the only randomised trial of breast 
feeding in Belarus (PROBIT) challenged any effect of breast feeding on obesity 
(Kramer, Matush et al. 2008). 
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We considered that differences in IGF receptor distribution might contribute to these 
IGF-II depot-specific actions (Lefebvre, Laville et al. 1998). As we showed, in 
agreement with other reports, IGF-IR abundance decreases with pre-adipocyte 
differentiation (Zizola, Balañá et al. 2002), while insulin receptor expression increases 
and visceral fat has a higher insulin receptor abundance than subcutaneous fat 
(Lefebvre, Laville et al. 1998). Insulin receptor isoform distribution—which can 
markedly alter tissue-specific biological responses to IGF-II—shows a higher 
distribution of IR-B in tissues that are primarily responsive to insulin action, such as 
adipocytes, muscle, and liver, whilst IR-A is more abundant in fetal cells and some 
cancer cells, where mitogenic responses are important (Mosthaf, Grako et al. 1990, 
Frasca, Pandini et al. 1999); this is consistent with the mainly mitogenic signalling 
that is reportedly activated by IR-A. Our data indicate that IR-A is the predominant 
isoform in visceral pre-adipocytes, whilst IR-B predominates in subcutaneous pre-
adipocytes. Although the IR-B/IR-A ratio increased with differentiation, IR-A remains 
significantly higher in visceral adipocytes in comparison to subcutaneous adipocytes, 
rendering them potentially more IGF-II responsive.  
Distribution of the IGF-IIR/M6P differs between the fat depots, which might influence 
tissue levels of IGF-II. Our data demonstrated that a higher level of IGF-IIR/M6P was 
found in visceral in comparison to subcutaneous pre-adipocytes.  IGF-IIR/M6P plays 
a role in degrading IGF-II and alterations in IGF-II tissue bio-availability might 
consequently affect the phosphorylation of other receptors such as the IGF-IR and 
insulin receptors (Hawkes and Kar 2003). The increased abundance of the IGF-
IIR/M6P in visceral cells might indicate lower levels of IGF-II; however, our data 
show that there was no difference in IGF-II secreted levels between visceral and 
subcutaneous cells. The IGF-IIR/M6P is not specific to IGF-II alone; the M6P 
  Chapter 7: General discussion 
 228 
component could mediate the effects of other ligands, one of which is TGF-β, which 
is known to inhibit adipogenesis (Choy, Skillington et al. 2000) and could also 
contribute to the fat depot differences in differentiation that were reported to cause 
less visceral fat growth.  
Fine-tuning the regulation of IGF-II bioavailability is important to control activity and 
prevent over-exposure, which might be detrimental to health. As previously 
mentioned, IGFBPs play a crucial role in controlling the amount of free IGFs that are 
available. IGFBP-3, in particular, is highly related to adipogenesis (Chan, Schedlich 
et al. 2009) and circulating IGFBP-3 levels have been correlated to body weight in 
several studies. In younger age groups, IGFBP-3 levels were increased in obese 
children (Park, Kim et al. 1999) and adolescents and were more closely related to 
cardiovascular risk (Kong, Choi et al. 2011). In contrast, another study reported that 
IGFBP-3 levels were decreased in obese adolescents but this was associated with an 
increase in IGFBP-3 proteolysis (Mohanraj, Kim et al. 2013). Proteolysed IGFBP-3 
results in changes in conformation of the motifs responsible for IGF binding, which 
leads to a lower IGF binding affinity, further explaining the increase in IGF bio-
activity related to obesity. The increase in proteolysis was consistent with our findings 
when cells were subjected to hyperglycaemic conditions. Interestingly, IGFBP-3 has 
been suggested to be a key factor linking breast cancer advancement with obesity; 
IGFBP-3 was shown to increase breast cancer progression by T-cell infiltration and 
enhanced adipose tissue growth in mouse models (Scully, Firth et al. 2016).  
Although IGFBP-3 is the most abundant binding protein in the circulation, IGF-II has 
the greatest affinity for IGFBP-6; however, there are no published data about the role 
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of IGFBP-6 in adipose tissue development and its influence on IGF-II metabolic 
regulation is still to be explored.  
Additionally, we investigated how acute IGF-II treatment affected mRNA expression 
of the IGF-IR, the insulin receptor and its isoforms in adipocytes. As predicted, our 
results indicate that IGF-II exposure has minimal effect on the IGF-IR in adipocytes. 
However, IGF-II caused down-regulation of total insulin receptor mRNA levels, 
particularly with respect to IR-A in visceral adipocytes. This down-regulation was 
associated with reduction in total GLUT4 (insulin sensitive glucose transporter) and 
glucose uptake into the cell. The reason for IGF-II actions being more profound in 
visceral adipocytes may include the higher ratio of IR-A in visceral adipocytes in 
comparison to subcutaneous fat, the higher relative affinity of IGF-II binding to the 
IR-A (Denley, Bonython et al. 2004), and the fact that the IR-A has a higher 
internalisation rate than IR-B (Vogt, Carrascosa et al. 1991). It has previously been 
reported that IGF-II can activate the insulin receptor in human adipocytes at 
physiological levels (Bäck, Brännmark et al. 2011) and that the ability of IGF-II to 
modulate glucose uptake is mediated through insulin receptors (Sinha, Buchanan et 
al. 1990).  
The ability of IGF-II to regulate IR-A expression in visceral fat might be of clinical 
importance, because insulin resistance has been linked to the higher mRNA expression 
of insulin receptor isoform A (Okabayashi, Maddux et al. 1989). Furthermore, IGF-II 
has been reported to have an anti-inflammatory effect by reducing TNF-α, associated 
with obesity and insulin resistance (Morita, Horii et al. 2014). However, the 
relationship between obesity and IGF-II is far from clear (Chao and D’Amore 2008). 
A high fat diet has been reported to cause down-regulation of IGF-II expression from 
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adipocytes and up-regulation of mRNA for the IGF-IIR/M6P, that resulted in a 
decrease in tissue availability with obesity (Morita, Horii et al. 2014). A conflicting 
study has indicated that IGF-II secretion and bioavailability are increased in obese 
individuals, particularly from visceral fat (Gude, Hjortebjerg et al. 2016). The 
inflammatory cytokines associated with obesity have also been reported to alter the 
production of IGF-II and IGF binding proteins from the adipose tissue; TNF-α caused 
a decrease in the production of IGF-II, IGF-I and their IGF binding proteins, whereas 
IL-1β had no effect on IGF-II but reduced the production of IGF-I. However, whether 
this obesity-related change in IGF-II is a compensatory mechanism associated with 
obesity or a cause of obesity requires further investigation and understanding.  
Recently, mRNA alternative splicing has been proposed as a mechanism for the 
pathogenicity of obesity (Wong, Xu et al. 2018). Alternative splicing is an important 
mechanism for protein generation multiplicity, as genetic splicing is highly regulated 
(Wang, Liu et al. 2015). Dysregulation of this genetic process was shown to promote 
metabolic diseases (Kaminska, Hämäläinen et al. 2014) and aging (Holly, Melzer et 
al. 2013, Latorre and Harries 2017). Insulin receptor mRNA splicing is one of the 
major receptors involved, with dysregulation noted in diabetes (Huang, Bodkin et al. 
1996). The receptor splicing variant was shown to be influenced by weight loss, 
whether related to nutritional restriction (Kaminska, Hämäläinen et al. 2014) or 
surgical intervention (Besic, Shi et al. 2015). Insulin receptor alternative splicing can 
be affected by multiple binding splicing factors, such as the heterogeneous nuclear 
ribonucleoproteins (hnRNPA1) and serine-arginine rich proteins (SF3A); these factors 
can bind within exon 11 and promote exon inclusion or exclusion (Talukdar, Sen et 
al. 2011). In addition to the insulin receptor, other examples of receptor isoforms that 
are related to obesity include the leptin receptor (OB-R) long, short and soluble 
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isoforms. The absence of the long isoform has been associated with early onset obesity 
in a mouse model (Lee, Proenca et al. 1996, Uotani, Bjørbaek et al. 1999), the short 
leptin isoform is responsible for leptin degradation and has been found to be increased 
in obesity (Uotani, Bjørbaek et al. 1999), while the soluble isoform of the leptin 
receptor has been correlated with BMI (Van Dielen, van ‘t Veer et al. 2002). Other 
receptor isoforms where genetic mis-splicing is associated with obesity pathology 
include the lamin A/C gene (LMNA), Lipin-1 and serotonin 2C receptor (5-HTR2c) 
(Phan and Reue 2005, Miranda, Chacon et al. 2008, Galiveti, Raabe et al. 2014).  
This suggests that mRNA alternative splicing can be used as a future therapeutic 
approach for obesity, by using gene therapy to target and modulate the errors in 
splicing of these metabolic regulatory genes. Using animals, splice-specific KO mice 
models have been created, where a particular splice-variant can be overexpressed 
(Wong, Xu et al. 2018). Furthermore, mRNA alternative splicing was shown to be 
involved in the regulation of adipose tissue growth, in terms of regulating the 
processing of brown adipose tissue and thermogenesis, which also makes it an 
important mechanism for therapeutic obesity intervention (Vernia, Edwards et al. 
2016).  
 
Having shown that IGF-II acts as a regulator of adipose tissue biology and growth, we 
investigated whether IGF-II serum levels could be used as an indicator of future 
weight and body fat accumulation. In the ALSPAC study, we assessed the relationship 
between early childhood IGF-II serum levels and pubertal fat accumulation. 
Interestingly, our data showed that IGF-II is negatively correlated with trunk fat mass 
and shows a positive association with peripheral fat, in particular on the arms and legs; 
however, the correlation between IGF-II and peripheral body fat was inconsistent 
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throughout the peripheral fat measurements (android and gynoid) and was attenuated 
when confounders other than age and sex were added to the model. Our data indicate 
that BMI was weakly associated with IGF-II and that the increase in weight was 
mainly due to peripheral fat increase, as no association with lean mass was observed. 
Our study was unique in looking for fat accumulation in different body compartments 
and the use of DXA scans gave more strength and precision to adiposity 
measurements. Most studies have investigated prenatal IGF-II levels in relation to 
birth weight, since IGF-II plays an important role in fetal development; the levels of 
IGF-II correlated positively (Smerieri, Petraroli et al. 2011) or showed no correlation 
with birth weight (Reece, Wiznitzer et al. 1994). Different results have also been 
obtained in relation to IGF-II and postnatal obesity: in obese children, low IGF-II 
levels have been documented, along with lower IGFBP-2 concentrations, particularly 
in those with insulin resistance and evidence of chronic inflammation (higher 
expression of TNF-alpha and IL-6 ) (Street, Smerieri et al. 2013). In contrast, another 
study showed that IGF-II was significantly higher in obese children and correlated 
with parameters of insulin sensitivity (Inzaghi, Baldini Ferroli et al. 2017). 
Nevertheless, the increase in IGF-II associated with obesity might be predicted to 
correspond to the increase in adipose tissue accompanying obesity. The question of 
whether IGF-II can be used as a biomarker to predict obesity or insulin-resistant risk 
later in life has not yet been answered. A more recent report indicated that IGF-II or 
IGF-I prenatally was not strongly associated with adiposity after birth measured at 1 
year of age; however, in that study, they used skinfold thickness as an indicator of 
obesity, which might not be very accurate. The study further suggested other 
biomarkers to be better able to predict metabolic health postnatally; higher levels of 
prenatal adiponectin were correlated to lower beta cell function (HOMA-) at age 1 
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year and were positively associated with skinfold thickness measured at age 3 years.  
In contrast, blood cord insulin levels were positively related to adiposity, and Ghrelin 
was negatively related to skinfold thickness and BMI (Zhang, Du et al. 2018). 
Moreover, leptin cord blood levels were negatively related to weight gain in early 
childhood, as indicated by BMI measurements (Mantzoros, Rifas-Shiman et al. 2009, 
Boeke, Mantzoros et al. 2013). The identification of obesity biomarkers earlier in life 
may help to facilitate early preventive approaches e.g. activity and dietary 
interventions that may positively impact on future obesity risk and its associated 
metabolic dysfunction (Must and Strauss 1999). This is of particular importance 
because early onset obesity has been associated with a higher risk of obesity in 
adulthood (Deshmukh-Taskar, Nicklas et al. 2006).  
Taken together, our results indicate that IGF-II might have a role as a physiological 
regulator of pre-adipocyte growth and metabolism and may play an important role in 
regulating body fat composition. IGF-II favours more subcutaneous and limited 
visceral fat growth. Furthermore, our present study suggests that early life levels of 
IGF-II could be a prognostic biomarker for body fat distribution later in adolescent 
life. Interestingly, the actions of IGF-II are not only limited to fat, as IGF-II has been 
previously reported to be a regulator of muscle mass and skeletal muscle cell 
differentiation (Wilson and Rotwein 2006). IGF-II expression is needed for the 
transcription factor MyoD promoting the differentiation of fibroblasts to myoblasts 
(Wilson and Rotwein 2006). Furthermore, the increased expression of IGF-II was 
found to be associated with a more muscular, leaner phenotype in pigs (Van Laere, 
Nguyen et al. 2003). This suggests IGF-II may physiologically modulate body 
composition and cause a reduction of metabolic risk by favouring muscle formation 
over that of fat.   
  Chapter 7: General discussion 
 234 
7.2 Future directions 
 
Our study provides a detailed assessment of the distribution of IGF receptors in 
subcutaneous and visceral fat samples obtained from children, which is fundamental 
information for further studies on adipose tissue regulation. As insulin receptor 
isoforms were shown to be affected by age (Serrano, Villar et al. 2005) and metabolic 
dysregulation associated with obesity (Sesti, Marini et al. 1991), it will be useful to 
compare the changes in receptor predominance in subcutaneous and visceral fat 
samples obtained from obese children. Another avenue for future study may be 
examining differences by ethnicity: for example, South Asians have a tendency to 
greater visceral fat accumulation for any given body mass index (Raji, Seely et al. 
2001). One might predict that IGF-II may have different effects in South Asians 
(perhaps a lesser influence on visceral fat) in comparison to other groups. Our model 
may also prove useful to examine potential interventions that can modify insulin 
receptor alternative splicing, for example, the anti-diabetic drug Metformin has been 
shown to influence the mRNA splicing of insulin receptor though AMPK pathway 
activation and the regulation of specific RNA binding proteins (Laustriat, Gide et al. 
2015). Recent reports have also indicated that the natural polyphenolic phytoalexin, 
Resveratrol regulates hnRNPA1 splicing factor that modulates insulin receptor 
splicing (Otsuka, Yamamoto et al. 2018).  Both of these reagents has been associated 
with effects on body weight (Golay 2008, Macarulla, Alberdi et al. 2009), therefore it 
would be interesting to examine how these reagents can manipulate alternate splicing, 
and the consequential effect on adipocyte biology .   
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Furthermore, an important aspect of the development of obesity is diet composition; 
having paediatric subcutaneous and visceral cultures in our laboratory will allow the 
effect of multiple dietary products that might alter the growth of adipose tissue to be 
studied. Well-recognised gut microbial metabolites are short-chain fatty acids 
(SCFAs) which include acetate, propionate acid, and butyrate acid. It has been 
reported in animal studies that adding SCFAs to high-fat diet-fed rodents improved 
body weight and was protective against body fat mass increase and diet-induced 
obesity (Arora, Loo et al. 2012). In addition, adult human studies showed that SCFAs 
improve glucose homeostasis, insulin sensitivity and blood lipid measurements 
(Bourdon, Yokoyama et al. 1999) and induced an increase in leptin production (Xiong, 
Miyamoto et al. 2004). It would be interesting to study the effect of those fatty acids 
on pre-adipocyte proliferation and differentiation and examine fat depot differences in 
metabolism. As short-chain fatty acids are a digestive product from fibre consumed in 
the diet and are believed to influence the regulation of appetite (Frost, Sleeth et al. 
2014), an understanding of the effect of SCFAs on childhood fat tissue development 
would be important to inform if modulating children’s daily intake by increasing fibre 
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and Y. Le Bouc (2001). "Experimental IGF-I receptor deficiency generates a sexually 
dimorphic pattern of organ-specific growth deficits in mice, affecting fat tissue in 
particular." Endocrinology 142(10): 4469-4478. 
Hopkins, S. A., J. C. Baldi, W. S. Cutfield, L. McCowan and P. L. Hofman (2010). 
"Exercise Training in Pregnancy Reduces Offspring Size without Changes in Maternal 
Insulin Sensitivity." The Journal of Clinical Endocrinology & Metabolism 95(5): 
2080-2088. 
Hoyo, C., K. Fortner, A. P. Murtha, J. M. Schildkraut, A. Soubry, W. Demark-
Wahnefried, R. L. Jirtle, J. Kurtzberg, M. R. Forman and F. Overcash (2012). 
"Association of cord blood methylation fractions at imprinted insulin-like growth 
factor 2 (IGF2), plasma IGF2, and birth weight." Cancer Causes & Control 23(4): 635-
645. 
Hu, C., S. McCall, J. Madden, H. Huang, R. Clough, R. Jirtle and M. Anscher (2006). 
"Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of 
prostate cancer." Prostate cancer and prostatic diseases 9(1): 62. 
Chapter 8: Bibliography 
 249 
Huang, R. C., J. C. Galati, S. Burrows, L. J. Beilin and X. Li (2012). "DNA 
methylation of the IGF2/H19 imprinting control region and adiposity distribution in 
young adults." Clinical epigenetics, 4(1): 21. 
Huang, Z., N. L. Bodkin, H. K. Ortmeyer, B. C. Hansen and A. R. Shuldiner (1994). 
"Hyperinsulinemia is associated with altered insulin receptor mRNA splicing in 
muscle of the spontaneously obese diabetic rhesus monkey." The Journal of clinical 
investigation 94(3): 1289-1296. 
Huang, Z., N. L. Bodkin, H. K. Ortmeyer, M. E. Zenilman, N. Webster, B. C. Hansen 
and A. R. Shuldiner (1996). "Altered insulin receptor messenger ribonucleic acid 
splicing in liver is associated with deterioration of glucose tolerance in the 
spontaneously obese and diabetic rhesus monkey: analysis of controversy between 
monkey and human studies." The Journal of Clinical Endocrinology & Metabolism 
81(4): 1552-1556. 
Humbel, R. E. (1990). "Insulin‐like growth factors I and II." European Journal of 
Biochemistry 190(3): 445-462. 
Imbeault, P., C. Couillard, A. Tremblay, J. Després and P. Mauriège (2000). "Reduced 
α2-adrenergic sensitivity of subcutaneous abdominal adipocytes as a modulator of 
fasting and postprandial triglyceride levels in men." Journal of Lipid Research 41(9): 
1367-1375. 
Inzaghi, E., B. Baldini Ferroli, D. Fintini, A. Grossi, V. Nobili and S. Cianfarani 
(2017). "Insulin-Like Growth Factors and Metabolic Syndrome in Obese Children." 
Hormone Research in Paediatrics 87(6): 400-404. 
Irwin, J. C., L. de las Fuentes, B. A. Dsupin and L. C. Giudice (1993). "Insulin-like 
growth factor regulation of human endometrial stromal cell function: coordinate 
effects on insulin-like growth factor binding protein-1, cell proliferation and prolactin 
secretion." Regulatory peptides 48(1-2): 165-177. 
Jacinto, E., R. Loewith, A. Schmidt, S. Lin, M. A. Rüegg, A. Hall and M. N. Hall 
(2004). "Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin 
insensitive." Nature cell biology 6(11): 1122. 
Jernström, H., W. Chu, D. Vesprini, Y. Tao, N. Majeed, C. Deal, M. Pollak and S. A. 
Narod (2001). "Genetic factors related to racial variation in plasma levels of insulin-
like growth factor-1: implications for premenopausal breast cancer risk." Molecular 
genetics and metabolism 72(2): 144-154. 
Jeyaratnaganthan, N., K. Højlund, J. P. Kroustrup, J. F. Larsen, M. Bjerre, K. Levin, 
H. Beck-Nielsen, S. Frago, A. B. Hassan and A. Flyvbjerg (2010). "Circulating levels 
of insulin-like growth factor-II/mannose-6-phosphate receptor in obesity and type 2 
diabetes." Growth Hormone & IGF Research 20(3): 185-191. 
Johansson, H., L. Baglietto, A. Guerrieri-Gonzaga, B. Bonanni, F. Mariette, D. Macis, 
D. Serrano and A. Decensi (2004). "Factors associated with circulating levels of 
insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 
women at risk for breast cancer." Breast cancer research and treatment 88(1): 63-73. 
Chapter 8: Bibliography 
 250 
Jones, J. I. and D. R. Clemmons (1995). "Insulin-Like Growth Factors and Their 
Binding Proteins: Biological Actions*." Endocrine reviews 16(1): 3-34. 
Juul, A. (2003). "Serum levels of insulin-like growth factor I and its binding proteins 
in health and disease." Growth hormone & IGF research 13(4): 113-170. 
Juul, A., P. Dalgaard, W. F. Blum, P. Bang, K. Hall, K. F. Michaelsen, J. Müller and 
N. E. Skakkebæk (1995). "Serum levels of insulin-like growth factor (IGF)-binding 
protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-
I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation." 
The Journal of Clinical Endocrinology & Metabolism 80(8): 2534-2542. 
Kalscheuer, V. M., E. C. Mariman, M. T. Schepens, H. Rehder and H.-H. Ropers 
(1993). "The insulin–like growth factor type–2 receptor gene is imprinted in the mouse 
but not in humans." Nature genetics 5(1): 74. 
Kameswaran, V. and K. H. Kaestner (2014). "The Missing lnc (RNA) between the 
pancreatic β-cell and diabetes." Frontiers in genetics 5: 200. 
Kaminska, D., M. Hämäläinen, H. Cederberg, P. Käkelä, S. Venesmaa, P. Miettinen, 
I. Ilves, K.-H. Herzig, M. Kolehmainen and L. Karhunen (2014). "Adipose tissue 
INSR splicing in humans associates with fasting insulin level and is regulated by 
weight loss." Diabetologia 57(2): 347-351. 
Kang, H. M., S. Park and H. Kim (2011). "Insulin‐like growth factor 2 enhances 
insulinogenic differentiation of human eyelid adipose stem cells via the insulin 
receptor." Cell proliferation 44(3): 254-263. 
Kanzaki, M. and J. E. Pessin (2001). "Insulin-stimulated GLUT4 translocation in 
adipocytes is dependent upon cortical actin remodeling." Journal of Biological 
Chemistry. 
Kaplan, L. A., T. L. Bott and J. K. Bielicki (1992). "Assessment of [3H] thymidine 
incorporation into DNA as a method to determine bacterial productivity in stream bed 
sediments." Applied and Environmental Microbiology 58(11): 3614-3621. 
Kawai, M. and C. J. Rosen (2010). "The IGF‐I regulatory system and its impact on 
skeletal and energy homeostasis." Journal of cellular biochemistry 111(1): 14-19. 
Kellerer, M., R. Lammers, B. Ermel, S. Tippmer, B. Vogt, B. Obermaier-Kusser, A. 
Ullrich and H. U. Häring (1992). "Distinct alpha-subunit structures of human insulin 
receptor A and B variants determine differences in tyrosine kinase activities." 
Biochemistry 31(19): 4588-4596. 
Kern, P. A., M. E. Svoboda, R. H. Eckel and J. J. Van Wyk (1989). "Insulinlike growth 
factor action and production in adipocytes and endothelial cells from human adipose 
tissue." Diabetes 38(6): 710-717. 
Kiess, W., Y. Yang, U. Kessler and A. Hoeflich (1994). "Insulin-like growth factor II 
(IGF-II) and the IGF-II/mannose-6-phosphate receptor: the myth continues." 
Hormone Research in Paediatrics 41(Suppl. 2): 66-73. 
Chapter 8: Bibliography 
 251 
Kilroy, G., H. Kirk-Ballard, L. E. Carter and Z. E. Floyd (2012). "The Ubiquitin 
Ligase Siah2 Regulates PPARγ Activity in Adipocytes." Endocrinology 153(3): 1206-
1218. 
Kim, H.-S. (2013). "Role of insulin-like growth factor binding protein-3 in glucose 
and lipid metabolism." Annals of pediatric endocrinology & metabolism 18(1): 9-12. 
Kim, J. J. and D. Accili (2002). "Signalling through IGF-I and insulin receptors: where 
is the specificity?" Growth Hormone & IGF Research 12(2): 84-90. 
King, G. L., M. Rechler and C. Kahn (1982). "Interactions between the receptors for 
insulin and the insulin-like growth factors on adipocytes." Journal of Biological 
Chemistry 257(17): 10001-10006. 
Klaus, S., M. Ely, D. Encke and G. Heldmaier (1995). "Functional assessment of white 
and brown adipocyte development and energy metabolism in cell culture. Dissociation 
of terminal differentiation and thermogenesis in brown adipocytes." Journal of cell 
science 108(10): 3171-3180. 
Klein, S., L. Fontana, V. L. Young, A. R. Coggan, C. Kilo, B. W. Patterson and B. S. 
Mohammed (2004). "Absence of an effect of liposuction on insulin action and risk 
factors for coronary heart disease." New England Journal of Medicine 350(25): 2549-
2557. 
Kondaveeti, Y., I. K. G. Reed and B. A. White (2015). "Epithelial–mesenchymal 
transition induces similar metabolic alterations in two independent breast cancer cell 
lines." Cancer letters 364(1): 44-58. 
Kong, A. P. S., K.-C. Choi, G. W. K. Wong, G. T. C. Ko, C.-S. Ho, M. H. M. Chan, 
R. Ozaki, R. C. W. Ma, J. T. F. Lau and J. C. N. Chan (2011). "Serum concentrations 
of insulin-like growth factor-I, insulin-like growth factor binding protein-3 and 
cardiovascular risk factors in adolescents." Annals of Clinical Biochemistry 48(3): 
263-269. 
Körner, C., B. Nürnberg, M. Uhde and T. Braulke (1995). "Mannose 6-
Phosphate/Insulin-like Growth Factor II Receptor Fails to Interact with G-proteins 
Analysis Of Mutant Cytoplasmic Receptor Domains." Journal of Biological 
Chemistry 270(1): 287-295. 
Kornfeld, S. (1992). "Structure and function of the mannose 6-phosphate/insulinlike 
growth factor II receptors." Annual review of biochemistry 61(1): 307-330. 
Kosaki, A., T. S. Pillay, L. Xu and N. J. Webster (1995). "The B isoform of the insulin 
receptor signals more efficiently than the A isoform in HepG2 cells." Journal of 
Biological Chemistry 270(35): 20816-20823. 
Kosaki, A. and N. Webster (1993). "Effect of dexamethasone on the alternative 
splicing of the insulin receptor mRNA and insulin action in HepG2 hepatoma cells." 
Journal of Biological Chemistry 268(29): 21990-21996. 
Kramer, M. S., L. Matush, I. Vanilovich, R. W. Platt, N. Bogdanovich, Z. 
Sevkovskaya, I. Dzikovich, G. Shishko, J.-P. Collet and R. M. Martin (2008). "A 
Chapter 8: Bibliography 
 252 
randomized breast-feeding promotion intervention did not reduce child obesity in 
Belarus." The Journal of nutrition 139(2): 417S-421S. 
Lan, X., E. C. Cretney, J. Kropp, K. Khateeb, M. Berg, F. Peñagaricano, R. Magness, 
A. Radunz and H. Khatib (2013). "Maternal diet during pregnancy induces gene 
expression and DNA methylation changes in fetal tissues in sheep." Frontiers in 
genetics 4: 49. 
Latorre, E. and L. W. Harries (2017). "Splicing regulatory factors, ageing and age-
related disease." Ageing research reviews 36: 165-170. 
Lau, M., C. Stewart, Z. Liu, H. Bhatt, P. Rotwein and C. L. Stewart (1994). "Loss of 
the imprinted IGF2/cation-independent mannose 6-phosphate receptor results in fetal 
overgrowth and perinatal lethality." Genes & Development 8(24): 2953-2963. 
Laursen, L. S., M. T. Overgaard, R. Søe, H. B. Boldt, L. Sottrup-Jensen, L. C. Giudice, 
C. A. Conover and C. Oxvig (2001). "Pregnancy‐associated plasma protein‐A (PAPP‐
A) cleaves insulin‐like growth factor binding protein (IGFBP)‐5 independent of IGF: 
implications for the mechanism of IGFBP‐4 proteolysis by PAPP‐A." FEBS letters 
504(1-2): 36-40. 
Laustriat, D., J. Gide, L. Barrault, E. Chautard, C. Benoit, D. Auboeuf, A. Boland, C. 
Battail, F. Artiguenave and J.-F. Deleuze (2015). "In vitro and in vivo modulation of 
alternative splicing by the biguanide metformin." Molecular Therapy-Nucleic Acids 
4. 
Laviola, L., S. Perrini, A. Cignarelli, A. Natalicchio, A. Leonardini, F. De Stefano, M. 
Cuscito, M. De Fazio, V. Memeo and V. Neri (2006). "Insulin signaling in human 
visceral and subcutaneous adipose tissue in vivo." Diabetes 55(4): 952-961. 
Lawrence, J. B., C. Oxvig, M. T. Overgaard, L. Sottrup-Jensen, G. J. Gleich, L. G. 
Hays, J. R. Yates and C. A. Conover (1999). "The insulin-like growth factor (IGF)-
dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-
associated plasma protein-A." Proceedings of the National Academy of Sciences 
96(6): 3149-3153. 
Le Stunff, C., D. Fallin and P. Bougnères (2001). "Paternal transmission of the very 
common class I INS VNTR alleles predisposes to childhood obesity." Nature genetics 
29(1): 96-99. 
Lee, G. H., R. Proenca, J. M. Montez, K. M. Carroll, J. G. Darvishzadeh, J. I. Lee and 
J. M. Friedman (1996). "Abnormal splicing of the leptin receptor in diabetic mice." 
Nature 379(6566): 632-635. 
Lee, S. Y. and D. Gallagher (2008). "Assessment methods in human body 
composition." Current opinion in clinical nutrition and metabolic care 11(5): 566. 
Lefebvre, A.-M., M. Laville, N. Vega, J. P. Riou, L. van Gaal, J. Auwerx and H. Vidal 
(1998). "Depot-specific differences in adipose tissue gene expression in lean and 
obese subjects." Diabetes 47(1): 98-103. 
Chapter 8: Bibliography 
 253 
Leibiger, B., I. B. Leibiger, T. Moede, S. Kemper, R. N. Kulkarni, C. R. Kahn, L. M. 
de Vargas and P. O. Berggren (2001). "Selective insulin signaling through A and B 
insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic 
beta cells." Molecular cell 7(3): 559-570. 
Leksa, V., K. Pfisterer, G. Ondrovičová, B. Binder, S. Lakatošová, C. Donner, H. B. 
Schiller, A. Zwirzitz, K. Mrvová and V. Pevala (2012). "Dissecting mannose 6-
phosphate-insulin-like growth factor 2 receptor complexes that control activation and 
uptake of plasminogen in cells." Journal of Biological Chemistry 287(27): 22450-
22462. 
Lemamy, G. J., B. Ndeboko, S. T. Omouessi and J. Mouecoucou (2016). Mannose-6-
Phosphate/Insulin-Like Growth Factor 2 Receptor (M6P/IGF2-R) in Growth and 
Disease: A Review. Restricted Growth-Clinical, Genetic and Molecular Aspects, 
InTech. 
Lemieux, I., A. Pascot, D. Prud’homme, N. Alméras, P. Bogaty, A. Nadeau, J. 
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9.3 Participant information sheet (PIS) 
9.3.1 Parent Information sheet 
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9.3.2 Child information sheet (5-8 years) 
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9.3.3 Child information sheet (under 5 years) 
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9.4 Participant consent form  
9.4.1 Consent form  
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9.5. ALSPAC study ethical approval 
B2840 - Depot specific effect of pre-pubertal IGF-II on post 
pubertal fat distribution in ALSPAC cohort - 07/03/2017 
B number:  
B2840 
Principal applicant name:  
Andy Ness | University of Bristol (Avon) 
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Dr.Maiadah ALfares, Dr Sam Leary, Prof Andy Ness 
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Depot specific effect of pre-pubertal IGF-II on post pubertal fat distribution in ALSPAC 
cohort  
Proposal summary:  
Insulin like growth factor II (IGF-II) is a hormone. IGF-II levels in the human circulation are 
maintained at high levels throughout life unlike those of rodents. IGF-II has been strongly 
linked to obesity in genetic studies but its metabolic role is still far from understood. We 
were able to confirm using fat biopsies from children that IGF-II is a key regulator of fat cell 
biology. Our results suggest it acts as a buffer to excess visceral fat accumulation in children. 
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